SEARCH

Search Details

Shimamura Tsuyoshi

Hokkaido University Hospital Central Clinical Facilities Division of Organ TransplantationAssociate Professor

Researcher basic information

■ Degree
  • 博士(医学), 北海道大学
■ URL
researchmap URLホームページURL■ Various IDs
Researcher number
  • 00333617
ORCID IDJ-Global ID■ Research Keywords and Fields
Research Keyword
  • 拒絶反応
  • Tacrolimus
  • Costimulation
  • 臓器移植
  • 新規免疫抑制剤
  • 慢性拒絶反応
  • Cyclosporin
  • ピリミジン代謝阻害
  • NF-κB
  • CTLA4Ig
  • 肝類洞内皮障害
  • CD40Ig
  • DHMEQ
  • 小腸移植
  • タクロリムス
  • ホスホジエステラーゼIII阻害剤
  • Tolerance
  • サイクリックAMP
  • edaravone
  • 小腸虚血再灌流障害
Research Field
  • Life Science, Digestive surgery
  • Others, Others, Laboratory medicine
  • Life Science, General surgery and pediatric surgery
■ Educational Organization

Career

■ Career
Career
  • 2011
    Hokkaido University, 大学病院, 准教授

Research activity information

■ Papers
  • Hydrogen gas with hypothermic machine perfusion induces lipidomic alterations in donation-after-cardiac-death rat livers
    Yusuke Minami; Siddabasave Gowda B. Gowda; Kengo Shibata; Sodai Sakamoto; Divyavani Gowda; Tsuyoshi Shimamura; Akinobu Taketomi; Hitoshi Chiba; Moto Fukai; Shu-Ping Hui
    Journal of Lipid Research, 101040, 101040, Elsevier BV, Apr. 2026
    Scientific journal
  • Successful Recovery From a Severe Graft Dysfunction Due to Acute Rejection After Liver Transplantation: A Case Report.
    Marina Isokawa; Ryoichi Goto; Takuji Ota; Norio Kawamura; Masaaki Watanabe; Tsuyoshi Shimamura; Akinobu Taketomi
    Cureus, 17, 12, e98504, Dec. 2025, [International Magazine]
    English, Scientific journal, Graft failure remains a major challenge after liver transplantation (LT), and rejection is one of its leading causes. We report a rare case of severe graft dysfunction due to acute rejection that successfully recovered without re-transplantation. A 58-year-old man with hepatocellular carcinoma (HCC) secondary to alcoholic liver cirrhosis was registered on the waiting list for deceased donor LT. He developed intractable ascites and renal dysfunction caused by hepatorenal syndrome and subsequently underwent deceased donor LT. On postoperative day 23, severe acute rejection resulted in the destruction of approximately 90% of hepatocytes in the graft and permanent renal failure. The peak total bilirubin level was 29.6 mg/dL. Although re-transplantation was considered, it was not feasible due to the severe donor shortage in Japan. Comprehensive and meticulous medical management was continued for approximately four months, and the liver graft eventually recovered, allowing the patient to return to work. This rare case demonstrates successful recovery from severe liver graft failure after transplantation through conservative treatment, and identifying clinical parameters that predict graft recovery may help determine optimal treatment strategies.
  • Potential indications for liver transplant in Child-Pugh A and Model for End-stage Liver Disease exception for hepatocellular carcinoma in Japan.
    Ryoichi Goto; Tsuyoshi Shimamura; Tomoaki Nakajima; Koji Ogawa; Kazunari Tanaka; Takao Shimizu; Ryosuke Minami; Takeshi Matsui; Noriyuki Akutsu; Shigeru Sasaki; Tatsuhiko Kakisaka; Norio Kawamura; Masaaki Watanabe; Akinobu Taketomi
    Hepatology research : the official journal of the Japan Society of Hepatology, 55, 6, 896, 907, Jun. 2025, [International Magazine]
    English, Scientific journal, AIM: In 2019, expanded criteria for hepatocellular carcinoma (HCC), known as 5-5-500 (size ≤5 cm, number ≤5, alpha-fetoprotein ≤500 ng/mL), as well as Model for End-stage Liver Disease (MELD) exception, were implemented in Japan. In the present study, we evaluated liver transplantation indications and the Japanese allocation policy for HCC. METHODS: Adults with HCC were evaluated between January 2013 and December 2017 in a multicenter study in Japan. The patients were aged ≤65 years, in line with the limits of Japanese transplant center limits. RESULTS: HCC patients (n = 289) were classified as Child-Pugh A (74%), B (18%), or C (8%). Of these, 178 (62%) and 185 (64%) met the Milan and 5-5-500 criteria, respectively. The respective 1- and 5-year overall survival rates of patients who met the criteria were 100% and 88.1% in Child-Pugh A, 91.7% and 30.6% in B, and 72.9% and 0% in C without access to liver transplantation. For Child-Pugh A patients, we developed a risk score using the Child-Pugh score, des-gamma-carboxy prothrombin, tumor-node-metastasis stage grade, as well as albumin-bilirubin and albumin-bilirubin tumor-node-metastasis stage , which predicted worse prognosis. Additionally, we showed the characteristics of patients who achieved MELD exception points high enough to receive an organ: survival at least 2 years after waitlist registration, relatively good liver functional reserve, and sufficient tumor control with multiple treatments. CONCLUSIONS: High-risk patients, identified by our scoring system and albumin-bilirubin tumor-node-metastasis stage ≥2 in Child-Pugh A, should be considered for liver transplantation eligibility. The allocation policy for HCC should be revised based on precise evaluations on a regular basis.
  • Intestinal obstruction caused by disseminated mycobacterium avium complex disease following solid organ transplantation: a case report.
    Akane Mita; Sho Nakakubo; Yusuke Nishimura; Hideki Shima; Masaaki Watanabe; Tsuyoshi Shimamura; Satoshi Konno
    BMC infectious diseases, 25, 1, 120, 120, 25 Jan. 2025, [International Magazine]
    English, Scientific journal, BACKGROUND: Mycobacterium avium complex (MAC) is a common pathogen causing non-tuberculous mycobacterial infections, primarily affecting the lungs. Disseminated MAC disease occurs mainly in immunocompromised individuals, such as those with acquired immunodeficiency syndrome, hematological malignancies, or those positive for anti-interferon-γ antibodies. However, its occurrence in solid organ transplant recipients is uncommon. Herein, we report a rare case of disseminated MAC disease following liver transplantation, which led to an obstructive mass in the intestinal tract that required differentiation from a malignant tumor. CASE PRESENTATION: A 76-year-old woman, who had undergone living-donor liver transplantation 15 years earlier for primary biliary cirrhosis, presented with persistent fever and vomiting three months before admission. She had a history of pulmonary MAC diagnosed five years earlier but remained untreated due to stable lung lesions. Abdominal computed tomography (CT) during her current illness revealed new thickening at the jejuno-jejunal anastomosis site and enlarged mesenteric lymph nodes. Positron emission tomography-CT indicated increased uptake at these sites, suggesting a possible malignancy. Endoscopy revealed an elevated lesion with circumferential ulcers, leading to a suspicion of primary malignant lymphoma. However, biopsies showed CD68-positive histiocyte-like cells with numerous acid-fast bacilli, confirming disseminated MAC infection. Despite ongoing antimicrobial therapy, the patient's intestinal lesions persisted, and she required prolonged hospitalization and interventions for bile drainage and enteral nutrition. CONCLUSION: This case underscores the importance of considering disseminated MAC as a potential complication in solid organ transplant recipients, even when a long period has passed since transplantation. Disseminated MAC can mimic malignancy, presenting with significant lesions causing intestinal obstruction. Awareness and thorough differential diagnosis are essential for timely and accurate management in such complex cases. The patient's outcome emphasizes the need for vigilance in managing long-term immunosuppressed patients, particularly when they present with atypical infections.
  • Anti-Inflammatory Effects of Ex Vivo-Generated Donor Antigen-Specific Immunomodulatory Cells on Pancreatic Islet Transplantation.
    Agustina Forgioni; Masaaki Watanabe; Ryoichi Goto; Takuya Harada; Takuji Ota; Tsuyoshi Shimamura; Akinobu Taketomi
    Cell transplantation, 34, 9636897251317887, 9636897251317887, 2025, [International Magazine]
    English, Scientific journal, Pancreatic islet transplantation (PITx) is a promising treatment option for patients with type 1 diabetes mellitus. Previously, we demonstrated that therapy with alloantigen-specific immunomodulatory cells (IMCs) generated ex vivo in the presence of anti-CD80 and CD86 monoclonal antibodies (mAbs), successfully induced tolerance following clinical liver transplantation. To extend IMC therapy to PITx, it is crucial to address the strong inflammatory and innate immune responses that occur immediately after PITx. In this study, we investigated the efficacy of IMCs in modulating macrophage activation and mitigating inflammatory damage of pancreatic islets. IMCs were induced using mouse splenocytes in the presence of anti-mouse anti-CD80 (RM80) and anti-CD86 (GL-1) mAbs. IMCs exerted donor-specific immunosuppressive effects in a mixed lymphocyte reaction. During lipopolysaccharide (LPS) stimulation, the addition of IMCs suppressed conversion to the M1 phenotype and promoted a shift toward the M2 phenotype, particularly under direct cell-cell contact conditions. Nitric oxide production, a hallmark of M1 polarized macrophages, was significantly reduced in LPS-stimulated RAW264 macrophages by IMC treatment. These findings were associated with reduced secretion of pro-inflammatory cytokines, tumoral necrosis factor α, and interleukin-6, and increased interleukin-10 production by macrophages. IMCs effectively prevented macrophage-mediated islet destruction after 12 h of co-culture with LPS-stimulated macrophages and significantly inhibited macrophage migration toward allogeneic islets in vitro. Intraportal co-infusion of IMCs with syngeneic islets in a mouse PITx model resulted in reduced messenger RNA (mRNA) expression of pro-inflammatory cytokines in the recipient liver. Immunohistochemical staining revealed a significantly lower number of F4/80+ macrophages at the transplantation site in IMCs-treated mice. These results demonstrate that IMCs modulate macrophage polarization, promoting a shift toward the M2 phenotype and protecting islets from macrophage-mediated damage. These effects combined with its intrinsic donor antigen-specific immunosuppressive capacity make IMC therapy a promising strategy for improving outcomes after PITx.
  • A case of simultaneous pancreatoduodenectomy and living donor liver transplantation for biliary cancer complicated with congenital biliary dilatation.
    Tsuyoshi Shimamura; Masaaki Watanabe; Yasuyuki Koshizuka; Ryoichi Goto; Norio Kawamura; Tatsuya Orimo; Hirofumi Kamachi; Toshiya Kamiyama; Tomoko Mitsuhashi; Taizo Hibi; Akinobu Taketomi
    Surgical case reports, 10, 1, 274, 274, 04 Dec. 2024, [Domestic magazines]
    English, Scientific journal, BACKGROUND: In patients with pancreaticobiliary maljunction complicated by congenital biliary dilatation, the pancreatic enzyme flows back into the bile, leading to bile duct carcinogenesis. Although the biliary tract resection and reconstruction is well documented to decrease the rate of malignancy, cancer occurrence has been reported in the residual intrahepatic or intrapancreatic bile duct, even after resection. We report a case of multiple biliary tract cancers in the liver complicated by congenital biliary dilatation, whose tumor lesions were resected en bloc without disconnecting the biliary tract by simultaneous pancreatoduodenectomy and living donor liver transplantation. CASE PRESENTATION: A 27-year-old woman presented with epigastric discomfort. Examination indicated multiple biliary tract cancers complicated by congenital biliary dilatation. Computed tomography scan revealed three papillary tumors in the right hepatic duct with increased 18F-FDG accumulation on positron emission tomography. Contrast-enhanced ultrasound revealed another lesion in the left hepatic duct. Adenocarcinoma cells were detected using bile and choledochal brush cytology. Tumors resection by right lobectomy or trisegmentectomy of the liver and extrahepatic bile duct resection indicated a high risk of postoperative liver failure; the residual liver volumes were calculated only 277 ml or 176 ml, respectively. In addition, tumor recurrence owing to bile leakage during the surgery and carcinogenesis from the remaining bile duct were concerned. Pancreatoduodenectomy was performed without disconnecting the biliary tract, and the tumors were resected en bloc with the whole liver. The left lobe liver graft from the husband was then transplanted. After 5 years of adjuvant treatment with tegafur/gimeracil/oteracil potassium, she remained in remission eight and half years after the surgery. CONCLUSIONS: Given the mechanism and development of cancer in the congenital biliary dilatation, simultaneous pancreatoduodenectomy and liver transplantation may be considered, especially in the case of young patients.
  • Role of Heavy Water in Modified University of Wisconsin Solution for Extended Cold Storage of Rat Liver.
    Moto Fukai; Kengo Shibata; Sodai Sakamoto; Takahisa Ishikawa; Norio Kawamura; Masato Fujiyoshi; Sunao Fujiyoshi; Kosei Nakamura; Hiroki Bochimoto; Shingo Shimada; Tsuyoshi Shimamura; Akinobu Taketomi
    Transplantation proceedings, 56, 8, 1890, 1895, Oct. 2024, [International Magazine]
    English, Scientific journal, To resolve the critical donor shortage worldwide, enlarging the potential donor pool to include expanded criteria donors is necessary. Despite numerous attempts to establish new preservation solutions, no dramatic innovation has occurred since University of Wisconsin (UW) solution displaced Euro Collins' solution; UW solution remains the global gold standard. We previously developed a heavy water (D2O)-containing organ storage solution, Dsol, which is effective for livers subjected to extended cold storage (CS), and reported its effectiveness. Dsol is a modified UW solution; however, the substances or conditions that exhibit a synergistic or additive effect with D2O are unclear. Here we made UWD solution by removing hydroxyethyl starch (HES) from and adding 30%-D2O to UW solution, and compared the effects of these solutions. After 48 hours of CS, the livers were reperfused at 37 °C on an isolated perfused rat liver apparatus, and their perfusion kinetics, functions, and injuries were compared. In the UW group, portal vein resistance significantly increased and the oxygen consumption rate and bile production decreased; in contrast, these changes were suppressed in the UWD group. Organ expansion and liver damage progressed in both groups. These results confirmed that the removal of HES from and addition of D2O to the UW solution reduced CS-induced cellular function impairments and microcirculatory disorders. However, to reduce injury during reperfusion after CS, it is necessary to provide conditions that inhibit injury progression after reperfusion.
  • Unusual rapid development of portopulmonary hypertension after shunt closure for congenital portosystemic shunt.
    Shohei Honda; Issei Kawakita; Kazuyoshi Okumura; Momoko Ara; Ryoichi Goto; Atsuhito Takeda; Tsuyoshi Shimamura; Insu Kawahara; Akinobu Taketomi
    Journal of paediatrics and child health, 06 Aug. 2024, [International Magazine]
    English, Scientific journal
  • Early graft-infiltrating lymphocytes are not associated with graft rejection in a mouse model of skin transplantation.
    Ryo Kanazawa; Ryoichi Goto; Takuya Harada; Takuji Ota; Nozomi Kobayashi; Kazuaki Shibuya; Yoshikazu Ganchiku; Masaaki Watanabe; Masaaki Zaitsu; Norio Kawamura; Tsuyoshi Shimamura; Akinobu Taketomi
    Scandinavian journal of immunology, e13397, 30 Jul. 2024, [International Magazine]
    English, Scientific journal, Graft-infiltrating lymphocytes (GILs) play an important role in promoting rejection after organ transplantation. We recently reported that GILs that accumulated up to 3 days post-transplantation did not promote rejection, whereas GILs present 3-5 days post-transplantation promoted rejection in a mouse heart transplantation model. However, the immunological behaviour of GILs in murine skin transplantation remains unclear. GILs were isolated on days 3, 5 or 7 post-transplantation from C57BL/6 (B6) allogeneic skin grafts transplanted onto BALB/c mice. BALB/c Rag2-/- γc-/- mice (BRGs) underwent B6 skin graft transplantation 10 weeks after adoptive transfer of day 3, 5, or 7 GILs. BRGs reconstituted with day 5 or 7 GILs completely rejected B6 grafts. However, when B6 grafts harvested from recipient BALB/c mice on day 5 or 7 were re-transplanted into BRGs, half of the re-transplanted day 5 grafts established long-term survival, although all re-transplanted day 7 grafts were rejected. BRGs reconstituted with day 3 GILs did not reject B6 grafts. Consistently, re-transplantation using day 3 skin grafts resulted in no rejection. Administration of anti-CD25 antibodies did not prevent the phenomenon observed for the day 3 skin grafts. Furthermore, BRGs reconstituted with splenocytes from naïve BALB/c mice immediately rejected the naïve B6 skin grafts and the re-transplanted day 3 B6 grafts, suggesting that day 3 GILs were unable to induce allograft rejection during the rejection process. In conclusion, the immunological role of GILs depends on the time since transplantation. Day 3 GILs had neither protective nor alloreactive effects in the skin transplant model.
  • 急性肝不全に対する移植スコアリングシステム High-flow hemodiafiltration時代の急性肝不全診療
    川村 典生; 嶋村 剛; 後藤 了一; 巖築 慶一; 渡辺 正明; 中井 正人; 荘 拓也; 森川 賢一; 小川 浩司; 武冨 紹信
    肝臓, 65, 5, 249, 249, (一社)日本肝臓学会, May 2024
    Japanese
  • 救命率向上のための急性肝不全に対するチーム医療 急性肝不全に対するチーム医療肝癌治療における複数診療科での対応を参考に
    後藤 了一; 巖築 慶一; 川村 典生; 渡辺 正明; 柏浦 愛美; 山本 真由美; 神山 俊哉; 松居 剛志; 姜 貞憲; 嶋村 剛; 武冨 紹信
    肝臓, 65, 5, 245, 245, (一社)日本肝臓学会, May 2024
    Japanese
  • 急性肝不全に対する移植スコアリングシステム High-flow hemodiafiltration時代の急性肝不全診療
    川村 典生; 嶋村 剛; 後藤 了一; 巖築 慶一; 渡辺 正明; 中井 正人; 荘 拓也; 森川 賢一; 小川 浩司; 武冨 紹信
    肝臓, 65, 5, 249, 249, (一社)日本肝臓学会, May 2024
    Japanese
  • E型肝炎ウイルス感染による急性肝不全5例の検討
    市村 健太郎; 川村 典生; 渡辺 正明; 後藤 了一; 巖築 慶一; 嶋村 剛; 武冨 紹信
    肝臓, 65, 5, 254, 255, (一社)日本肝臓学会, May 2024
    Japanese
  • 侵襲性アスペルギルス症を発症し,脳出血にて死亡した急性肝不全2例の検討
    巖築 慶一; 川村 典生; 渡辺 正明; 後藤 了一; 嶋村 剛; 武冨 紹信
    肝臓, 65, 5, 257, 257, (一社)日本肝臓学会, May 2024
    Japanese
  • 昏睡型亜急性型急性肝不全に対し,保存的加療または肝移植にて救命しえた2例
    松井 双葉; 後藤 了一; 川村 典生; 渡辺 正明; 金沢 亮; 津坂 隼也; 松居 剛志; 中井 正人; 荘 拓也; 小川 浩司; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 124回, RS, 3, (一社)日本外科学会, Apr. 2024
    Japanese
  • ラット肝温阻血再灌流障害におけるUDPNアセチルヘキソサミンの動態
    柴田 賢吾; 深井 原; 今泉 健; 藤好 直; 坂本 聡大; 市川 伸樹; 吉田 雅; 川村 典夫; 藤好 真人; 本間 重紀; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 124回, SF, 4, (一社)日本外科学会, Apr. 2024
    Japanese
  • マウス心移植モデルにおける冷阻血中インフラマソーム阻害がグラフト機能や早期浸潤に及ぼす影響
    原田 拓弥; 後藤 了一; Agustina Forgioni; 太田 拓児; 巖築 慶一; 渡辺 正明; 川村 典生; 深井 原; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 124回, PS, 6, (一社)日本外科学会, Apr. 2024
    Japanese
  • HBV陽性レシピエントに対する肝移植後再発予防の取り組み
    川村 典生; 嶋村 剛; 後藤 了一; 渡辺 正明; 金沢 亮; 武冨 紹信
    日本外科学会定期学術集会抄録集, 124回, PS, 3, (一社)日本外科学会, Apr. 2024
    Japanese
  • 重水含有臓器保存液の有効成分の検証 体外灌流によるグラフト機能評価
    深井 原; 柴田 賢吾; 坂本 聡大; 石川 隆壽; 藤好 真人; 藤好 直; 川村 典生; 島田 慎吾; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 124回, PS, 7, (一社)日本外科学会, Apr. 2024
    Japanese
  • 急速な肝腎不全を呈したWilson病非代償性肝硬変に対し脳死肝移植にて救命しえた1例
    津坂 隼也; 後藤 了一; 太田 拓児; 川村 典夫; 渡辺 正明; 松居 剛志; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 124回, RS, 6, (一社)日本外科学会, Apr. 2024
    Japanese
  • 昏睡型亜急性型急性肝不全に対し,保存的加療または肝移植にて救命しえた2例
    松井 双葉; 後藤 了一; 川村 典生; 渡辺 正明; 金沢 亮; 津坂 隼也; 松居 剛志; 中井 正人; 荘 拓也; 小川 浩司; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 124回, RS, 3, (一社)日本外科学会, Apr. 2024
    Japanese
  • TCF1highPD-1+Ly108+CD8+ T Cells Are Associated with Graft Preservation in Sensitized Mice Treated with Non-Fc Receptor-Binding CD3 Antibodies.
    Takuji Ota; Ryoichi Goto; Takuya Harada; Agustina Forgioni; Ryo Kanazawa; Yoshikazu Ganchiku; Norio Kawamura; Masaaki Watanabe; Moto Fukai; Tsuyoshi Shimamura; Akinobu Taketomi
    ImmunoHorizons, 8, 4, 295, 306, 01 Apr. 2024, [International Magazine]
    English, Scientific journal, The non-Fc-binding anti-CD3 Ab [anti-CD3F(ab')2] can induce graft acceptance depending on the therapeutic window in a rodent heart transplant model. The delayed protocol allows for early graft infiltration of lymphocytes, which may behave in an inhibitory manner. We investigated the most effective protocol for anti-CD3F(ab')2 in sensitized conditions to confirm the evidence for clinical application. C57BL/6 mice were sensitized with BALB/c tail skin grafts and transplanted with BALB/c heart grafts at 8-12 wk after sensitization. Fifty micrograms of anti-CD3F(ab')2 was administered daily for 5 consecutive days on days 1-5 (day 1 protocol) or days 3-7 (delayed protocol). In nonsensitized mice, the delayed protocol significantly prolonged graft survival after transplantation from BALB/c to naive B6 (median survival time [MST], >100 d). In contrast, the delayed protocol was unable to prevent graft rejection in sensitized mice (MST, 5 d). A significantly increased percentage of granzyme B+ CD8+ T cells was observed in the graft on day 3 posttransplantation in sensitized conditions. Further, the day 1 protocol significantly prolonged graft survival (MST, 18 d), even in sensitized conditions. Day 1 treatment significantly increased the percentage of Foxp3+CD25+CD4+ T cells and phenotypically changed CD8+ T cells in the graft (i.e., caused a significant increase in the proportion of Ly108+TCF1highPD-1+CD8+ T cells). In conclusion, different timings of delayed anti-CD3F(ab')2 treatment promoted allograft preservation in association with phenotypic changes in CD4+ and CD8+ T cells in the graft under sensitized conditions.
  • Important Constituents of Heavy Water-containing Solution for Cold Storage and Subsequent Reperfusion on an Isolated Perfused Rat Liver.
    Moto Fukai; Sodai Sakamoto; Kengo Shibata; Takahisa Ishikawa; Norio Kawamura; Masato Fujiyoshi; Sunao Fujiyoshi; Kosei Nakamura; Hiroki Bochimoto; Shingo Shimada; Tsuyoshi Shimamura; Akinobu Taketomi
    Transplantation proceedings, 09 Jan. 2024, [International Magazine]
    English, Scientific journal, The University of Wisconsin (UW) solution is the most effective preservation solution currently used; however, to safely use expanded-criteria donor grafts, a new cold storage solution that alleviates graft injury more effectively is required. We prepared a heavy water (D2O)-containing buffer, Dsol, and observed strong protective effects during extended cold storage of rat hearts and livers. In the current study, we modified Dsol (mDsol) and tested its efficacy. The aim of the present study was to determine whether mDsol could protect the rat liver more effectively than the UW solution and to clarify the roles of D2O and deferoxamine (DFX). Rat livers were subjected to cold storage for 48 hours in test solutions: UW, mDsol, mDsol without D2O or DFX (mDsol-D2O[-], mDsol-DFX[-]), and subsequently reperfused on an isolated perfused rat liver for 90 minutes at 37°C. In the UW group, the liver was dehydrated during cold storage and rapidly expanded during reperfusion. Accordingly, the cumulative weight change was the highest in the UW group, together with augmented portal veinous resistance and ALT leakage and decreased oxygen consumption rate and bile production. These changes were significantly suppressed in the mDsol-treated group. In the mDsol-D2O(-) and mDsol-DFX(-) groups offered partial protection. In conclusion, mDsol appeared to be superior to the UW solution for simple cold storage of the rat liver, presumably due to improved microcirculation in the early phase of reperfusion. Both heavy water and deferoxamine are essential for alleviating seamless organ swelling that occurs during cold storage and subsequent reperfusion.
  • 肝細胞癌への肝移植: 適応と加点MELDの検討
    後藤 了一; 嶋村 剛; 中島 知明; 小川 浩司; 田中 一成; 清水 孝夫; 南 亮輔; 松居 剛志; 阿久津 典之; 佐々木 茂; 長津 明久; 川村 典生; 渡辺 正明; 柿坂 達彦; 武冨 紹信
    移植, 59, Supplement, s322_1, s322_1, 一般社団法人 日本移植学会, 2024
    Japanese, 【背景】HCCは5-5-500への適応拡大, 加点MELDが採用されている.【目的】Japan基準を満たすHCCの予後から適応, 脳死肝移植における適切な加点MELDを検討する.【対象】2013年-2017年の札幌厚生病院, 北海道大学, 手稲渓仁会病院, 札幌医科大学における18-65歳の初発肝細胞癌289例.【結果】HCC 289例のChild-Pugh(C-P)別割合はA: 74%, B: 18%, C: 8%であった. 179 (62%)がミラノ内, 185(64%)が5-5-500内であった. Japan基準内HCCの移植無しのC-P別1, 5生率はA: 100%, 88.1%, B: 95.8%, 35.2%, C: 72.9%, 0%であり, B以上の移植適応は妥当であった. C-P AのJapan基準内HCCはALBI またはmALBIと腫瘍因子(TNM)によるスコア(ALBI-T, mALBI-T)で予後が層別化され, ALBI-T 2点≦(n=32), mALBI-T 3点≦(n=18)の5生率はそれぞれ64.1%, 50.6%で移植を検討しうると考えた. 更に現行の移植適応であるC-P B以上, Japan基準内(n=43)で十分な加点MELD (28点に設定)を獲得できるのは58.2%で, 局所療法でHCC制御可能なC-P Bで, 2年以上待機できる症例であった.【結語】C-P Aで移植を考慮すべき症例が存在すること, 現行の加点MELD制によるC-P B以上症例の移植到達率が算出された. これらのデータはHCCに対する適応拡大ならびに公平な臓器配分ルール構築の一助となる.
  • ラット肝の27℃体外灌流における至適灌流pHの検討
    中村 恒星; 深井 原; 藤好 真人; 藤好 直; 柴田 賢吾; 坂本 聡大; 川村 典生; 後藤 了一; 長津 明久; 渡辺 正明; 嶋村 剛; 武冨 紹信
    移植, 59, Supplement, s291_3, s291_3, 一般社団法人 日本移植学会, 2024
    Japanese, 【背景】 易傷害性肝グラフトに対する機械灌流の有用性が報告されたが、灌流時の液組成、温度、pH等の条件検討は不十分である。我々は7℃での肝体外灌流の至適pHを既に報告したが (坂本 2023 J Clin Med)、異なる温度でのMPにおける至適pHは明らかではない。【目的】 27℃の肝機械灌流における至適灌流pHを明らかにすること。【方法】 ラット肝をUW液中で48時間の冷保存(CS)後、UWMP液で27℃, 3時間酸素化灌流(MP)し、さらに単離ラット肝灌流装置で37℃, 90分再灌流した。実験群: CSせずに再灌流 (CT群); MPなしで再灌流 (CS群); UWMP液でMPする際にpH無調節 (No群); あるいは、UWMP液のpHを7.2~7.6に調節してMP (pH7.2群~7.6群)(各n>6)。再灌流時の肝逸脱酵素、胆汁産生量、酸素消費率、門脈抵抗等を評価した。【結果】 再灌流後の肝逸脱酵素はpH7.4群で最低、No群で最高であった。再灌流時の酸素消費率はCS群では著明に低下したが、全てのMP実施群ではCT群と同等の高値であった。胆汁産生量はCS群、No群で低値、pH7.4群では有意に増加した。肝逸脱酵素はCS群で上昇、No群でも上昇したが、pH7.4群ではCS群と同等であった。pH7.5群はpH7.4群とほぼ同様の結果であった。門脈抵抗値は、全てのpH調節群とCT群、No群間に有意差はなかった。【考察・結語】 温度に応じた至適pHが灌流における重要な条件と考えられた。27℃の肝機械灌流における至適灌流pHは7.4-7.5の範囲と考えられた。
  • ラットにおけるischemia free liver transplantation法の確立
    藤好 直; 藤好 真人; 山本 葉一; 相山 健; 長津 明久; 川村 典生; 渡辺 正明; 後藤 了一; 柿坂 達彦; 深井 原; 嶋村 剛; 武冨 紹信
    移植, 59, Supplement, s344_2, s344_2, 一般社団法人 日本移植学会, 2024
    Japanese, 緒言:肝移植において、機械灌流法は臨床応用の段階にあり、有効性が報告されている。治療的機械灌流の目的は臓器保存環境の最適化であり、体内外での機械灌流により臓器無灌流状態を排除したischemia free liver transplantation (IFLT)法はその究極的な形態の一つである。この方法はGuangzhouグループにより開発され、臨床研究が行われてきたが、技術的要求が高く、基礎研究モデルは未確立である。我々は、ラットIFLTモデルの開発に成功しており、改良により良好な成績を達成したのでここに報告する。方法:ドナー、レシピエントともWister Rat (250g, オス)を用い、灌流形式は経門脈的冷温酸素化機械灌流とした。ドナー肝血流を維持しながら、脾静脈より灌流カテーテル、肝下部下大静脈より排液カテーテルを挿入し、血流遮断と同時に機械灌流を開始し、機械灌流下に摘出および体外保存を行った。レシピエントの肝全摘後、機械灌流下に肝上部下大静脈と門脈を手縫い吻合し、血流再開と同時に機械灌流を停止した。結果:灌流液を冷温細胞外液、保存時間を短時間 (臓器摘出後すぐにレシピエント手術を開始)としたIFLTにおいて、全例でレシピエントの生存が得られた。考察:IFLTは将来性の高い機械灌流法であり、当モデルはその基礎研究に寄与しうるものと考えられる。
  • 成人肝移植後の就労状況の実態と支援の検討
    柏浦 愛美; 後藤 了一; 有賀 知里; 三宅 亜矢; 金沢 亮; 川村 典生; 渡辺 正明; 嶋村 剛
    移植, 59, Supplement, s307_3, s307_3, 一般社団法人 日本移植学会, 2024
    Japanese, 【はじめに】成人肝移植後の社会復帰・就労は生きがいの醸成や社会の担い手創出に重要だが, 肝移植後の就労の報告は少ない.

    【目的】当院の肝移植後の就労実態と問題を明らかにする.

    【方法】成人肝移植後, 外来フォロー症例の移植前後5年の就労状況を調査した. 病院倫理委員会の承認を得た.

    【結果】126例中117 (92.9%) から回答を得た. 117例の移植時年齢は52.7歳 (19.2-70.0), 男性69例 (59.0%), 生体75例 (64.1%) であった. 移植5年前からの就業率 (%) は1年毎に71.8, 72.6, 72.6, 69.2, 65.0と低下した (p<0.05, 4年前vs. 1年前). 移植後5年までの就業率は1年毎に46.2, 56.1, 58.2, 63.6, 65.7と増加した (p<0.05, 1年後vs. 2-5年後). 移植1年前の有職76例は無職20例と比較し移植後就業率が有意に高かった (p<0.05, 移植1-5年後の就業率, 有職76: 65.8, 77.0, 81.4, 86.8, 86.4 vs. 無職20: 20.0, 35.0, 35.0, 42.1, 44.4). 117例の復職時の勤務形態はフルタイムが47.9%, 時短や業務変更の支援を44.7%が得ていた. 移植後の就労困難な理由は体力や合併症による「身体的理由」と通院, 易感染性, 業務内容への配慮に対する「職場の理解不足」「就労継続への不安」が挙げられた.

    【結語】肝移植後2年で半数以上が就労した. 移植直前の就労状況が移植後就業率に関連した. 移植後の就労は体調面に加え職場の理解が重要と考えられた. 多職種連携による両立支援が移植後の復職において課題である.
  • 新型コロナウイルス感染蔓延下での長期待機後に脳死肝腎同時移植を実施した末期原発性硬化性胆管炎の1例
    坂村 颯真; 後藤 了一; 山口 将功; 植林 毅行; 伊藤 啓一郎; 津坂 翔一; 原田 拓弥; 太田 拓児; 川村 典生; 渡辺 正明; 田邉 起; 堀田 記世彦; 篠原 信雄; 嶋村 剛; 武冨 紹信
    北海道外科雑誌, 68, 2, 106, 110, 北海道外科学会, Dec. 2023
    Japanese
  • 膵移植後の抗体関連型拒絶反応治療に免疫グロブリン静注療法(intravenous immunoglobulin:IVIG)を使用した症例の調査研究 本邦膵移植後IVIG4症例の報告
    伊藤 泰平; 剣持 敬; 後藤 了一; 渡辺 正明; 武冨 紹信; 嶋村 剛; 平光 高久; 鳴海 俊治; 富丸 慶人; 小林 省吾; 江口 英利; 大島 稔; 岡野 圭一; 中川 健; 江川 裕人
    移植, 58, 3, 273, 280, (一社)日本移植学会, Dec. 2023
    Japanese, 2001~2121年度の膵臓移植474例のうち膵移植後の抗体関連型拒絶反応(ABMR)に対し免疫グロブリン静注療法(IVIG)を用いた4例(男性2例、女性2例、移植時年齢40代3例、50代1例)について調査した。原疾患は4例全てI型糖尿病で、糖尿病性腎症の合併による血液透析中2例、腎移植後2例であった。観察期間中、全例で抗ドナー特異抗体(DSA)陽性を認めた。転帰は、ABMRを制御できず膵・腎グラフトを摘出しインスリン、透析再導入1例、膵グラフト生着3例のうち1例はABMR発症後にインスリン再導入となった。IVIG治療による有害事象は無く、治療後1年時点で全例生存しており生命予後は良好であった。
  • 臓器保存の生物学と技術 機械灌流中の最適pHは温度によって変化する(Organ preservation Biology and technology The optimal pH during machine perfusion varies depending on the temperature)
    深井 原; 柴田 賢吾; 藤好 直; 川村 典生; 本井 慧路; 藤好 真人; 石川 隆壽; 中村 恒星; 暮地本 宙己; 嶋村 剛; 武冨 紹信
    Organ Biology, 30, 3, 52, 52, (一社)日本臓器保存生物医学会, Oct. 2023
    English
  • Exploration of Optimal pH in Hypothermic Machine Perfusion for Rat Liver Grafts Retrieved after Circulatory Death.
    Sodai Sakamoto; Hiroki Bochimoto; Kengo Shibata; Nur Khatijah Mohd Zin; Moto Fukai; Kosei Nakamura; Takahisa Ishikawa; Masato Fujiyoshi; Tsuyoshi Shimamura; Akinobu Taketomi
    Journal of clinical medicine, 12, 11, 04 Jun. 2023, [International Magazine]
    English, Scientific journal, Ex vivo hypothermic machine perfusion (HMP) is a strategy for controlling ischemia-reperfusion injury in donation after circulatory death (DCD) liver transplantation. The pH of blood increases with a decrease in temperature and water dissociation, leading to a decrease in [H+]. This study aimed to verify the optimal pH of HMP for DCD livers. Rat livers were retrieved 30 min post-cardiac arrest and subjected to 3-h cold storage (CS) in UW solution (CS group) or HMP with UW-gluconate solution (machine perfusion [MP] group) of pH 7.4 (original), 7.6, 7.8, and 8.0 (MP-pH 7.6, 7.8, 8.0 groups, respectively) at 7-10 °C. The livers were subjected to normothermic perfusion to simulate reperfusion after HMP. All HMP groups showed greater graft protection compared to the CS group due to the lower levels of liver enzymes in the former. The MP-pH 7.8 group showed significant protection, evidenced by bile production, diminished tissue injury, and reduced flavin mononucleotide leakage, and further analysis by scanning electron microscopy revealed a well-preserved structure of the mitochondrial cristae. Therefore, the optimum pH of 7.8 enhanced the protective effect of HMP by preserving the structure and function of the mitochondria, leading to reduced reperfusion injury in the DCD liver.
  • Combination of Cold Storage in a Heavy Water-Containing Solution and Post-Reperfusion Hydrogen Gas Treatment Reduces Ischemia-Reperfusion Injury in Rat Livers.
    Moto Fukai; Sodai Sakamoto; Kengo Shibata; Masato Fujiyoshi; Sunao Fujiyoshi; Hiroki Bochimoto; Takahisa Ishikawa; Shingo Shimada; Kosei Nakamura; Norio Kawamura; Tsuyoshi Shimamura; Akinobu Taketomi
    Transplantation proceedings, 55, 4, 1027, 1031, May 2023, [International Magazine]
    English, Scientific journal, We previously reported the efficacy of cold storage (CS) using a heavy water-containing solution (Dsol) and post-reperfusion hydrogen gas treatment separately. This study aimed to clarify the combined effects of these treatments. Rat livers were subjected to 48-hour CS and a subsequent 90-minute reperfusion in an isolated perfused rat liver system. The experimental groups were the immediately reperfused control group (CT), the CS with University of Wisconsin solution (UW) group, the CS with Dsol group, the CS with UW and post-reperfusion H2 treatment group (UW-H2), and the CS with Dsol and post-reperfusion H2 group (Dsol-H2). We first compared the Dsol-H2, UW, and CT groups to evaluate this alternative method to conventional CS. The protective potential of the Dsol-H2 group was superior to that of the UW group, as evidenced by lower portal venous resistance and lactate dehydrogenase leakage, a higher oxygen consumption rate, and increased bile production. Multiple comparison tests among the UW, Dsol, UW-H2, and Dsol-H2 groups revealed that both treatments, during CS and after reperfusion, conferred a similar extent of protection and showed additive effects in combination therapy. Furthermore, the variance in all treatment groups appeared smaller than that in the no-treatment or no-stress groups, with excellent reproducibility. In conclusion, combination therapy with Dsol during CS and hydrogen gas after reperfusion additively protects against graft injury.
  • 当施設における肝移植後de novo腫瘍の検討
    太田 拓児; 後藤 了一; 原田 拓弥; 川村 典生; 渡辺 正明; 嶋村 剛; 武冨 紹信
    日本外科系連合学会誌, 48, 3, 424, 424, 日本外科系連合学会, May 2023
    Japanese
  • Warm Ischemia Induces Spatiotemporal Changes in Lysophosphatidylinositol That Affect Post-Reperfusion Injury in Normal and Steatotic Rat Livers.
    Kengo Shibata; Takahiro Hayasaka; Sodai Sakamoto; Satsuki Hashimoto; Norio Kawamura; Masato Fujiyoshi; Taichi Kimura; Tsuyoshi Shimamura; Moto Fukai; Akinobu Taketomi
    Journal of clinical medicine, 12, 9, 27 Apr. 2023, [International Magazine]
    English, Scientific journal, Warm ischemia-reperfusion injury is a prognostic factor for hepatectomy and liver transplantation. However, its underlying molecular mechanisms are unknown. This study aimed to elucidate these mechanisms and identify the predictive markers of post-reperfusion injury. Rats with normal livers were subjected to 70% hepatic warm ischemia for 15, 30, or 90 min, while those with steatotic livers were subjected to 70% hepatic warm ischemia for only 30 min. The liver and blood were sampled at the end of ischemia and 1, 6, and 24 h after reperfusion. The serum alanine aminotransferase (ALT) activity, Suzuki injury scores, and lipid peroxidation (LPO) products were evaluated. The ALT activity and Suzuki scores increased with ischemic duration and peaked at 1 and 6 h after reperfusion, respectively. Steatotic livers subjected to 30 min ischemia and normal livers subjected to 90 min ischemia showed comparable injury. A similar trend was observed for LPO products. Imaging mass spectrometry of normal livers revealed an increase in lysophosphatidylinositol (LPI (18:0)) and a concomitant decrease in phosphatidylinositol (PI (18:0/20:4)) in Zone 1 (central venous region) with increasing ischemic duration; they returned to their basal values after reperfusion. Similar changes were observed in steatotic livers. Hepatic warm ischemia time-dependent acceleration of PI (18:0/20:4) to LPI (18:0) conversion occurs initially in Zone 1 and is more pronounced in fatty livers. Thus, the LPI (18:0)/PI (18:0/20:4) ratio is a potential predictor of post-reperfusion injury.
  • Rapid and Reliable Steatosis Rat Model Shrsp5-Dmcr for Cold Storage Experiment.
    Moto Fukai; Hiroyuki Sugimori; Sodai Sakamoto; Kengo Shibata; Hiroyuki Kameda; Takahisa Ishikawa; Norio Kawamura; Masato Fujiyoshi; Sunao Fujiyoshi; Kohsuke Kudo; Tsuyoshi Shimamura; Akinobu Taketomi
    Transplantation proceedings, 55, 4, 1032, 1035, 10 Apr. 2023, [International Magazine]
    English, Scientific journal, Interventions for liver grafts with moderate macrovesicular steatosis have been important in enlarging donor pools. Here, we tested a high-fat and cholesterol (HFC) diet to create a steatosis model for cold hepatic preservation and reperfusion experiments. The aim of the present study was to assess the steatosis model's reliability and to show the resulting graft's quality for cold preservation and reperfusion experiment. Male SHRSP5-Dmcr rats were raised with an HFC diet for up to 2 weeks. The fat content was evaluated using magnetic resonance imaging (MRI) proton density fat fraction (PDFF). The nonalcoholic fatty liver disease activity score (NAS) was evaluated after excision. Steatosis created by 2 weeks of HFC diet was subjected to 24-hour cold storage in the University of Wisconsin and the original test solution (new sol.). Grafts were applied to isolated perfused rat livers for simulating reperfusion. The NAS were 2.2 (HFC 5 days), 3.3 (HFC 1 week), and 5.0 (HFC 2 weeks). Ballooning and fibrosis were not observed in any group. An MRI-PDFF showed 0.2 (HFC 0 days), 12.0 (HFC 1 week), and 18.9 (HFC 2 weeks). The NAS and MRI-PDFF values correlated. Many indices in the isolated perfused rat liver experiment tended to improve in the new sol. group but were insufficient. Although the new sol. failed to be effective, it acted at multiple sites under difficult conditions. In conclusion, the HFC diet for 2 weeks in SHRSP5-Dmcr rats, together with MRI-PDFF evaluation, is a reliable method for creating simple steatosis and provides good-quality cold preservation and reperfusion experiments.
  • 肝移植をめぐる諸問題 当院における肝移植後de novo非アルコール性脂肪性肝疾患(NAFLD)の検討
    後藤 了一; 嶋村 剛; 武冨 紹信
    肝臓, 64, Suppl.1, A189, A189, (一社)日本肝臓学会, Apr. 2023
    Japanese
  • 生体肝移植後の胆管空腸吻合合併症に対するバルーン補助下消化管内視鏡を用いた治療
    渡辺 正明; 嶋村 剛; 後藤 了一; 川村 典生; 太田 拓児; 武冨 紹信
    日本外科学会定期学術集会抄録集, 123回, DP, 6, (一社)日本外科学会, Apr. 2023
    Japanese
  • 当施設における肝移植後de novo腫瘍の検討
    太田 拓児; 後藤 了一; 原田 拓弥; 川村 典生; 渡辺 正明; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 123回, DP, 5, (一社)日本外科学会, Apr. 2023
    Japanese
  • マウス心移植モデルにおける冷阻血中インフラマソーム阻害がグラフト生存期間に与える影響
    原田 拓弥; 後藤 了一; Agustina Forgioni; 太田 拓児; 巖築 慶一; 渡辺 正明; 川村 典生; 深井 原; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 123回, DP, 2, (一社)日本外科学会, Apr. 2023
    Japanese
  • 肝移植後の急性拒絶反応によるグラフト不全から回復した移植前腎障害合併の2例
    磯川 真里奈; 後藤 了一; 太田 拓児; 川村 典生; 渡辺 正明; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 123回, RS, 12, (一社)日本外科学会, Apr. 2023
    Japanese
  • 肺MAC症を併発したWilson病による非代償性肝硬変,肝細胞癌合併症例に対し,脳死肝移植を施行した1例
    谷口 広樹; 渡辺 正明; 嶋村 剛; 後藤 了一; 川村 典生; 太田 拓児; 武冨 紹信
    日本外科学会定期学術集会抄録集, 123回, RS, 1, (一社)日本外科学会, Apr. 2023
    Japanese
  • Hypothermic Machine Perfusion with Hydrogen Gas Reduces Focal Injury in Rat Livers but Fails to Restore Organ Function.
    Moto Fukai; Sodai Sakamoto; Hiroki Bochimoto; Nur Khatijah Mohd Zin; Kengo Shibata; Takahisa Ishikawa; Shingo Shimada; Norio Kawamura; Masato Fujiyoshi; Sunao Fujiyoshi; Kosei Nakamura; Tsuyoshi Shimamura; Akinobu Taketomi
    Transplantation proceedings, 55, 4, 1016, 1020, 20 Mar. 2023, [International Magazine]
    English, Scientific journal, BACKGROUND: We have previously reported the efficacy of post-reperfusion H2 gas treatment in cold storage (CS) and subsequent reperfusion of the rat liver. The present study aimed to evaluate the effect of H2 gas treatment during hypothermic machine perfusion (HMP) in rat livers retrieved from donation after circulatory death (DCD) and elucidate the mechanism of action of H2 gas. METHODS: Liver grafts were procured from rats after 30 min of cardiopulmonary arrest. The graft was subjected to HMP for 3 hours at 7°C using Belzer MPS with or without dissolved H2 gas. The graft was reperfused using an isolated perfused rat liver apparatus at 37°C for 90 minutes. Perfusion kinetics, liver damage, function, apoptosis, and ultrastructure were evaluated. RESULTS: Portal venous resistance, bile production, and oxygen consumption rates were identical in the CS, MP, and MP-H2 groups. Liver enzyme leakage was suppressed by MP (vs control), whereas H2 treatment did not show a combination effect. Histopathology revealed poorly stained areas with a structural deformity just below the liver surface in the CS and MP groups, whereas these findings disappeared in the MP-H2 group. The apoptotic index in the CS and MP groups was high but decreased in the MP-H2 group. Mitochondrial cristae were damaged in the CS group but preserved in the MP and MP-H2 groups. CONCLUSIONS: In conclusion, HMP and H2 gas treatment are partly effective in DCD rat livers but insufficient. Hypothermic machine perfusion can improve focal microcirculation and preserve mitochondrial ultrastructure.
  • 急性肝不全の病態と治療~基礎・臨床の観点から~ 当院における急性肝不全に対する肝移植
    後藤 了一; 川村 典生; 渡辺 正明; 巖築 慶一; 嶋村 剛; 武冨 紹信
    肝臓, 64, 3, 168, 168, (一社)日本肝臓学会, Mar. 2023
    Japanese
  • Long‐term risk of a fatty liver in liver donors
    Ryoichi Goto; Norio Kawamura; Masaaki Watanabe; Yoshikazu Ganchiku; Akihisa Nagatsu; Kazufumi Okada; Yoichi M. Ito; Toshiya Kamiyama; Tsuyoshi Shimamura; Akinobu Taketomi
    Annals of Gastroenterological Surgery, 7, 4, 645, 653, Wiley, 02 Feb. 2023
    Scientific journal
  • Small-for-size syndromeに対する手術戦略の再考
    川村 典生; 嶋村 剛; 後藤 了一; 渡辺 正明; 金沢 亮; 武冨 紹信
    移植, 58, Supplement, s209_2, s209_2, 一般社団法人 日本移植学会, 2023
    Japanese, 背景:生体肝移植の短期予後を低下させる最大の要因はSmall-for-size syndrome(SFSS)の発生であり、手術適応の決定・術式の選択により患者予後は大きく影響を受ける。目的:SFSSに影響を及ぼす因子を検討し、生体肝移植の手術戦略を再考する。方法:1997年より2019年に当院にて施行した成人間生体肝移植140例を対象とした。SFSSの定義は術後2週間の血清総ビリルビン値10mg/dl以上かつ腹水量1L/日以上とした。結果:グラフト内訳は左葉84 例(60.0%)、右葉56例(40.0%)であった。GV/SV ratio 40%以上のstandard graftが61例(43.6%)、40%未満のsmall graftが79例(56.4%)であった。SFSSは19例(13.8%)に発生しており、SFSS症例の1年生存率は63.2%(非SFSS症例 95.0%、P<.0001)であった。SFSS発生に関するlogistic解析では、単変量解析ではドナー年齢55歳以上、ドナーの術前ALBI score >-3.0、GV/SV ratio <40%、MELD score>20、脾摘、Porto-caval shuntの造設が有意な予後因子であった。多変量解析では、ドナー年齢55歳以上(P<.0001)、GV/SV ratio<40%(P=0.003)、MELD score>20(P=0.001)、脾摘(P=0.043)が独立した予後因子であった。結語:SFSS発生にはドナー年齢、グラフトボリューム、MELD score、脾摘の有無が関与していた。これらのうち介入可能な因子は脾摘であり、ハイリスク症例に対しては脾摘により予後改善が得られる可能性が示唆された。
  • Solid pseudopapillary neoplasm of the pancreas after living-donor liver transplantation
    Shoichi Tsuzaka; Norio Kawamura; Takuya Harada; Takuji Ota; Yoshikazu Ganchiku; Masaaki Watanabe; Ryoichi Goto; Hirofumi Kamachi; Toshiya Kamiyama; Tsuyoshi Shimamura; Nanase Okazaki; Tomoko Mitsuhashi; Akinobu Taketomi
    Journal of Pediatric Surgery Case Reports, 88, Jan. 2023
    Scientific journal
  • Post-transplant donor-specific anti-HLA antibodies with a higher mean fluorescence intensity are associated with graft fibrosis in pediatric living donor liver transplantation.
    Ryoichi Goto; Yasutomo Fukasaku; Yoshikazu Ganchiku; Norio Kawamura; Masaaki Watanabe; Takuji Ota; Kanako C Hatanaka; Tomomi Suzuki; Tsuyoshi Shimamura; Akinobu Taketomi
    Frontiers in pediatrics, 11, 1172516, 1172516, 2023, [International Magazine]
    English, Scientific journal, The roles of post-transplant anti-HLA donor specific antibody (DSA) in pediatric liver transplantation (LT), including therapeutic strategies, remain controversial. This study aimed to identify the risks of post-transplant DSA for graft fibrosis progression in pediatric living donor LT (LDLT). We retrospectively evaluated 88 LDLT pediatric cases between December 1995 and November 2019. DSAs were assessed with single antigen bead test. Graft fibrosis was histopathologically scored with METAVIR and the centrilobular sinusoidal fibrosis system. Post-transplant DSAs were detected in 37 (52.9%) cases at 10.8 (1.3-26.9) years post-LDLT. The histopathological examination of 32 pediatric cases with post-transplant DSA revealed that 7 (21.9%) with a high DSA-MFI (≥9,378) showed graft fibrosis progression (≥F2). No graft fibrosis was observed in the subjects with a low DSA-MFI. The risk factors for developing graft fibrosis in pediatric cases with post-transplant DSA were an older graft age (>46.5 years old), lower platelet count (<10.7 × 104/ml) and higher Fib4 index (>0.7807, recipient age; >1.8952, donor age). Limited efficacy of additional immunosuppressants was observed in DSA positive pediatric cases. In conclusion, pediatric cases with a high DSA-MFI and risk factors should undergo a histological examination. The appropriate treatment for post-transplant DSA in pediatric LT needs to be determined.
  • 若年発症の急性肝不全型Wilson病に対し待機的に脳死肝移植を施行した1例
    和久井 洋佑; 後藤 了一; 渡辺 正明; 川村 典生; 小川 浩司; 三橋 智子; 嶋村 剛; 武冨 紹信
    日本消化器病学会雑誌, 119, 12, 1096, 1102, (一財)日本消化器病学会, Dec. 2022
    Japanese
  • 肝移植後の急性拒絶反応によるグラフト不全から回復した2例
    磯川 真里奈; 後藤 了一; 太田 拓児; 武冨 紹信; 川村 典生; 渡辺 正明; 嶋村 剛
    北海道外科雑誌, 67, 2, 183, 184, 北海道外科学会, Dec. 2022
    Japanese
  • 新型コロナウイルス感染蔓延下での長期待機後に脳死肝腎同時移植を実施した末期原発性硬化性胆管炎の1例
    植林 毅行; 後藤 了一; 山口 将功; 伊藤 啓一郎; 津坂 翔一; 原田 拓弥; 太田 拓児; 川村 典生; 渡辺 正明; 増谷 祥; 秋山 久; 田邉 起; 堀田 記世彦; 篠原 信雄; 嶋村 剛; 武冨 紹信
    日本臨床外科学会雑誌, 83, 10, 1839, 1840, 日本臨床外科学会, Oct. 2022
    Japanese
  • 生体肝移植後に発生した膵充実性偽乳頭腫瘍(Solid pseudopapillary neoplasm of pancreas,SPNP)に対し核出術を施行した1例
    津坂 翔一; 川村 典生; 植林 毅行; 竹元 小乃美; 原田 拓弥; 太田 拓児; 渡辺 正明; 後藤 了一; 蒲池 浩文; 神山 俊哉; 嶋村 剛; 武冨 紹信
    日本臨床外科学会雑誌, 83, 10, 1840, 1840, 日本臨床外科学会, Oct. 2022
    Japanese
  • 肝癌治療における肝移植の役割 Japan criteria導入後の変化と現状
    渡辺 正明; 嶋村 剛; 後藤 了一; 川村 典生; 太田 拓児; 武冨 紹信
    日本癌治療学会学術集会抄録集, 60回, OF, 6, (一社)日本癌治療学会, Oct. 2022
    English
  • 肝癌に対する肝移植の新基準の適応状況 肝癌治療における肝移植の役割 Japan criteria導入後の変化と現状
    渡辺 正明; 嶋村 剛; 後藤 了一; 川村 典生; 太田 拓児; 武冨 紹信
    移植, 57, 総会臨時, 213, 213, (一社)日本移植学会, Oct. 2022
    Japanese
  • 肝移植後小児レシピエントに対する弱毒性ワクチン投与
    渡辺 正明; 嶋村 剛; 後藤 了一; 川村 典生; 太田 拓児; 武冨 紹信
    移植, 57, 総会臨時, 329, 329, (一社)日本移植学会, Oct. 2022
    Japanese
  • 生体肝移植ドナー長期経過後脂肪肝発生リスク因子の検討
    後藤 了一; 嶋村 剛; 太田 拓児; 川村 典生; 渡辺 正明; 武冨 紹信
    移植, 57, 総会臨時, 379, 379, (一社)日本移植学会, Oct. 2022
    Japanese
  • 肝細胞癌に対する肝移植 Japan criteria導入後の肝細胞癌に対する肝移植の現状と今後の課題
    渡辺 正明; 嶋村 剛; 藤吉 真人; 後藤 了一; 川村 典生; 武冨 紹信
    日本臨床外科学会雑誌, 83, 増刊, S124, S124, 日本臨床外科学会, Oct. 2022
    Japanese
  • 肝移植後の長期成績 生体ドナー術前Fib-4 indexの長期予後に及ぼす影響
    川村 典生; 嶋村 剛; 後藤 了一; 渡辺 正明; 太田 拓児; 武冨 紹信
    日本臨床外科学会雑誌, 83, 増刊, S125, S125, 日本臨床外科学会, Oct. 2022
    Japanese
  • 生体肝移植ドナー長期経過後脂肪肝発生リスク因子の検討
    後藤 了一; 嶋村 剛; 太田 拓児; 川村 典生; 渡辺 正明; 武冨 紹信
    移植, 57, 総会臨時, 379, 379, (一社)日本移植学会, Oct. 2022
    Japanese
  • Impact of sustained viral response for hepatitis C virus on the outcomes of liver transplantation in hemophilic patients with human immunodeficiency virus/hepatitis C virus co-infection: A nationwide survey in Japan.
    Masaaki Hidaka; Susumu Eguchi; Kiyoshi Hasegawa; Tsuyoshi Shimamura; Etsuro Hatano; Hideki Ohdan; Taizo Hibi; Yasushi Hasegawa; Junichi Kaneko; Ryoichi Goto; Hiroto Egawa; Hidetoshi Eguchi; Kunihisa Tsukada; Hiroshi Yotsuyanagi; Akihiko Soyama; Takanobu Hara; Mitsuhisa Takatsuki
    Hepatology research : the official journal of the Japan Society of Hepatology, 24 Aug. 2022, [International Magazine]
    English, Scientific journal, AIM: Human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infection from blood products for hemophilia has been a social problem in Japan, and liver transplantation (LT) for these patients has been a challenging procedure. However, with the advent of the direct-acting antiviral agent for HCV and change in the policy for prioritization of deceased donor LT, the results of LT for patients co-infected with HCV/HIV may have improved. METHODS: This study was conducted to provide updated results of our nationwide survey of LT for patients co-infected with HCV/HIV, from January 1997 to December 2019. We collected data on 17 patients with HIV/HCV co-infection who underwent either deceased donor LT (n = 5) or living donor LT (n = 12). RESULTS: All the patients were men with hemophilia, and the median age was 41 (range, 23-61) years. The median CD4 count before LT was 258 (range, 63-751). Most patients had poor liver function before surgery with Child-Pugh grade C and a Model for End-stage Liver Disease score of 20 (range, 11-48). The right lobe was used for most grafts for living donor liver transplantation (n = 10). Overall survival was significantly better with a sustained viral response (SVR) than without an SVR, and a univariate analysis indicated that SVR after direct-acting antiviral or interferon/ribavirin showed the highest hazard ratio for patient survival after LT. A multivariate analysis was not possible because of the limited number of cases. CONCLUSION: SVR for HCV showed the highest impact on the outcome of LT for patients with hemophilia co-infected with HIV/HCV. SVR for HCV should be achieved before or after LT for patients with hemophilia co-infected with HIV/HCV for a better outcome.
  • Efficient multiple treatments including molecular targeting agents in a case of recurrent hepatocellular carcinoma, post-living donor liver transplantation.
    Reimi Suzuki; Ryoichi Goto; Norio Kawamura; Masaaki Watanabe; Yoshikazu Ganchiku; Kanako C Hatanaka; Yutaka Hatanaka; Toshiya Kamiyama; Tsuyoshi Shimamura; Akinobu Taketomi
    Clinical journal of gastroenterology, 15, 4, 755, 764, Aug. 2022, [Domestic magazines]
    English, Scientific journal, Despite the promising efficacies of recently developed molecular targeting therapies for hepatocellular carcinoma, their role in liver transplantation is unknown. Here we report that multidisciplinary treatment, including novel molecular targeting therapy with lenvatinib, achieved long-term survival of a patient with post-liver transplantation recurrence of hepatocellular carcinoma. A 62 year-old man with hepatocellular carcinoma beyond the Milan criteria, arising from hepatitis B virus-associated cirrhotic liver, underwent living donor liver transplantation. However, alpha-fetoprotein level increased a month post-transplantation, and pleural dissemination and lung metastasis of hepatocellular carcinoma in the right lung were detected. The patient was initially treated with sorafenib and rapamycin, right pleurectomy and upper and middle lobectomies were attempted as the second treatment. However, remnant tumors started to grow. Subsequently, the newly molecular targeting agents; regorafenib and lenvatinib, approved for recurrent hepatocellular carcinoma in Japan, were administered. Lenvatinib efficiently reduced tumor volumes and the alpha-fetoprotein level, which contributed to maintaining better quality of life for 26 months as an outpatient. Unfortunately, sepsis caused by cholangitis and liver abscess required the discontinuation of lenvatinib, and the patient died 73 months after the recurrence of hepatocellular carcinoma. Multidisciplinary treatment including lenvatinib is potentially acceptable for recurrent hepatocellular carcinoma after liver transplantation.
  • No impact of donor sex on the recurrence of hepatocellular carcinoma after liver transplantation.
    Kojiro Taura; Tsuyoshi Shimamura; Nobuhisa Akamatsu; Koji Umeshita; Masato Fujiyoshi; Hiroyasu Abe; Satoshi Morita; Shinji Uemoto; Susumu Eguchi; Hiroyuki Furukawa; Yasutsugu Takada; Hiroto Egawa; Hideki Ohdan; Etsuro Hatano
    Journal of hepato-biliary-pancreatic sciences, 29, 5, 570, 584, Wiley, May 2022, [Domestic magazines]
    English, Scientific journal, BACKGROUND/PURPOSE: We aimed to verify a recent theory that female donors reduced the risk of hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT). METHODS: A total of 1118 recipients registered in the Japanese Liver Transplantation Society database were evaluated for HCC, of whom 446 received a graft from female donors (F-D group) and 672 from male donors (M-D group). RESULTS: Between the groups, donor age, recipient age and sex, positivity of hepatitis viruses, and graft type were different, whereas tumor-related factors were all comparable. The 5-year overall recurrence rates were 14% and 16% in the F-D and M-D groups, respectively (P = 0.59). The 5-year graft recurrence rate was also comparable between the groups (4% and 6%, respectively, P = 0.17). Neither univariate nor multivariate analysis identified donor sex as a significant risk factor for recurrence. Propensity score matching showed similar 5-year overall recurrence rates (15% in the F-D group and 14% in the M-D group, P = 0.63) and graft recurrence rates (5% and 5%, respectively, P = 0.94) between the groups. CONCLUSION: Donor sex did not affect post-LT recurrence of HCC in the Japanese cohort and should not be considered in the process of donor selection or organ allocation.
  • 肝細胞癌に対するsalvage liver transplantationの適応検討
    川村 典生; 嶋村 剛; 後藤 了一; 渡辺 正明; 巖築 慶一; 神山 俊哉; 武冨 紹信
    日本外科学会定期学術集会抄録集, 122回, SF, 2, (一社)日本外科学会, Apr. 2022
    Japanese
  • アロ感作マウスを用いた異所性アロ心移植に対する抗CD3F(ab')2の効果の検討
    太田 拓児; 後藤 了一; 原田 拓弥; アグスティーナ・フォルジオニ; 巖築 慶一; 川村 典生; 渡辺 正明; 深井 原; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 122回, SF, 1, (一社)日本外科学会, Apr. 2022
    Japanese
  • マウスにおける抗CD80/86抗体で誘導した抑制性T細胞の検討
    原田 拓弥; 後藤 了一; Agustina Forgioni; 太田 拓児; 巖築 慶一; 渡辺 正明; 川村 典生; 深井 原; 内田 浩一郎; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 122回, DP, 8, (一社)日本外科学会, Apr. 2022
    Japanese
  • 肝移植後小児レシピエントに対する弱毒生ワクチン投与
    渡辺 正明; 後藤 了一; 川村 典生; 巌築 慶一; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 122回, DP, 3, (一社)日本外科学会, Apr. 2022
    Japanese
  • 生体肝移植で治療し得た肝内門脈肝静脈シャントの1例
    津坂 翔一; 巌築 慶一; 川村 典夫; 渡辺 正明; 後藤 了一; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 122回, RS, 5, (一社)日本外科学会, Apr. 2022
    Japanese
  • 非アルコール性脂肪肝炎、非代償性肝硬変のhigh MELD例に実施した脳死肝移植の一例
    中村 恒星; 後藤 了一; 巖築 慶一; 川村 典生; 渡辺 正明; 森川 賢一; 小川 浩司; 坂本 直哉; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 122回, RS, 2, (一社)日本外科学会, Apr. 2022
    Japanese
  • 生体肝移植後、膵頭部に生じたSolid pseudopapillary neoplasmに核出術を施行した1例
    津坂 翔一; 荒 桃子; 河北 一誠; 川村 典生; 渡辺 正明; 後藤 了一; 本多 昌平; 蒲池 浩文; 神山 俊哉; 嶋村 剛; 武冨 紹信
    日本小児外科学会雑誌, 58, 3, 410, 410, (一社)日本小児外科学会, Apr. 2022
    Japanese
  • 3,5-dihydroxy-4-methoxybenzyl alcohol(DHMBA)は心筋細胞の冷保存傷害を軽減する
    深井 原; 大谷 晋太郎; 千葉 仁志; 惠 淑萍; 坂本 聡大; 柴田 賢吾; 石川 隆壽; 川村 典生; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 122回, SF, 8, (一社)日本外科学会, Apr. 2022
    Japanese
  • 3,5-dihydroxy-4-methoxybenzyl alcohol(DHMBA)は心筋細胞の冷保存傷害を軽減する
    深井 原; 大谷 晋太郎; 千葉 仁志; 惠 淑萍; 坂本 聡大; 柴田 賢吾; 石川 隆壽; 川村 典生; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 122回, SF, 8, (一社)日本外科学会, Apr. 2022
    Japanese
  • 巨大な肝内門脈肝静脈短絡を伴った自己免疫性肝硬変に対する生体肝移植
    津坂 翔一; 巌築 慶一; 川村 典生; 渡辺 正明; 後藤 了一; 嶋村 剛; 武冨 紹信
    日本臨床外科学会雑誌, 83, 3, 602, 602, 日本臨床外科学会, Mar. 2022
    Japanese
  • 肝移植適応疾患の病態解明と診療展開 当院におけるNASH肝硬変肝移植後NASH、NAFLD再発の検討
    後藤 了一; 嶋村 剛; 武冨 紹信
    日本消化器病学会雑誌, 119, 臨増総会, A218, A218, (一財)日本消化器病学会, Mar. 2022
    Japanese
  • National survey of hepatobiliary and pancreatic surgery in hemophilia patients in Japan.
    Tomoko Yoshimoto-Haramura; Masaaki Hidaka; Kiyoshi Hasegawa; Kazuhiro Suzumura; Nobuyuki Takemura; Naoki Hama; Takashi Mizuno; Takeo Nomi; Tsuyoshi Kobayashi; Keiji Sano; Hiroshi Yokomizo; Hiroyuki Nitta; Masanao Kurata; Yasushi Hasegawa; Minoru Nagayama; Masaji Tani; Takumi Fukumoto; Masayuki Ohta; Hironori Hayashi; Hiroki Taniguchi; Shinichiro Ishino; Tsukasa Aihara; Takaaki Murase; Akihiko Tsuchida; Tsuyoshi Shimamura; Shigeru Marubashi; Junichi Kaneko; Takanobu Hara; Hajime Matsushima; Akihiko Soyama; Tomoyuki Endo; Susumu Eguchi
    Journal of hepato-biliary-pancreatic sciences, 29, 3, 385, 393, Mar. 2022, [Domestic magazines]
    English, Scientific journal, BACKGROUND: Approximately 8300 hemophiliacs are registered in Japan, but no comprehensive reports on hepatobiliary and pancreatic surgery (HBPS) have been conducted. This report investigates the current status of HPBS in hemophilia patients in Japan. METHODS: The subjects were hemophiliac patients seen between January 1 2007, and December 31 2017, at facilities participating in this study among the facilities for performing high-difficulty cases nationwide designated by the Japanese Society for HBPS. A retrospective examination of short-term outcomes in 49 cases was conducted to assess patient background, disease, surgical procedure, and complications. RESULTS: The types of hemophilia were A: 43 cases, B: four cases, and von Willebrand disease: two cases (hemophilia severity: mild 32, moderate seven, severe 10). The target malignant diseases for surgery were hepatocellular carcinoma (HCC) in 20 cases, intrahepatic cholangiocellular carcinoma (CCC) in four cases, combined HCC-CCC in two cases, hilar CCC in two cases, and pancreatic cancer in four cases. As for the surgical procedure, limited resection (subsegmentectomy and partial hepatectomy) was performed in 16 cases of HCC even with normal liver function tests. Pancreaticoduodenectomy and distal pacreatectomy were performed for pancreatic cancers as in the standard procedure. Postoperative complications were postoperative bleeding in two cases after hepatectomy and one after pancreatectomy in one case. When compared with Japanese National Clinical Data base, the complication rates after hepatectomy and pancreatectomy were not conspicuous in hemophilic patients. CONCLUSIONS: As long as they are performed in qualified centers, complication rate is not increased in hemophilic patients undergoing HBPS.
  • The impact of preformed donor-specific antibodies in living donor liver transplantation according to graft volume.
    Ryoichi Goto; Makoto Ito; Norio Kawamura; Masaaki Watanabe; Yoshikazu Ganchiku; Toshiya Kamiyama; Tsuyoshi Shimamura; Akinobu Taketomi
    Immunity, inflammation and disease, 10, 3, e586, Wiley, Mar. 2022, [International Magazine]
    English, Scientific journal, INTRODUCTION: The roles of preformed anti-HLA donor-specific antibodies (DSAs) in liver transplantation remain controversial. We evaluated the impact of preformed DSAs in living donor liver transplantation. METHODS: Adults who underwent living donor liver transplantation (n = 175) in our institute were included in this study. Lymphocyte cytotoxicity test (LCT), flow cytometric crossmatch (FCXM), and single-antigen bead assays were performed. RESULTS: Among adult living donor liver transplantation recipients, 27 (16.5%) and 14 (8.5%) had pretransplant FCXM-positive findings and LCT-positive findings, respectively. FCXM-positive patients displayed a significantly worse 5-year graft survival rate (77.3%; vs. DSA-negative, 91.6%). Six of 14 LCT-positive patients exhibited graft loss shortly after transplantation (5-year survival rate: 57.1%). All LCT-positive patients with graft loss underwent left lobe living donor liver transplantation. Significantly lower ratio of graft volume relative to standard liver volume (32.9 ± 5.7%) and smaller graft size (365.3 ± 57.9 g) were observed in patients with graft loss (p < .03, vs. surviving grafts). Significantly higher DSA-mean fluorescence intensity (MFI) values were present in patients with graft loss (p = .0012, vs. surviving grafts). CONCLUSIONS: Patients with preformed DSAs exhibited worse graft outcomes in living donor liver transplantation. Higher DSA-MFI values and smaller graft size were associated with worse outcomes in LCT-positive patients. High-risk patients with preformed DSAs should be considered for appropriate graft selection and application of a desensitization protocol.
  • Liver Transplantation for Hepatocellular Carcinoma: How Should We Improve the Thresholds?
    Tsuyoshi Shimamura; Ryoichi Goto; Masaaki Watanabe; Norio Kawamura; Yasutsugu Takada
    Cancers, 14, 2, 14 Jan. 2022, [International Magazine]
    English, Scientific journal, Hepatocellular carcinoma (HCC) is the third highest cause of cancer-related mortality, and liver transplantation is the ideal treatment for this disease. The Milan criteria provided the opportunity for HCC patients to undergo LT with favorable outcomes and have been the international gold standard and benchmark. With the accumulation of data, however, the Milan criteria are not regarded as too restrictive. After the implementation of the Milan criteria, many extended criteria have been proposed, which increases the limitations regarding the morphological tumor burden, and incorporates the tumor's biological behavior using surrogate markers. The paradigm for the patient selection for LT appears to be shifting from morphologic criteria to a combination of biologic, histologic, and morphologic criteria, and to the establishment of a model for predicting post-transplant recurrence and outcomes. This review article aims to characterize the various patient selection criteria for LT, with reference to several surrogate markers for the biological behavior of HCC (e.g., AFP, PIVKA-II, NLR, 18F-FDG PET/CT, liquid biopsy), and the response to locoregional therapy. Furthermore, the allocation rules in each country and the present evidence on the role of down-staging large tumors are addressed.
  • [Successful treatment of a fulminant-type Wilson's disease with deceased donor liver transplantation after recovery from critical illness].
    Yosuke Wakui; Ryoichi Goto; Masaaki Watanabe; Norio Kawamura; Koji Ogawa; Tomoko Mitsuhashi; Tsuyoshi Shimamura; Akinobu Taketomi
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 119, 12, 1096, 1102, 2022, [Domestic magazines]
    Japanese, Scientific journal, A 15-year-old female patient was diagnosed with a fulminant-type Wilson's disease. She had severe illness with a Model for End-Stage Liver Disease score of 25 and new Wilson Index score of 11. She underwent plasma exchanges, hemodiafiltration, and administration of fresh frozen plasma on consecutive days. Finally, she had recovered from severe illness and was discharged from the hospital. After 18 months of waiting time, she underwent deceased liver transplantation and returned to normal daily life. In Japan, the critical shortage of donated organs requires a long waiting time. Previous studies demonstrated that artificial liver support systems, including plasma exchange and hemodiafiltration, could be useful for a fulminant-type Wilson's disease. For such a disease, multidisciplinary bridging treatments are crucial for a successful liver transplantation.
  • Living Donor Liver Transplantation for Hepatic Venoocclusive Disease/Sinusoidal Obstruction Syndrome Originating from Hematopoietic Stem Cell Transplantation.
    Kentaro Ichimura; Norio Kawamura; Ryoichi Goto; Masaaki Watanabe; Yoshikazu Ganchiku; Tsuyoshi Shimamura; Akinobu Taketomi
    Case reports in transplantation, 2022, 8361769, 8361769, 2022, [International Magazine]
    English, Background: Venoocclusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is a life-threatening hematopoietic stem cell transplantation (HSCT) complication. Cases of mild and moderate VOD/SOS are self-limiting; however, the mortality for severe VOD/SOS has reached 80%. Recently, defibrotide became available and has been used for VOD/SOS; however, the outcome for patients with severe VOD/SOS is not satisfactory, and liver transplantation is attempted in these severe cases. Method: We describe a case of living donor liver transplantation (LDLT) for acute liver failure secondary to VOD/SOS that originates from HSCT. Result: Liver regeneration after LDLT was impaired, and several infections were developed before liver regeneration completion. Our patient suffered sepsis and finally died of multiorgan failure. Conclusion: Severe VOD/SOS originating from HSCT is associated with a very poor prognosis. The liver transplantation outcome for VOD/SOS has not been satisfied, but it may provide long-term survival if successful. We considered liver transplantation as a therapeutic option, especially in cases where sufficient graft volume is secured, considering impaired liver regeneration under bone marrow suppression after HSCT.
  • 肝癌に対する肝移植の新たな適応基準に基づいた治療成績 肝細胞癌治療における肝移植の役割 Japan criteria導入後に予想される変化
    渡辺 正明; 後藤 了一; 川村 典生; 巌築 慶一; 嶋村 剛; 武冨 紹信
    日本臨床外科学会雑誌, 82, 増刊, S166, S166, 日本臨床外科学会, Oct. 2021
    Japanese
  • 脂肪肝の温阻血再灌流傷害に伴うリゾフォスファチジルイノシトールの変動と局在変化 イメージング質量分析による網羅的解析
    柴田 賢吾; 橋本 咲月; 早坂 孝宏; 深井 原; 島田 慎吾; 三野 和宏; 嶋村 剛; 武冨 紹信
    日本消化器病学会雑誌, 118, 臨増大会, A702, A702, (一財)日本消化器病学会, Oct. 2021
    Japanese
  • 移植後de novo発がんに関する諸問題 本邦の多施設共同研究による生体肝移植後グラフト肝に発生するde novo HCCのリスク因子の検討
    後藤 了一; 八木 真太郎; 小斉 侑希子; 嶋村 剛; 大段 秀樹; 島田 光生; 小倉 靖弘; 長谷川 潔; 吉住 朋晴; 前原 喜彦; 武冨 紹信
    日本臨床外科学会雑誌, 82, 増刊, S233, S233, 日本臨床外科学会, Oct. 2021
    Japanese
  • 肝移植後小児レシピエントに対する弱毒生ワクチン投与
    渡辺 正明; 後藤 了一; 川村 典生; 巌築 慶一; 嶋村 剛; 武冨 紹信
    移植, 56, 総会臨時, O12, 5, (一社)日本移植学会, Sep. 2021
    Japanese
  • 肝移植におけるABO不適合・抗体関連拒絶への対策 小児生体肝移植後de novo抗ドナー抗体陽性の線維化進行リスク因子の検討
    後藤 了一; 巖築 慶一; 川村 典生; 渡辺 正明; 長津 明久; 神山 俊哉; 嶋村 剛; 武冨 紹信
    移植, 56, 総会臨時, SSY7, 3, (一社)日本移植学会, Sep. 2021
    Japanese
  • 肝移植後にPleuroparenchymal fibroelastosis(PPFE)合併肺癌を発症した一例
    大塚 慎也; 加藤 達哉; 氏家 秀樹; 椎谷 洋彦; 加賀 基知三; 若狭 哲; 中村 順一; 中久保 祥; 木村 孔一; 渡辺 正明; 嶋村 剛; 岡崎 ななせ; 松野 吉宏; 田中 敏
    移植, 56, 総会臨時, P2, 7, (一社)日本移植学会, Sep. 2021
    Japanese
  • Indications and waiting list priority for deceased donor liver transplantation in HIV/HCV co-infected hemophilic patients in Japan through contaminated blood product.
    Susumu Eguchi; Hiroto Egawa; Hidetoshi Eguchi; Tomoko Uehira; Tomoyuki Endo; Takuya Genda; Masahiro Shinoda; Kiyoshi Hasegawa; Tsuyoshi Shimamura; Kunihisa Tsukada; Tetsuya Hara; Kazuhiko Nakao; Hiroshi Yatsuhashi; Hiroshi Yotsuyanagi; Koji Natsuda; Akihiko Soyama; Masaaki Hidaka; Takanobu Hara; Mitsuhisa Takatsuki
    Hepatology research : the official journal of the Japan Society of Hepatology, 51, 8, 909, 914, Aug. 2021, [International Magazine]
    English, Scientific journal, HIV/HCV co-infection from blood products for hemophilia has been a social problem in Japan. Liver transplantation (LT) is an important treatment option for hepatic failure and cirrhosis of the liver in co-infected patients, and appropriate indications for LT, especially organ form deceased donors, are required by society. The aim is to propose priority status for the waiting list for deceased donor (DD) LT in HIV/HCV co-infected patients in Japan based on medical and scientific considerations. Since 2009, we have been working on the subject in research projects under grants-in-aid for health and labour sciences research on AIDS measures provided by the Ministry of Health, Labour and Welfare (the Kanematsu project and Eguchi project). Our research showed that hepatic fibrosis is advanced in HIV/HCV co-infected Japanese patients, especially those with hemophilia who became infected from blood products at a faster rate than HCV mono-infected patients. In addition, those patients who developed portal hypertension had a poor prognosis at a young age. The results of our research contributed to increasing the priority score of those patients on the deceased donor liver transplantation (DDLT) waiting list in 2013 and to establishing a scoring system for DDLT corresponding to the Model for End-stage Liver disease (MELD) score in 2019. This paper introduces changes in priority and the current state of priority of the DDLT waiting list for HIV/HCV co-infected patients in Japan.
  • 本邦膵臓移植症例におけるrituximab(遺伝子組換え)に関する使用実態調査の結果 膵移植後rituximab使用4症例の報告
    伊藤 泰平; 剣持 敬; 栗原 啓; 會田 直弘; 後藤 了一; 渡辺 正明; 嶋村 剛; 武冨 紹信; 大島 稔; 岡野 圭一; 鈴木 康之; 中川 健; 江川 裕人
    移植, 56, 1, 35, 42, (一社)日本移植学会, Jul. 2021
    Japanese, 膵移植後に抗体関連型拒絶反応(AMR)を発現し、rituximabを使用した4例を報告した。移植時年齢は30歳代から50歳代で、男女各2例であった。AMRは移植後40日目から143日目に診断され、rituximabは拒絶反応発現から最短で1日、最長で20日に1回投与されていた。投与量は81mg/bodyが1例、200mg/bodyが3例で、AMR治療後の膵グラフト生着は1例(25%)で得られていた。有害事象としてはサイトメガロウイルス抗原血症による感染症が1例、骨髄抑制が2例で認められたが、いずれも回復し、患者生命予後に影響を与える有害事象はみられなかった。
  • 本邦膵臓移植症例におけるrituximab(遺伝子組換え)に関する使用実態調査の結果 膵移植後rituximab使用4症例の報告
    伊藤 泰平; 剣持 敬; 栗原 啓; 會田 直弘; 後藤 了一; 渡辺 正明; 嶋村 剛; 武冨 紹信; 大島 稔; 岡野 圭一; 鈴木 康之; 中川 健; 江川 裕人
    移植, 56, 1, 35, 42, (一社)日本移植学会, Jul. 2021
    Japanese
  • A case report of percutaneous direct injection of N-butyl-2-cyanoacrylate (NBCA) to treat a pancreatic duodenal stump leak after a simultaneous pancreas and kidney transplantation.
    Chisato Shirakawa; Masaaki Watanabe; Tsuyoshi Shimamura; Yasuyuki Koshizuka; Norio Kawamura; Ryoichi Goto; Takeshi Soyama; Daiki Iwami; Kiyohiko Hotta; Akinobu Taketomi; Daisuke Abo
    Surgical case reports, 7, 1, 139, 139, Springer Science and Business Media LLC, 08 Jun. 2021, [International Magazine]
    English, Scientific journal, Abstract
    Background
    Simultaneous pancreas and kidney transplantation (SPK) is a treatment option for patients with end-stage renal disease due to type 1 diabetes mellitus. We report a patient with a refractory fistula due to leakage from the duodenal stump of the pancreas graft after an SPK with bladder drainage who was successfully treated with a percutaneous direct injection of N-butyl-2-cyanoacrylate (NBCA).



    Case presentation
    A 60-year-old female with a 33-year history of type 1 diabetes mellitus and a 10-year history of renal replacement therapy underwent an SPK in 2015. At the time of transplantation, an abdominal aortic aneurysm with a high risk of rupture was treated by a Y-graft replacement prior to the SPK. Bladder drainage of the pancreas graft was chosen to avoid a vessel graft infection. The patient’s postoperative course was uneventful. The patient was discharged on postoperative day 93 with good-functioning pancreas and kidney grafts. One and a half years after the operation, the patient was found to have acute graft pancreatitis and a leak from the duodenal stump of the pancreas graft due to a paralytic neurogenic bladder. The insertion of an indwelling catheter into the bladder and the endoscopic-guided insertion of a catheter into the graft pancreatic duct through the duodenum/bladder anastomosis did not result in the closure of the fistula. Therefore, NBCA was injected at the site of the leak point using CT-guided technique. The fistula was completely closed immediately after the injection, with no recurrences of leaks.



    Conclusions
    A percutaneous direct injection of NBCA is one of the treatment options to treat intractable fistulas.


  • The Phenolic Antioxidant 3,5-dihydroxy-4-methoxybenzyl Alcohol (DHMBA) Prevents Enterocyte Cell Death under Oxygen-Dissolving Cold Conditions through Polyphyletic Antioxidant Actions.
    Moto Fukai; Takuya Nakayabu; Shintaro Ohtani; Kengo Shibata; Shingo Shimada; Soudai Sakamoto; Hirotoshi Fuda; Takayuki Furukawa; Mitsugu Watanabe; Shu-Ping Hui; Hitoshi Chiba; Tsuyoshi Shimamura; Akinobu Taketomi
    Journal of clinical medicine, 10, 9, 04 May 2021, [International Magazine]
    English, Scientific journal, Cold preservation in University of Wisconsin (UW) solution is not enough to maintain the viability of the small intestine, due to the oxidative stress. The novel phenolic antioxidant 3,5-dihydroxy-4-methoxybenzyl alcohol (DHMBA) has dual properties to reduce oxidative stress, radical scavenging, and antioxidant protein induction, in other cells. This study was designed to determine whether DHMBA reduces cold preservation injury of enterocytes, and to identify the effector site. Enterocytes were subjected to 48-h cold preservation under atmosphere in UW solution (±DHMBA), and then returned to normal culture to replicate reperfusion of the small intestine after cold preservation. At the end of cold preservation (ECP) and at 1, 3, 6, and 72 h after rewarming (R1h, R3h, R6h, and R72h), we evaluated cell function and the injury mechanism. The results showed that DHMBA protected mitochondrial function mainly during cold preservation, and suppressed cell death after rewarming, as shown by the MTT, ATP, mitochondrial membrane potential, LDH, and lipid peroxidation assays, together with enhanced survival signals (PI3K, Akt, p70S6K) and induction of antioxidant proteins (HO-1, NQO-1, TRX-1). We found that DHMBA mitigates the cold-induced injury of enterocytes by protecting the mitochondria through direct and indirect antioxidative activities.
  • 門脈還流異常症に対する治療適応時期 術後に肺高血圧症を発症した症例の経験から
    本多 昌平; 荒 桃子; 奥村 一慶; 近藤 享史; 河北 一誠; 後藤 了一; 辻岡 孝郎; 武田 充人; 嶋村 剛; 神山 俊哉; 武冨 紹信
    日本小児外科学会雑誌, 57, 2, 323, 323, (一社)日本小児外科学会, Apr. 2021
    Japanese
  • 肝・膵移植における最新の進歩と課題 脾摘の生体肝移植短期予後に及ぼす影響の検討
    川村 典生; 嶋村 剛; 後藤 了一; 渡辺 正明; 巖築 慶一; 長津 明久; 神山 俊哉; 武冨 紹信
    日本外科学会定期学術集会抄録集, 121回, SY, 1, (一社)日本外科学会, Apr. 2021
    Japanese
  • 心停止ドナー肝に対する機械灌流における水素ガスの有効性の検討
    坂本 聡大; 柴田 賢吾; 石川 隆壽; 島田 慎吾; 若山 顕治; 藤好 真人; 加藤 紘一; 巖築 慶一; 川村 典生; 渡辺 正明; 後藤 了一; 嶋村 剛; 深井 原; 武冨 紹信
    日本外科学会定期学術集会抄録集, 121回, PS, 4, (一社)日本外科学会, Apr. 2021
    Japanese
  • 生体肝移植後肝細胞癌再発に対し新規分子標的薬を含む集学的治療により長期生存が得られた一例
    鈴木 麗美; 後藤 了一; 巌築 慶一; 川村 典生; 渡辺 正明; 神山 俊哉; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 121回, RS, 5, (一社)日本外科学会, Apr. 2021
    Japanese
  • 肝腎症候群による腎不全併発非代償性肝硬変症例に対する、脳死肝単独と、脳死肝腎同時移植症例の比較検討
    伊藤 栄祐; 渡辺 正明; 渋谷 一陽; 巖築 慶一; 川村 典生; 後藤 了一; 堀田 記世彦; 篠原 信雄; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 121回, RS, 6, (一社)日本外科学会, Apr. 2021
    Japanese
  • 小児領域における他診療科との合同手術 先天性門脈体循環シャントに対するIVR・外科治療戦略
    本多 昌平; 荒 桃子; 奥村 一慶; 近藤 享史; 河北 一誠; 後藤 了一; 阿保 大介; 工藤 與亮; 嶋村 剛; 神山 俊哉; 武冨 紹信
    日本外科学会定期学術集会抄録集, 121回, WS, 5, (一社)日本外科学会, Apr. 2021
    Japanese
  • 肝エキノコックス症に対する下大静脈切除再建を伴う肝切除治療成績
    神山 俊哉; 柿坂 達彦; 折茂 達也; 長津 明久; 旭 よう; 坂本 譲; 蒲池 浩文; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 121回, PS, 1, (一社)日本外科学会, Apr. 2021
    Japanese
  • Incidental intrahepatic cholangiocarcinoma in patients undergoing liver transplantation: A multi-center study in Japan.
    Takanobu Hara; Susumu Eguchi; Tomoharu Yoshizumi; Nobuhisa Akamatsu; Toshimi Kaido; Takashi Hamada; Hiroyuki Takamura; Tsuyoshi Shimamura; Yuzo Umeda; Masahiro Shinoda; Yasuhiro Ogura; Takumi Fukumoto; Mureo Kasahara; Taizo Hibi; Koji Umeshita; Hiroyuki Furukawa; Hideki Ohdan
    Journal of hepato-biliary-pancreatic sciences, 28, 4, 346, 352, Apr. 2021, [Domestic magazines]
    English, Scientific journal, BACKGROUND: Intrahepatic cholangiocarcinoma had been considered a contraindication for liver transplantation because of poorer outcomes. However, incidental intrahepatic cholangiocarcinoma in the explanted liver has been reported because of the difficulty of obtaining an accurate diagnosis in cirrhotic livers on preoperative imaging. METHODS: We conducted a nationwide survey to analyze the incidence of incidental intrahepatic cholangiocarcinoma and outcomes after liver transplantation, in Japan. RESULTS: Forty-five of 64 institutions (70%) responded to our initial investigation. Between January 2001 and December 2015, 6627 liver transplantations were performed in these 45 institutions, with 19 cases (0.3%) of incidental intrahepatic cholangiocarcinoma reported from 12 transplant centers. Six cases were diagnosed as hepatocellular carcinoma preoperatively. The 1-, 3-, and 5-year recurrence-free survival rates were 79%, 45%, and 45%, respectively. Tumor recurrence after liver transplantation was found in 10 patients (53%). The 1-, 3-, and 5-year overall survival rates were 79%, 63%, and 46%, respectively. CONCLUSIONS: Intrahepatic cholangiocarcinoma at liver transplantation is associated with a high risk of recurrence and poor prognosis, even these tumors are detected incidentally in the explanted liver.
  • Triazolopyrimidine derivative NK026680 and donor-specific transfusion induces CD4+CD25+Foxp3+ T cells and ameliorates allograft rejection in an antigen-specific manner.
    Shin Emoto; Susumu Shibasaki; Akihisa Nagatsu; Ryoichi Goto; Hitoshi Ono; Yasutomo Fukasaku; Rumi Igarashi; Takuji Ota; Moto Fukai; Tsuyoshi Shimamura; Kan Saiga; Akinobu Taketomi; Masaaki Murakami; Satoru Todo; Kenichiro Yamashita
    Transplant immunology, 65, 101338, 101338, Apr. 2021, [International Magazine]
    English, Scientific journal, We have previously demonstrated the unique properties of a new triazolopyrimidine derivative, NK026680, which exerts immunosuppressive effects in rat heart transplant model and confers tolerogeneic properties on ex vivo-conditioned dendritic cells in mice. We herein demonstrate that NK026680 promotes the expansion of regulatory T cells (Tregs) with potent immunoregulatory effects when used in combination with donor-specific transfusion (DST). BALB/c (H-2d) heart graft were transplanted into C57BL/6 (H-2b) mice following intravenous injection of donor splenocytes (DST) and oral administration of NK026680. The NK026680 plus DST treatment markedly prolonged the survival time of the donor-graft, but not that of the 3rd party-graft (C3H; H-2k). Treg cells in the recipient spleen on day 0 expanded when stimulated with donor-antigens in vivo and in vitro. After heart transplantation, Treg cells accumulated into the graft and increased in the spleen. NK026680 plus DST also decreased activated CD8+ T cells in the spleen and inhibited infiltration of CD8+ T cells into the graft. Depletion of CD25+ cells inhibited the graft prolonging effect of the NK026680 plus DST treatment. NK026680 administration together with DST induces potent immunoregulatory effects in an antigen-specific manner, likely due to the in vivo generation of donor-specific Tregs.
  • 肝臓のMR弾性造影に関する半自動化定量ソフトウエアの結果の妥当性と再現性に関する研究(Validation and Reproducibility Study on Semi-automatic Quantification Software for MR Elastography of the Liver)
    Katsuumi Yuri; Kamishima Tamotsu; Sugimori Hiroyuki; Shimamura Tsuyoshi; Kawamura Norio; Takeda Hiroshi
    日本放射線技術学会総会学術大会予稿集, 77回, 248, 249, (公社)日本放射線技術学会, Mar. 2021
    English
  • 肝腎症候群を併発した非代償性肝硬変に対する脳死肝腎同時移植
    堀田 記世彦; 渡辺 正明; 川村 典生; 後藤 了一; 田邉 起; 嶋村 剛; 篠原 信雄; 武富 紹信
    日本臨床腎移植学会プログラム・抄録集, 54回, 134, 134, (一社)日本臨床腎移植学会, Feb. 2021
    Japanese
  • Multicenter study on the consciousness-regaining effect of a newly developed artificial liver support system in acute liver failure: An on-line continuous hemodiafiltration system.
    Yasuhiro Takikawa; Keisuke Kakisaka; Yuji Suzuki; Akio Ido; Tsuyoshi Shimamura; Osamu Nishida; Shigeto Oda; Tooru Shimosegawa
    Hepatology research : the official journal of the Japan Society of Hepatology, 51, 2, 216, 226, Feb. 2021, [International Magazine]
    English, Scientific journal, AIM: Acute liver failure (ALF) patients with coma need to be revived not only for spontaneous recovery but also as a bridge to liver transplantation. We developed a new high-volume plasma purification system using an on-line continuous hemodiafiltration (CHDF) system, and evaluated its safety and efficacy in a multicenter study. METHODS: A single arm interventional study using the new apparatus was undertaken in the six major liver centers in Japan. The primary end-point was the proportion of patients who regained consciousness within 10 days, which was compared with a historical control (47%). Nine ALF patients were enrolled and treated with the new machine. One patient was excluded because of the need for artificial respiration support according to the established protocol. RESULTS: Seven of eight (87.5%) patients regained consciousness during the on-line CHDF session, with five of those seven waking within 4 days. After waking, one patient spontaneously recovered, three received liver transplantation, two died of liver failure, and one died of another disease. The plasma ammonia levels significantly decreased after the start of on-line CHDF from 182.5 ± 64.8 μg/dL (mean ± SD) on day 0 to 87.0 ± 38.9 μg/dL on the last day of the session (P < 0.001). Similarly, the plasma glutamine level also significantly decreased from 2069 ± 1234 μmol/L to 628 ± 193 μmol/L. Although seven severe adverse events occurred during on-line-CHDF, no causal relationship with liver support was recognized. CONCLUSIONS: The newly developed on-line CHDF system showed high efficacy for regain of consciousness and excellent therapeutic safety for managing ALF.
  • 肝腎症候群を併発した非代償性肝硬変に対する脳死肝腎同時移植
    堀田 記世彦; 渡辺 正明; 川村 典生; 後藤 了一; 田邉 起; 嶋村 剛; 篠原 信雄; 武富 紹信
    日本臨床腎移植学会プログラム・抄録集, 54回, 134, 134, (一社)日本臨床腎移植学会, Feb. 2021
    Japanese
  • 生体肝ドナー術中所見により、生体肝移植術を断念した8例の検討
    川村 典生; 後藤 了一; 渡辺 正明; 巖築 慶一; 長津 明久; 神山 俊哉; 嶋村 剛; 武冨 紹信
    日本消化器外科学会総会, 75回, P224, 1, (一社)日本消化器外科学会, Dec. 2020
    Japanese
  • HEVによる昏睡型急性肝不全症例についての検討
    腰塚 靖之; 川村 典生; 渡辺 正明; 後藤 了一; 太田 稔; 山下 健一郎; 武冨 紹信; 嶋村 剛
    肝臓, 61, 12, 750, 750, (一社)日本肝臓学会, Dec. 2020
    Japanese
  • 原発性胆汁性胆管炎による非代償性肝硬変、腎不全に対し脳死下肝腎同時移植を実施した一例
    山本 啓一朗; 後藤 了一; 深澤 拓夢; 巖築 慶一; 川村 典生; 渡辺 正明; 小川 浩司; 堀田 記世彦; 岩見 大基; 篠原 信雄; 嶋村 剛; 武冨 紹信
    北海道外科雑誌, 65, 2, 158, 163, 北海道外科学会, Dec. 2020
    Japanese
  • HEVによる昏睡型急性肝不全症例についての検討
    腰塚 靖之; 川村 典生; 渡辺 正明; 後藤 了一; 太田 稔; 山下 健一郎; 武冨 紹信; 嶋村 剛
    肝臓, 61, 12, 750, 750, (一社)日本肝臓学会, Dec. 2020
    Japanese
  • 生体肝ドナー術中所見により、生体肝移植術を断念した8例の検討
    川村 典生; 後藤 了一; 渡辺 正明; 巖築 慶一; 長津 明久; 神山 俊哉; 嶋村 剛; 武冨 紹信
    日本消化器外科学会総会, 75回, P224, 1, (一社)日本消化器外科学会, Dec. 2020
    Japanese
  • 原発性胆汁性胆管炎による非代償性肝硬変、腎不全に対し脳死下肝腎同時移植を実施した一例
    山本 啓一朗; 後藤 了一; 深澤 拓夢; 巖築 慶一; 川村 典生; 渡辺 正明; 小川 浩司; 堀田 記世彦; 岩見 大基; 篠原 信雄; 嶋村 剛; 武冨 紹信
    北海道外科雑誌, 65, 2, 158, 163, 北海道外科学会, Dec. 2020
    Japanese
  • De novo hepatocellular carcinoma in living donor liver grafts: A Japanese multicenter experience.
    Ryoichi Goto; Yukiko Kosai-Fujimoto; Shintaro Yagi; Tsuyoshi Kobayashi; Nobuhisa Akamatsu; Tsuyoshi Shimamura; Satoru Imura; Satoshi Ogiso; Shugo Mizuno; Mitsuhisa Takatsuki; Takasuke Fukuhara; Tatsuya Kanto; Susumu Eguchi; Katsuhiko Yanaga; Yasuhiro Ogura; Takumi Fukumoto; Mitsuo Shimada; Kiyoshi Hasegawa; Hideki Ohdan; Shinji Uemoto; Yuji Soejima; Toru Ikegami; Tomoharu Yoshizumi; Akinobu Taketomi; Yoshihiko Maehara
    Hepatology research : the official journal of the Japan Society of Hepatology, 50, 12, 1365, 1374, Dec. 2020, [International Magazine]
    English, Scientific journal, AIM: Direct-acting antivirals for hepatitis C virus have reduced the decompensation risk. Immunosuppressants for transplantation raise the risk of occurrence of de novo malignancies. We assessed the probabilities of and risk factors for de novo hepatocellular carcinoma (HCC) development post-living donor liver transplantation (LDLT). METHODS: We retrospectively evaluated the data of developed HCC in a graft including metastatic HCC post-LDLT from 2779 adult cases collected from nine major liver transplantation centers in Japan. RESULTS: Of 2779 LDLT adult recipients, 34 (1.2%) developed HCCs in their grafts. Of 34, five HCCs appeared to be de novo because of a longer period to tumor detection (9.7 [6.4-15.4] years) and no HCC within the native liver of the two recipients. The donor origin of three of five de novo HCCs was confirmed using microsatellite analysis in resected tissue. Primary disease of all five was hepatitis C virus-related cirrhosis, of which two were treated with direct-acting antivirals. Four of five developed HCC de novo in the hepatitis B core antibody-positive grafts. De novo HCCs had favorable prognosis; four of five were cured with complete remission. However, recurrent HCC (n = 29) in the graft had a poorer outcome, especially in patients with neutrophil to lymphocyte ratio scores above 4 (median survival time, 262 [19-463] days). CONCLUSION: Analysis of the database from major liver transplantation institutes in Japan revealed that de novo HCCs determined by microsatellite analysis were rarely detected, but the majority were successfully treated. LDLT recipients with higher risks of de novo HCC, including those with hepatitis B core antibody-positive grafts, should be carefully followed by surveillance of the liver graft.
  • よりよい肝移植医療のあり方を探る MELD制導入による脳死肝移植の変化
    渡辺 正明; 嶋村 剛; 武冨 紹信
    肝臓, 61, Suppl.3, A801, A801, (一社)日本肝臓学会, Nov. 2020
    Japanese
  • 【最新の肝癌外科診療】移植
    嶋村 剛; 藤好 真人; 巖築 慶一; 後藤 了一; 川村 典生; 渡辺 正明
    消化器外科, 43, 12, 1679, 1690, (株)へるす出版, Nov. 2020
    Japanese
  • MELD制導入による脳死肝移植の変化
    渡辺 正明; 後藤 了一; 川村 典生; 巌築 慶一; 渋谷 一陽; 嶋村 剛; 武冨 紹信
    移植, 55, 総会臨時, 273, 273, (一社)日本移植学会, Oct. 2020
    Japanese
  • 生体肝移植ドナーの長期経過後の脂肪肝リスクの検討
    後藤 了一; 嶋村 剛; 川村 典生; 渡辺 正明; 巖築 慶一; 渋谷 一陽; 神山 俊哉; 武冨 紹信
    移植, 55, 総会臨時, 392, 392, (一社)日本移植学会, Oct. 2020
    Japanese
  • Second Case of Deceased Donor Liver Transplantation in a Patient Co-infected with HIV and HCV in Japan: Special Reference to the Management of Complicated Coagulopathy Due to a Diverse Spectrum of Preformed Anti-HLA Antibodies.
    Norio Kawamura; Ryoichi Goto; Yasuyuki Koshizuka; Masaaki Watanabe; Tomomi Suzuki; Tomoyuki Endo; Takeshi Kondo; Akinobu Taketomi; Tsuyoshi Shimamura
    Japanese journal of infectious diseases, 73, 5, 369, 372, 24 Sep. 2020, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, We report the second case of deceased donor liver transplantation in a patient co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) in Japan. A 48- year-old patient with hemophilia A was infected with HIV and HCV through a contaminated factor VIII concentrate in his childhood and developed cirrhosis and hepatocellular carcinoma. The patient was on the transplant list for a deceased donor liver. The patient had broad spectrum anti-HLA class I and II antibodies, which may have been due to repeated whole blood transfusions in the past. Catastrophic coagulopathy during the surgery was predicted because of the underlying hemophilic status and severe thrombocytopenia requiring HLA-matched platelet products, which are difficult to obtain quickly. To maintain adequate platelet counts(>5x104/ μl) while waiting liver transplantation, a thrombopoietin receptor agonist and rituximab were administered. During surgery, factor VIII concentrate was administered according to the previously planned protocol. Adequate hemostasis was obtained, and the operation was completed without uncontrollable coagulopathy. The postoperative course was uneventful, and the patient was discharged on postoperative day 41. Detailed planning is required for surgical patients with hemophilia and HIV/HCV cirrhosis, especially for those with a diverse spectrum of anti-HLA antibodies.
  • 【変貌する肝移植-適応拡大・ドナー選択・治療戦略の最先端を知る】HCCに対する肝移植の新展開 国内外の最近の動向
    嶋村 剛; 後藤 了一; 藤好 真人; 渡辺 正明; 川村 典生
    臨床外科, 75, 9, 1029, 1035, (株)医学書院, Sep. 2020
    Japanese
  • 肝腎症候群による腎不全を伴った原発性胆汁性胆管炎、非代償性肝硬変に対し脳死肝移植を施行した3例の検討
    鈴木 大喜; 後藤 了一; 巖築 慶一; 川村 典生; 渡辺 正明; 山本 啓一朗; 深澤 拓夢; 堀田 記世彦; 岩見 大基; 篠原 信雄; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 120回, RS, 10, (一社)日本外科学会, Aug. 2020
    Japanese
  • リンパ球の再構築による移植片局所免疫機能解析法の開発
    巌築 慶一; 後藤 了一; 大田 拓児; 金沢 亮; 川村 典生; 財津 雅昭; 渡辺 正明; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 120回, SF, 3, (一社)日本外科学会, Aug. 2020
    Japanese
  • 脳死肝移植後早期グラフト機能不全(Early Graft Dysfunction)並びに短期成績の検討
    川村 典生; 嶋村 剛; 後藤 了一; 渡辺 正明; 巖築 慶一; 武冨 紹信
    日本外科学会定期学術集会抄録集, 120回, SF, 5, (一社)日本外科学会, Aug. 2020
    Japanese
  • 小腸冷保存中の酸素供給が抗酸化治療の有効性に与える影響の検討
    深井 原; 柴田 賢吾; 坂本 聡大; 島田 慎吾; 加藤 紘一; 藤好 真人; 若山 顕治; 石川 隆壽; 川村 典生; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 120回, DP, 8, (一社)日本外科学会, Aug. 2020
    Japanese
  • 移植医療における細胞治療の有用性
    渡辺 正明; 渋谷 一陽; 後藤 了一; 川村 典生; 巌築 慶一; 腰塚 靖之; 嶋村 剛; 深井 原; 藤堂 省; 武冨 紹信
    日本外科学会定期学術集会抄録集, 120回, DP, 8, (一社)日本外科学会, Aug. 2020
    Japanese
  • 肝内胆管癌、混合型肝癌に対する生体肝移植の2例
    山本 啓一朗; 川村 典生; 巌築 慶一; 渡辺 正明; 後藤 了一; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 120回, DP, 6, (一社)日本外科学会, Aug. 2020
    Japanese
  • 制御性T細胞を用いた免疫寛容誘導研究における免疫モニタリングの成果
    後藤 了一; 財津 雅昭; 長津 明久; 江本 慎; 深作 慶友; 巖築 慶一; 渡辺 正明; 太田 稔; 嶋村 剛; 藤堂 省; 山下 健一郎; 武冨 紹信
    日本外科学会定期学術集会抄録集, 120回, DP, 1, (一社)日本外科学会, Aug. 2020
    Japanese
  • 肝腎症候群による腎不全を伴った原発性胆汁性胆管炎、非代償性肝硬変に対し脳死肝移植を施行した3例の検討
    鈴木 大喜; 後藤 了一; 巖築 慶一; 川村 典生; 渡辺 正明; 山本 啓一朗; 深澤 拓夢; 堀田 記世彦; 岩見 大基; 篠原 信雄; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 120回, RS, 10, (一社)日本外科学会, Aug. 2020
    Japanese
  • リンパ球の再構築による移植片局所免疫機能解析法の開発
    巌築 慶一; 後藤 了一; 大田 拓児; 金沢 亮; 川村 典生; 財津 雅昭; 渡辺 正明; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 120回, SF, 3, (一社)日本外科学会, Aug. 2020
    Japanese
  • 脳死肝移植後早期グラフト機能不全(Early Graft Dysfunction)並びに短期成績の検討
    川村 典生; 嶋村 剛; 後藤 了一; 渡辺 正明; 巖築 慶一; 武冨 紹信
    日本外科学会定期学術集会抄録集, 120回, SF, 5, (一社)日本外科学会, Aug. 2020
    Japanese
  • 温阻血再灌流傷害における肝内脂質局在変化の視覚化 脂質分布と機能の基礎的解明と治療標的としての可能性
    柴田 賢吾; 橋本 咲月; 早坂 孝宏; 深井 原; 加藤 紘一; 中薮 拓哉; 島田 慎吾; 小林 希; 梅本 浩平; 鈴木 崇史; 大谷 晋太郎; 三野 和宏; 嶋村 剛; 木村 太一; 武冨 紹信
    日本外科学会定期学術集会抄録集, 120回, SF, 1, (一社)日本外科学会, Aug. 2020
    Japanese
  • 小腸冷保存中の酸素供給が抗酸化治療の有効性に与える影響の検討
    深井 原; 柴田 賢吾; 坂本 聡大; 島田 慎吾; 加藤 紘一; 藤好 真人; 若山 顕治; 石川 隆壽; 川村 典生; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 120回, DP, 8, (一社)日本外科学会, Aug. 2020
    Japanese
  • 移植医療における細胞治療の有用性
    渡辺 正明; 渋谷 一陽; 後藤 了一; 川村 典生; 巌築 慶一; 腰塚 靖之; 嶋村 剛; 深井 原; 藤堂 省; 武冨 紹信
    日本外科学会定期学術集会抄録集, 120回, DP, 8, (一社)日本外科学会, Aug. 2020
    Japanese
  • 肝内胆管癌、混合型肝癌に対する生体肝移植の2例
    山本 啓一朗; 川村 典生; 巌築 慶一; 渡辺 正明; 後藤 了一; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 120回, DP, 6, (一社)日本外科学会, Aug. 2020
    Japanese
  • 制御性T細胞を用いた免疫寛容誘導研究における免疫モニタリングの成果
    後藤 了一; 財津 雅昭; 長津 明久; 江本 慎; 深作 慶友; 巖築 慶一; 渡辺 正明; 太田 稔; 嶋村 剛; 藤堂 省; 山下 健一郎; 武冨 紹信
    日本外科学会定期学術集会抄録集, 120回, DP, 1, (一社)日本外科学会, Aug. 2020
    Japanese
  • Imaging Mass Spectrometry Reveals the Changes in the Taurine Conjugates of Dihydroxycholanoic Acid During Hepatic Warm Ischemia and Reperfusion in a Rat Model
    Kengo Shibata; Takahiro Hayasaka; Satsuki Hashimoto; Kohei Umemoto; Takahisa Ishikawa; Sodai Sakamoto; Koichi Kato; Shingo Shimada; Norio Kawamura; Kenji Wakayama; Nozomi Kobayashi; Yuka Hama; Moto Fukai; Tsuyoshi Shimamura; Akinobu Taketomi
    Transplantation Proceedings, 52, 6, 1880, 1883, Elsevier USA, 01 Jul. 2020
    English, Scientific journal
  • Novel immunological approach to asses donor reactivity of transplant recipients using a humanized mouse model.
    Yasutomo Fukasaku; Ryoichi Goto; Yoshikazu Ganchiku; Shin Emoto; Masaaki Zaitsu; Masaaki Watanabe; Norio Kawamura; Moto Fukai; Tsuyoshi Shimamura; Akinobu Taketomi
    Human immunology, 81, 7, 342, 353, Jul. 2020, [Peer-reviewed], [International Magazine]
    English, Scientific journal, In organ transplantation, a reproducible and robust immune-monitoring assay has not been established to determine individually tailored immunosuppressants (IS). We applied humanized mice reconstituted with human (hu-) peripheral blood mononuclear cells (PBMCs) obtained from living donor liver transplant recipients to evaluate their immune status. Engraftment of 2.5 × 106 hu-PBMCs from healthy volunteers and recipients in the NSG mice was achieved successfully. The reconstituted lymphocytes consisted mainly of hu-CD3+ lymphocytes with predominant CD45RA-CD62Llo TEM and CCR6-CXCR3+CD4+ Th1 cells in hu-PBMC-NSG mice. Interestingly, T cell allo-reactivity of hu-PBMC-NSG mice was amplified significantly compared with that of freshly isolated PBMCs (p < 0.05). Furthermore, magnified hu-T cell responses to donor antigens (Ag) were observed in 2/10 immunosuppressed recipients with multiple acute rejection (AR) experiences, suggesting that the immunological assay in hu-PBMC-NSG mice revealed hidden risks of allograft rejection by IS. Furthermore, donor Ag-specific hyporesponsiveness was maintained in recipients who had been completely weaned off IS (n = 4), despite homeostatic proliferation of hu-T cells in the hu-PBMC-NSG mice. The immunological assay in humanized mice provides a new tool to assess recipient immunity in the absence of IS and explore the underlying mechanisms to maintaining operational tolerance.
  • Post-transplant indolent T cell lymphoproliferative disorder in living donor liver transplantation: a case report.
    Ryoichi Goto; Norio Kawamura; Masaaki Watanabe; Yasuyuki Koshizuka; Souichi Shiratori; Momoko Ara; Shohei Honda; Tomoko Mitsuhashi; Yoshihiro Matsuno; Tsuyoshi Shimamura; Akinobu Taketomi
    Surgical case reports, 6, 1, 147, 147, 26 Jun. 2020, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) of T cell type has been rarely reported. Accurate diagnosis of this life-threatening rare form of PTLD is important for the treatment strategy. CASE PRESENTATION: A 7-year-old boy had severe diarrhea and weight loss progressively at 7 years post-living donor liver transplantation (LDLT) for biliary atresia. Endoscopy in the gastrointestinal (GI) tract revealed multiple erosions and ulcer lesions with prominent intraepithelial lymphocytosis in the duodenum and terminal ileum. Immunohistochemical examination demonstrated that these accumulated lymphocytes mainly comprised small- to medium-sized T cells expressing CD3, CD4, CD5, CD7, and CD103, but lacking CD8, CD56, and Epstein-Barr virus-encoded small RNAs. In addition, T cell receptor β gene rearrangement was detected by polymerase chain reaction analysis. Comprehensively, the lesions were best interpreted as post-transplant indolent T cell lymphoproliferative disorder (LPD) of the intestine. Clinical remission was achieved by reducing the immunosuppressant. CONCLUSION: A rarely reported indolent type of T cell LPD in post-LDLT was diagnosed by direct inspection and histological investigation. Although the histological classification and therapeutic strategy for post-transplant indolent T cell LPD have not been established, reducing immunosuppression allowed complete remission in our case. To prevent the incidence of PTLD and de novo malignancy, developing a methodology to set a proper dose of immunosuppressant is required.
  • Analysis of the optimal psoas muscle mass index cut-off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people.
    Masatsugu Ohara; Goki Suda; Megumi Kimura; Osamu Maehara; Tomoe Shimazaki; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Tomoe Kobayashi; Minoru Uebayashi; Ryo Takagi; Isao Yokota; Tsuyoshi Shimamura; Naoya Sakamoto
    Hepatology research : the official journal of the Japan Society of Hepatology, 50, 6, 715, 725, Jun. 2020, [Peer-reviewed], [International Magazine]
    English, Scientific journal, This study aimed to determine the optimal psoas muscle mass index (PMI) cut-off values for diagnosis of skeletal muscle mass loss. METHODS: We evaluated PMI in two groups of normal controls: a medical check-up group and a liver donation candidate group. We analyzed two novel PMI cut-off values, one based on the mean - two standard deviations (2SD) and one based on the lower 5%. Skeletal muscle mass index (SMI) evaluations using computed tomography (sliceOmatic; TomoVision) and bioelectrical impedance analysis and PMI evaluation were undertaken simultaneously. We analyzed the correlation between our PMI cut-off values and the Japan Society of Hepatology-defined SMI cut-off values. The prevalence of skeletal muscle mass loss in patients with liver disease was assessed using the novel PMI cut-off values. RESULTS: In 504 normal controls aged ≤50 years, the PMI cut-off values based on mean -2SD and the lower 5% were set at 3.30 cm2 /m2 for men and 1.69 cm2 /m2 for women and 3.74 cm2 /m2 for men and 2.29 cm2 /m2 for women, respectively. The PMI cut-off values based on the lower 5% alone showed that skeletal muscle mass loss increased with age. Furthermore, they correlated well with Japan Society of Hepatology-defined SMI (sliceOmatic) cut-off values and showed a significantly higher prevalence of skeletal muscle mass loss in patients with liver cirrhosis than those without liver cirrhosis. CONCLUSIONS: We propose the following PMI cut-off values: 3.74 cm2 /m2 for male individuals and 2.29 cm2 /m2 for female individuals. These cut-off values can facilitate accurate diagnosis and management of sarcopenia in patients with chronic liver disease.
  • レシピエント移植コーディネーターによる在宅療養支援
    柏浦 愛美; 山本 真由美; 中野 政子; 後藤 了一; 嶋村 剛
    移植, 55, 1, 33, 38, (一社)日本移植学会, Apr. 2020
    Japanese, 症例は60代女性で、肝移植後15年経過した頃から慢性拒絶反応による肝不全の進行がみられ、肝性脳症が出現し、意識状態の悪化から入院を繰り返した。レシピエント移植コーディネーター(RTC)はまず病棟看護師、医師とカンファレンスを実施し、これまでの経過や緊急受診時の様子、家族背景といった情報を共有し、最終的に管理を適切に行って脳症をコントロールし、在宅療養を目指すという目標を設定した。家族のサポートにより服薬や食事の自己管理状況は改善したが、サポート体制をさらに構築する必要があると判断し、訪問看護の導入に至った。肝移植患者に対する初めての訪問看護導入であったため、まずRTCが連絡を受け、薬剤調整や体調に応じた早期受診の検討・受診結果の相談を行った。また、脳症コントロールのため分岐鎖アミノ酸製剤の点滴投与が開始となった際には、通院負担を考慮し自宅で受けられるよう調整を行った。
  • 南回りB2/3胆管を伴う肝左葉グラフトを用いた生体肝移植の一例
    高橋 直規; 後藤 了一; 財津 雅昭; 川村 典生; 渡辺 正明; 神山 俊哉; 嶋村 剛; 武冨 紹信
    移植, 54, 6, 299, 303, (一社)日本移植学会, Apr. 2020
    Japanese, 症例は20歳代女性で、生体肝移植ドナーとして、肝左葉グラフト採取術施行目的に入院となった。MRCPでは、短い左肝管とそこから分岐する平行から下に凸に走行するB2-3が疑われたが、術前には明らかな走行異型は指摘できなかった。肝左葉グラフト採取術を施行したところ、肝門部剥離の際に門脈左枝の尾側やや後方に南回りB2/3を認識した。術中胆道造影で、総肝管より左肝管が分岐した直後に、北回りB4と南回りB2/3の分岐異型を認めた。C-armによるリアルタイム胆管造影で切離予定ラインを確認しつつ血管鉗子をかけ、ドナー残存胆管に狭窄が無く、可及的にグラフト胆管が長く残る位置で胆管を切離、北回りB4と南回りB2/3の2穴となった。肝左葉グラフト採取後、バックテーブルでB2/3を十分に剥離してB4と緊張のない形で一穴化し、レシピエント側でこれと胆管空腸吻合を実施した。胆管空腸吻合部にはB2/3、B4それぞれにRTBD tubeを挿入し、吻合後の胆道造影で狭窄、胆汁漏がないことを確認した。ドナーは術後1日目に血清の総ビリルビン値5.0mg/dL、直接ビリルビン値0.2mg/dLと間接優位のビリルビン上昇とPT-INR 1.34と上昇を認めた。術後2日目には、総ビリルビン値2.4mg/dL、PT-INR 1.30と改善し、中肝静脈灌流領域の鬱血に伴う変化と考えられた。以後、経過良好で、予定通り術後14日で退院となった。
  • 原発性胆汁性胆管炎の非代償性肝硬変、腎不全に対し脳死下肝腎同時移植を実施した一例
    山本 啓一朗; 後藤 了一; 深澤 拓夢; 巖築 慶一; 川村 典生; 渡辺 正明; 堀田 記世彦; 岩見 大基; 篠原 信雄; 嶋村 剛; 武冨 紹信
    日本臨床外科学会雑誌, 81, 4, 799, 799, 日本臨床外科学会, Apr. 2020
    Japanese
  • 南回りB2/3胆管を伴う肝左葉グラフトを用いた生体肝移植の一例
    高橋 直規; 後藤 了一; 財津 雅昭; 川村 典生; 渡辺 正明; 神山 俊哉; 嶋村 剛; 武冨 紹信
    移植, 54, 6, 299, 303, (一社)日本移植学会, Apr. 2020, [Peer-reviewed]
    Japanese
  • A Multicenter Japanese Survey Assessing the Long-term Outcomes of Liver Retransplantation Using Living Donor Grafts.
    Kaori Kuramitsu; Takumi Fukumoto; Hiroto Egawa; Hideki Ohdan; Koji Umeshita; Shinji Uemoto; Taizo Hibi; Mureo Kasahara; Tomoharu Yoshizumi; Koichi Mizuta; Tsuyoshi Shimamura; Hiroyuki Furukawa
    Transplantation, 104, 4, 754, 761, Apr. 2020, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND: Liver transplantation is the most suitable treatment option available for end-stage liver disease. However, some patients require retransplantation, despite medical advances that have led to improved survival. We aimed to compile a definitive, nationwide resource of liver retransplantation data in Japan, seeking to identify the predictors of patient survival posttransplantation. METHODS: Questionnaires were sent to 32 institutions that had conducted 281 retransplantations before 2015. RESULTS: Among the 265 patients included in this study (142 pediatric cases), the average age at primary transplantation was 23 years, and retransplantation was performed after an average of 1468 days. The main indication for retransplantation was graft rejection (95 patients). Living-donor liver transplantation accounted for 94.7% of primary transplantations and 73.2% of retransplantations. Patient survival at 1, 3, or 5 years did not differ by type of transplantation but was better for pediatric (70.8%, 68.3%, and 60.1%, respectively) than for adult (57.2%, 50.4%, and 45.2%, respectively) recipients (P = 0.0003). Small-for-size syndrome, retransplantation within 365 days, and inpatient status at retransplantation were significant predictors of poor survival in pediatric cases. Retransplantation within 365 days and conditions warranting retransplantation were significant predictors of poor survival in adult patients. CONCLUSIONS: In Japan, where >70% of retransplantations are performed using living donors, the indications and timing are different from those in previous reports from other countries, while maintaining comparable survival rates. Considering technical challenges, graft failure within 365 days should be thoroughly restricted to justify the use of living donor.
  • 肝臓のMRエラストグラフィにおける閾値によるSemi-automatic Quantification Softwareの検証研究(Validation Study on Semi-automatic Quantification Software by Threshold Value for MR Elastography of the Liver)
    Katsuumi Yuri; Kamishima Tamotsu; Sugimori Hiroyuki; Shimamura Tsuyoshi; Kawamura Norio; Takeda Hiroshi
    日本放射線技術学会総会学術大会予稿集, 76回, 318, 319, (公社)日本放射線技術学会, Mar. 2020
    English
  • 当院で管理中の先天性門脈体循環シャント6例の検討
    辻岡 孝郎; 泉 岳; 武田 充人; 小杉山 清隆; 山澤 弘州; 阿部 二郎; 谷口 宏太; 佐々木 大輔; 永井 礼子; 本多 昌平; 荒 桃子; 阿保 大介; 曽山 武士; 川村 典生; 渡辺 正明; 後藤 了一; 嶋村 剛; 神山 俊哉; 武冨 紹信; 真部 淳
    日本小児科学会雑誌, 124, 2, 250, 250, (公社)日本小児科学会, Feb. 2020
    Japanese
  • 当院で管理中の先天性門脈体循環シャント6例の検討
    辻岡 孝郎; 泉 岳; 武田 充人; 小杉山 清隆; 山澤 弘州; 阿部 二郎; 谷口 宏太; 佐々木 大輔; 永井 礼子; 本多 昌平; 荒 桃子; 阿保 大介; 曽山 武士; 川村 典生; 渡辺 正明; 後藤 了一; 嶋村 剛; 神山 俊哉; 武冨 紹信; 真部 淳
    日本小児科学会雑誌, 124, 2, 250, 250, (公社)日本小児科学会, Feb. 2020
    Japanese
  • Outcome of Living-Donor Liver Transplantation Using Grafts from Donors Treated for Fatty Liver.
    Yuki Fujii; Norio Kawamura; Masaaki Zaitsu; Masaaki Watanabe; Ryoichi Goto; Toshiya Kamiyama; Akinobu Taketomi; Tsuyoshi Shimamura
    Annals of transplantation, 25, e920677, 10 Jan. 2020, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND The aim of this study was to determine the efficacy of treating donors' fatty liver (FL) and to assess early graft function in recipients who received treated FL grafts in living-donor liver transplantation (LDLT). MATERIAL AND METHODS Data were collected for adult-to-adult LDLTs. Donors diagnosed with FL (FL group) received diet-exercise and pharmacological treatment. The perioperative findings and early transplanted graft function were compared with those of donors without FL (non-FL group) during the same period. RESULTS Of 30 donors, 8 were determined to have FL. The median duration of treatment for FL was 58 days. The liver-to-spleen attenuation ratios on CT scan in the FL group were significantly improved after treatment: 0.95 (0.62-1.06) to 1.2 (1.12-1.46) (P=0.003). Liver biopsy prior to donor surgery showed ≤10% fatty infiltration. Postoperative laboratory findings of the donors in the FL group were comparable to those in the non-FL group: maximum alanine transaminase (189.6±94.7 IU/L vs. 196.8±57.4) and maximum total bilirubin (2.2±1.1 mg/dL vs. 1.7±0.5 mg/dL). No major complications were observed after donor hepatectomy in either group. There were no significant differences between the 2 groups in early graft function, as evaluated by laboratory data, ascites volume, and bile production 2 weeks postoperatively. Graft and patient survival were 100% in both groups at 3 months. CONCLUSIONS Preoperative intentional treatment for FL was effective. Early graft function and donor postoperative course were comparable in the 2 groups. These results suggest that well-treated steatotic grafts can be used without jeopardizing donor safety.
  • 骨髄移植後の類洞閉塞症候群に対し生体肝移植を施行し救命しえた一例
    深澤 拓夢; 川村 典生; 市村 健太郎; 鈴木 琢士; 巖築 慶一; 財津 雅昭; 渡辺 正明; 藤好 真人; 長津 明久; 後藤 了一; 井口 晶裕; 五十嵐 敬太; 山本 雅樹; 神山 俊哉; 嶋村 剛; 武冨 紹信
    日本臨床外科学会雑誌, 80, 12, 2303, 2303, 日本臨床外科学会, Dec. 2019, [Peer-reviewed]
    Japanese
  • ICG蛍光法を利用した進行大腸癌に対する内視鏡的マーキング法
    小野 博美; 林 秀幸; 福島 拓; 嶋村 剛; 草野 満夫
    日本消化器病学会雑誌, 116, 臨増大会, A837, A837, (一財)日本消化器病学会, Nov. 2019, [Peer-reviewed]
    Japanese
  • Heavy Water (D2O) Containing Preservation Solution Reduces Hepatic Cold Preservation and Reperfusion Injury in an Isolated Perfused Rat Liver (IPRL) Model.
    Shingo Shimada; Moto Fukai; Kengo Shibata; Sodai Sakamoto; Kenji Wakayama; Takahisa Ishikawa; Norio Kawamura; Masato Fujiyoshi; Tsuyoshi Shimamura; Akinobu Taketomi
    Journal of clinical medicine, 8, 11, 01 Nov. 2019, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND: Heavy water (D2O) has many biological effects due to the isotope effect of deuterium. We previously reported the efficacy of D2O containing solution (Dsol) in the cold preservation of rat hearts. Here, we evaluated whether Dsol reduced hepatic cold preservation and reperfusion injury. METHODS: Rat livers were subjected to 48-hour cold storage in University of Wisconsin (UW) solution or Dsol, and subsequently reperfused on an isolated perfused rat liver. Graft function, injury, perfusion kinetics, oxidative stress, and cytoskeletal integrity were assessed. RESULTS: In the UW group, severe ischemia and reperfusion injury (IRI) was shown by histopathology, higher liver enzymes leakage, portal resistance, and apoptotic index, oxygen consumption, less bile production, energy charge, and reduced glutathione (GSH)/oxidized glutathione (GSSG) ratio (versus control). The Dsol group showed that these injuries were significantly ameliorated (versus the UW group). Furthermore, cytoskeletal derangement was progressed in the UW group, as shown by less degradation of α-Fodrin and by the inactivation of the actin depolymerization pathway, whereas these changes were significantly suppressed in the Dsol group. CONCLUSION: Dsol reduced hepatic IRI after extended cold preservation and subsequent reperfusion. The protection was primarily due to the maintenance of mitochondrial function, cytoskeletal integrity, leading to limiting oxidative stress, apoptosis, and necrosis pathways.
  • 水素ガスの虚血・再灌流障害軽減効果と臨床応用の展望 虚血再灌流傷害に対する水素ガスの作用点の探索
    柴田 賢吾; 坂本 聡大; 島田 慎吾; 小林 希; 石川 隆壽; 若山 顕治; 藤好 真人; 川村 典生; 嶋村 剛; 武冨 紹信
    Organ Biology, 26, 3, 45, 45, (一社)日本臓器保存生物医学会, Oct. 2019, [Peer-reviewed]
    Japanese
  • PREDICTION OF HEPATIC WARM ISCHEMIA AND REPERFUSION INJURY BY LYSOPHOSPHOLIPIDS - COMPREHENSIVE ANALYSIS BY IMAGING MASS SPECTROMETRY (IMS)
    Shibata Kengo; Hayasaka Takahiro; Fukai Moto; Kato Koichi; Ishikawa Takahisa; Umemoto Kohei; Shimada Shingo; Kobayashi Nozomi; Shimamura Tsuyoshi; Kimura Taichi; Taketomi Akinobu
    TRANSPLANT INTERNATIONAL, 32, 283, Oct. 2019, [Peer-reviewed]
  • 生体肝移植におけるヒト化マウス新規免疫モニタリング法の有用性の検討
    深作 慶友; 後藤 了一; 巖築 慶一; 渡辺 正明; 川村 典生; 嶋村 剛; 武冨 紹信
    移植, 54, 総会臨時, 240, 240, (一社)日本移植学会, Sep. 2019
    Japanese
  • 移植後早期グラフト浸潤リンパ球の抗原特異性に関する基礎的検討
    巌築 慶一; 後藤 了一; 太田 拓児; 金沢 亮; 川村 典生; 財津 雅昭; 渡辺 正明; 深井 元; 嶋村 剛; 武冨 紹信
    移植, 54, 総会臨時, 240, 240, (一社)日本移植学会, Sep. 2019
    Japanese
  • 当院における原発性胆汁性胆管炎に対する生体・脳死肝移植症例の特徴
    後藤 了一; 巖築 慶一; 川村 典生; 渡辺 正明; 神山 俊哉; 嶋村 剛; 武冨 紹信
    移植, 54, 総会臨時, 222, 222, (一社)日本移植学会, Sep. 2019
    Japanese
  • 肝臓のMR Elastography検査におけるスライス位置の検討
    勝海 友里; 神島 保; 杉森 博行; 嶋村 剛; 川村 典生; 武田 宏司
    日本放射線技術学会雑誌, 75, 9, 1056, 1056, (公社)日本放射線技術学会, Sep. 2019
    Japanese
  • 類洞閉塞症候群(SOS)の病態と治療 類洞閉塞症候群に対する生体肝移植の1例と、生体肝移植後類洞閉塞症候群をきたし再移植を必要とした1例
    川村 典生; 嶋村 剛; 後藤 了一; 渡辺 正明; 巖築 慶一; 神山 俊哉; 武冨 紹信
    日本門脈圧亢進症学会雑誌, 25, 3, 114, 114, (一社)日本門脈圧亢進症学会, Sep. 2019, [Peer-reviewed]
    Japanese
  • 生体肝移植におけるDe novoドナー特異的HLA抗体高力価症例のグラフト線維化の危険因子
    後藤 了一; 財津 雅昭; 川村 典生; 渡辺 正明; 神山 俊哉; 嶋村 剛; 武冨 紹信
    日本消化器外科学会総会, 74回, P197, 1, (一社)日本消化器外科学会, Jul. 2019, [Peer-reviewed]
    Japanese
  • Long-term donor quality of life after living donor liver transplantation in Japan.
    Yuki Morooka; Koji Umeshita; Akinobu Taketomi; Ken Shirabe; Tomoharu Yoshizumi; Mayumi Yamamoto; Tsuyoshi Shimamura; Akihiko Oshita; Hideki Ohdan; Naoki Kawagishi; Kuniko Hagiwara; Hidetoshi Eguchi; Hiroaki Nagano
    Clinical transplantation, 33, 6, e13584, Jun. 2019, [Peer-reviewed], [International Magazine]
    English, Scientific journal, AIMS: This study examined the long-term quality of life (QOL) of living liver donors (LLDs) in Japan using both generic and LLD-specific instruments. METHODS: The sample comprised 374 LLDs from five university hospitals in Japan who underwent surgery more than a year previously. QOL was evaluated using the Short Form-36 health survey (SF-36) and LLD-QOL scale. RESULTS: SF-36 results indicated that the overall long-term QOL of LLDs was significantly better than the Japanese standard. When comparing by donor factors, LLDs whose recipients were children scored higher for "satisfaction" than those whose recipients were adults on the LLD-QOL scale. LLDs with complications had lower QOL for "scars" and "burden" on the LLD-QOL scale but no differences in SF-36 scores. LLDs with longer hospital stay had lower physical QOL on SF-36 and lower QOL for "scars" and "after-effects" on the LLD-QOL scale. LLDs whose recipients have died showed lower mental QOL on SF-36 and lower "satisfaction" and greater "lack of understanding of donor health" on the LLD-QOL scale. CONCLUSIONS: Our multicenter study clarified the long-term QOL of LLDs and suggested that donors' QOL was related to the donors' and recipients' ages, donor's complications and hospital stay length, and recipient's prognosis.
  • Successful Treatment of Hepatocellular Carcinoma with Transcatheter Arterial Chemoembolization followed by Radical Liver Transplantation in a Patient with Severe Liver Damage
    Hajime Nakamura; Yutaka Kawano; Koji Miyanishi; Kazuma Ishikawa; Tomohiro Kubo; Shingo Tanaka; Kohichi Takada; Masayoshi Kobune; Kohei Harada; Norio Kawamura; Tsuyoshi Shimamura; Hiromi Kanno-Okada; Junji Kato
    Case Reports in Oncology, 12, 1, 289, 296, S. Karger AG, 03 Apr. 2019
    Scientific journal, Introduction: Liver transplantation for hepatocellular carcinoma (HCC) has been established as a curative therapy of underlying liver disease and cancer. However, the role of liver transplantation remains controversial for patients with HCC beyond Milan criteria. Case Presentation: A man in his 50s who was diagnosed as having two foci of HCC and advanced liver cirrhosis was referred to our hospital for further examination and treatment. Both foci of HCC were located in segment 8 of the liver and measured 39 and 9 mm. Endoscopy showed esophageal varices that had a high risk of bleeding. After endoscopic ligation of the esophageal varices, he underwent transcatheter arterial chemoembolization (TACE) for downstaging of the advanced HCCs. No further liver deterioration was observed after TACE, and HCC staging was successfully downstaged to within the Milan criteria. One hundred ten days after TACE, he underwent liver transplantation; at 2.5 years after transplantation, he remains alive without HCC recurrence. Discussion/Conclusion: There are only a few treatment options available for patients with advanced HCC and severe liver damage. Multidisciplinary treatment such as locoregional treatments and prophylaxis of variceal bleeding may result in tumor downstaging, enabling radical liver transplantation without further exacerbation of liver damage.
  • 胆道閉鎖症術後の生体肝移植適応因子
    本多 昌平; 荒 桃子; 河北 一誠; 後藤 了一; 渡辺 正明; 川村 典生; 財津 雅昭; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 119回, SF, 8, (一社)日本外科学会, Apr. 2019
    Japanese
  • 当科における脳死肝移植前抗ドナーHLA抗体値の推移の検討
    金沢 亮; 後藤 了一; 巌築 慶一; 財津 雅昭; 川村 典夫; 渡辺 正明; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 119回, SF, 6, (一社)日本外科学会, Apr. 2019
    Japanese
  • 小児生体肝移植後の肝動脈血栓症発症に及ぼす血管因子の検討
    原田 拓弥; 川村 典生; 財津 雅昭; 渡辺 正明; 後藤 了一; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 119回, SF, 7, (一社)日本外科学会, Apr. 2019
    Japanese
  • 早期移植片浸潤リンパ球の拒絶反応における役割に関する基礎的検討
    巌築 慶一; 後藤 了一; 金沢 亮; 渋谷 一陽; 深作 慶友; 川村 典生; 財津 雅昭; 渡辺 正明; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 119回, SF, 3, (一社)日本外科学会, Apr. 2019
    Japanese
  • HEV急性肝不全5例の検討
    市村 健太郎; 川村 典生; 財津 雅昭; 渡辺 正明; 後藤 了一; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 119回, PS, 8, (一社)日本外科学会, Apr. 2019
    Japanese
  • 当院における小児生体肝移植後門脈合併の検討
    佐藤 彩; 後藤 了一; 財津 雅昭; 川村 典生; 渡辺 正明; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 119回, PS, 7, (一社)日本外科学会, Apr. 2019
    Japanese
  • リンパ球-単球比を用いた肝移植後の急性拒絶反応と治療の評価
    財津 雅昭; 川村 典生; 渡辺 正明; 後藤 了一; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 119回, PS, 5, (一社)日本外科学会, Apr. 2019
    Japanese
  • Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule - a retrospective study.
    Tsuyoshi Shimamura; Nobuhisa Akamatsu; Masato Fujiyoshi; Atushi Kawaguchi; Satoshi Morita; Seiji Kawasaki; Shinji Uemoto; Norihiro Kokudo; Kiyoshi Hasegawa; Hideki Ohdan; Hiroto Egawa; Hiroyuki Furukawa; Satoru Todo
    Transplant international : official journal of the European Society for Organ Transplantation, 32, 4, 356, 368, Apr. 2019, [International Magazine]
    English, Scientific journal, Expansion of the liver transplantation indication criteria for patients with hepatocellular carcinoma (HCC) has long been debated. Here we propose new, expanded living-donor liver transplantation (LDLT) criteria for HCC patients based on a retrospective data analysis of the Japanese nationwide survey. A total of 965 HCC patients undergoing LDLT were included, 301 (31%) of whom were beyond the Milan criteria. Here, we applied the Greenwood formula to investigate new criteria enabling the maximal enrollment of candidates while securing a 5-year recurrence rate (95% upper confidence limit) below 10% by examining various combinations of tumor numbers and serum alpha-fetoprotein values, and maintaining the maximal nodule diameter at 5 cm. Finally, new expanded criteria for LDLT candidates with HCC, the 5-5-500 rule (nodule size ≤5 cm in diameter, nodule number ≤5, and alfa-fetoprotein value ≤500 ng/ml), were established as a new regulation with a 95% confidence interval of a 5-year recurrence rate of 7.3% (5.2-9.3) and a 19% increase in the number of eligible patients. In addition, the 5-5-500 rule could identify patients at high risk of recurrence, among those within and beyond the Milan criteria. In conclusion, the new criteria - the 5-5-500 rule - might provide rational expansion for LDLT candidates with HCC.
  • 脳死膵腎移植の臓器摘出チームにおける臨床工学技士の取り組み
    太田 稔; 岡本 花織; 千葉 裕基; 後藤 了一; 財津 雅昭; 川村 典生; 渡辺 正明; 山本 真由美; 柏浦 愛美; 鈴木 友己; 堀田 記世彦; 岩見 大基; 嶋村 剛
    日本臨床工学技士会会誌, 66, 253, 253, (公社)日本臨床工学技士会, Apr. 2019
    Japanese
  • 消化管出血に対してIPM/CSを用いたTAEが奏功した1例
    金谷 本真; 阿保 大介; 曽山 武士; 森田 亮; 吉野 裕紀; 木村 輔; 工藤 與亮; 川村 典生; 後藤 了一; 渡辺 正明; 嶋村 剛
    日本インターベンショナルラジオロジー学会雑誌, 33, 4, 422, 423, (一社)日本インターベンショナルラジオロジー学会, Apr. 2019
    Japanese
  • 肝MRエラストグラフィーの半自動定量化ソフトウェアに関する検証研究(Validation Study on Semi-Automatic Quantification Software for MR Elastography of the Liver)
    Katsuumi Yuri; Kamishima Tamotsu; Sugimori Hiroyuki; Shimamura Tsuyoshi; Kawamura Norio; Takeda Hiroshi
    日本放射線技術学会総会学術大会予稿集, 75回, 211, 212, (公社)日本放射線技術学会, Mar. 2019
    English
  • 南回りB2/3胆管を伴う肝左葉グラフトを用いた生体肝移植の一例
    高橋 直規; 後藤 了一; 渡辺 正明; 川村 典生; 財津 雅昭; 神山 俊哉; 嶋村 剛; 武冨 紹信
    日本臨床外科学会雑誌, 80, 2, 439, 439, 日本臨床外科学会, Feb. 2019
    Japanese
  • 生体肝移植後肝動脈血栓症に対する肝動脈再建において端側吻合を用いた1例
    和久井 洋佑; 財津 雅昭; 渡辺 正明; 川村 典生; 後藤 了一; 嶋村 剛; 武冨 紹信; 大岡 智学; 松居 喜郎
    北海道外科雑誌, 63, 2, 165, 165, 北海道外科学会, Dec. 2018
    Japanese
  • Post-reperfusion hydrogen gas treatment ameliorates ischemia reperfusion injury in rat livers from donors after cardiac death: a preliminary study.
    Takahisa Ishikawa; Shingo Shimada; Moto Fukai; Taichi Kimura; Kouhei Umemoto; Kengo Shibata; Masato Fujiyoshi; Sunao Fujiyoshi; Takahiro Hayasaka; Norio Kawamura; Nozomi Kobayashi; Tsuyoshi Shimamura; Akinobu Taketomi
    Surgery today, 48, 12, 1081, 1088, Dec. 2018, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, BACKGROUND AND PURPOSE: We reported previously that hydrogen gas (H2) reduced hepatic ischemia and reperfusion injury (IRI) after prolonged cold storage (CS) of livers retrieved from heart-beating donors. The present study was designed to assess whether H2 reduced hepatic IRI during donation of a cardiac death (DCD) graft with subsequent CS. METHODS: Rat livers were harvested after 30-min cardiac arrest and stored for 4 h in University of Wisconsin solution. The graft was reperfused with oxygenated buffer, with or without H2 (H2 or NT groups, respectively), at 37° for 90 min on isolated perfused rat liver apparatus. RESULTS: In the NT group, liver enzyme leakage, apoptosis, necrosis, energy depletion, redox status, impaired microcirculation, and bile production were indicative of severe IRI, whereas in the H2 group these impairments were significantly suppressed. The phosphorylation of cytoplasmic MKK4 and JNK were enhanced in the NT group and suppressed in the H2 group. NFkB-p65 and c-Fos in the nucleus were unexpectedly unchanged by IRI regardless of H2 treatment, indicating the absence of inflammation in this model. CONCLUSION: H2 was observed to ameliorate IRI in the DCD liver by maintaining microcirculation, mitochondrial functions, and redox status, as well as suppressing the cytoplasmic MKK4-JNK-mediated cellular death pathway.
  • 経皮的直接穿刺及びNBCA注入により治癒し得た膵移植後十二指腸断端漏の1例
    阿保 大介; 曽山 武士; 森田 亮; 加藤 大貴; 吉野 裕紀; 工藤 與亮; 川村 典生; 腰塚 靖之; 後藤 了一; 渡辺 正明; 嶋村 剛
    IVR: Interventional Radiology, 33, 3, 311, 311, (一社)日本インターベンショナルラジオロジー学会, Nov. 2018
    Japanese
  • Effect of herbal medicine daikenchuto on oral and enteral caloric intake after liver transplantation: A multicenter, randomized controlled trial.
    Toshimi Kaido; Masahiro Shinoda; Yukihiro Inomata; Takahito Yagi; Nobuhisa Akamatsu; Yasutsugu Takada; Hideki Ohdan; Tsuyoshi Shimamura; Yasuhiro Ogura; Susumu Eguchi; Hidetoshi Eguchi; Satoshi Ogata; Tomoharu Yoshizumi; Toshihiko Ikegami; Michio Yamamoto; Satoshi Morita; Shinji Uemoto
    Nutrition (Burbank, Los Angeles County, Calif.), 54, 68, 75, Oct. 2018, [Peer-reviewed], [International Magazine]
    English, Scientific journal, OBJECTIVE: Postoperative early oral or enteral intake is a crucial element of the Enhanced Recovery After Surgery (ERAS) protocol. However, normal food intake or enteral feeding cannot be started early in the presence of coexisting bowel dysfunction in patients undergoing liver transplantation (LT). The aim of this multicenter, randomized, double-blinded, placebo-controlled trial was to determine the enhancement effects of the Japanese herbal medicine Daikenchuto (DKT) on oral/enteral caloric intake in patients undergoing LT. METHODS: A total of 112 adult patients undergoing LT at 14 Japanese centers were enrolled. The patients were randomly assigned to receive either DKT or placebo from postoperative day (POD) 1 to 14. The primary endpoints were total oral/enteral caloric intake, abdominal distension, and pain on POD 7. The secondary endpoints included sequential changes in total oral/enteral caloric intake after LT, and portal venous flow volume and velocity in the graft. RESULTS: A total of 104 patients (DKT, n = 55; placebo, n = 49) were included in the analyses. There were no significant differences between the two groups in terms of primary endpoints. However, postoperative total oral/enteral caloric intake was significantly accelerated in the DKT group compared with the placebo group (P = 0.023). Moreover, portal venous flow volume (POD 10, 14) and velocity (POD 14) were significantly higher in the DKT group than in the placebo group (P = 0.047, P = 0.025, P = 0.014, respectively). CONCLUSIONS: Postoperative administration of DKT may enhance total oral/enteral caloric intake and portal venous flow volume and velocity after LT and favorably contribute to the performance of the ERAS protocol.
  • 本邦の膵島移植の今後の展開 本邦での膵島移植の成績改善に向けて 我々のこれまでの取り組みとこれからの展開
    渡辺 正明; 腰塚 靖之; 渋谷 一陽; 蔵谷 大輔; 吉田 雅; 後藤 了一; 財津 雅昭; 川村 典生; 嶋村 剛; 武冨 紹信
    移植, 53, 総会臨時, 276, 276, (一社)日本移植学会, Sep. 2018
    Japanese
  • 生体肝移植後の原発性胆汁性胆管炎再発による肝硬変に対して脳死再移植を施行した1例
    財津 雅昭; 川村 典生; 渡辺 正明; 後藤 了一; 嶋村 剛; 武冨 紹信
    移植, 53, 総会臨時, 534, 534, (一社)日本移植学会, Sep. 2018
    Japanese
  • 抗ドナーHLA抗体陽性の肝移植の短期・長期成績と問題点 De novoドナー特異的HLA抗体陽性の生体肝グラフト線維化進行症例の特徴
    後藤 了一; 川村 典生; 渡辺 正明; 財津 雅昭; 嶋村 剛; 武冨 紹信
    移植, 53, 総会臨時, 255, 255, (一社)日本移植学会, Sep. 2018
    Japanese
  • The Immune Monitoring for Operationally Tolerant Recipients Following a Regulatory T cell-based Cell Therapy
    Goto Ryoichi; Zaitsu Masaaki; Nagatsu Akihisa; Emoto Shin; Fukasaku Yasutomo; Ganchiku Yoshikazu; Watanabe Masaaki; Oura Tetsu; Ota Minoru; Suzuki Tomomi; Taketomi Akinobu; Shimamura Tsuyoshi; Todo Satoru; Yamashita Kenichiro
    TRANSPLANTATION, 102, S330, Jul. 2018, [Peer-reviewed]
  • Longitudinal CT study of sarcopenia due to hepatic failure after living donor liver transplantation.
    Takahiro Onuma; Tamotsu Kamishima; Tsuyoshi Shimamura; Norio Kawamura; Kenichiro Yamashita; Kenneth Sutherland; Hiroshi Takeda
    Quantitative imaging in medicine and surgery, 8, 1, 25, 31, Feb. 2018, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND: The quantity and quality of skeletal muscle have been observed to be closely related with post-transplantation mortality in patients undergoing living donor liver transplantation (LDLT). However, the effect of LDLT on skeletal muscle has not been thoroughly investigated. The aim of this study was to investigate the change of trunk muscle mass and adiposity in recipients of LDLT. METHODS: The study population included LDLT recipients at Hokkaido University Hospital who underwent pre- and post-operative computed tomography (CT) scans (31 recipients; 14 males, and 17 females). The cross-sectional area of the dorsal muscle group at the 12th thoracic vertebra (Th12) was measured with the dorsal muscle group mass index (DMGMI), while the psoas muscle at the upper border of 4th lumber vertebra (L4) was measured with the psoas muscle mass index (PMI). Muscle adiposity of the dorsal muscle group was also measured with the intramuscular adipose tissue content (IMAC). For these data, the correlation between pre-operative values and follow-up changes (post-operative values minus pre-operative values) were analyzed. Each sex was evaluated separately. RESULTS: A statistically significant correlation was detected between pre-operative values and follow-up differences in DMGMI for both sexes (male: r=-0.675, P=0.008; female: r=-0.687, P=0.002) and in PMI for both sexes (males: r=-0.739, P=0.003; females: r=-0.641, P=0.006). The correlation of pre-operative values and follow-up differences for IMAC was not statistically significant with r=0.132 (P=0.700) and r=-0.498 (P=0.071) for males and females, respectively. CONCLUSIONS: Improvement of sarcopenia in recipients of LDLT can be demonstrated regardless of sex using volumetric CT.
  • ADMINISTRATION OF FIBRINOGEN CONCENTRATE REDUCED TRANSFUSION VOLUME IN CADAVERIC LIVER TRANSPLANTATION SURGERY
    Uwatoko Takayo; Goto Ryoichi; Watanabe Chiaki; Akizawa Koji; Shimamura Tsuyoshi; Shimizu Chikara; Teshima Takanori; Hayase Eiko; Kahata Kaoru; Hashimoto Daigo; Ito Makoto; Uozumi Ryo; Hayashi Yasuhiro; Sugita Junichi; Koshizuka Yasuyuki
    Japanese Journal of Transfusion and Cell Therapy, 64, 5, 641, 648, 一般社団法人 日本輸血・細胞治療学会, 2018
    Japanese, <p><b>Background:</b> Liver transplantation is associated with massive bleeding and transfusion in recipients with coagulopathy. A previous study reported that intraoperative fibrinogen concentrate (IOFC) reduces transfusion volume in liver transplant procedures. In our institute, IOFC was introduced in 2012 for preventing massive bleeding in cadaveric liver transplantation. We studied the effects of IOFC on the amount of bleeding and transfusion during surgery.</p><p><b>Patients andMethods:</b> We retrospectively analyzed 44 adult patients who underwent cadaveric liver transplantation between February 2001 and August 2016. The amount of intraoperative bleeding and transfusion in 25 transplantations that did not use IOFC was compared to that in 19 cases that used IOFC. We also analyzed 33 patients who bled more than their circulating blood volume (16 cases without IOFC, 17 cases with IOFC).</p><p><b>Results:</b> The amount of intraoperative bleeding and transfusion was not significantly different between the two groups. In sub-analysis of 33 patients who bled more than their circulating blood volume, the amount of intraoperative bleeding was significantly reduced in the group that used IOFC. Further, the amount of intraoperative PC transfusion was significantly reduced and the amount of red blood cells and fresh frozen plasma tended to be lower.</p><p><b>Conclusion:</b> Use of IOFC reduced intraoperative massive hemorrhage and PC requirements in cadaveric liver transplantation.</p>
  • 先天性胆道拡張症に発生した多発胆道癌に対し、生体肝移植と膵頭十二指腸切除を同時に実施した1例
    腰塚 靖之; 川村 典生; 渡辺 正明; 後藤 了一; 太田 稔; 川久保 和道; 桑谷 将城; 山下 健一郎; 武冨 紹信; 蒲池 浩文; 神山 俊哉; 嶋村 剛
    移植, 52, 4-5, 454, 455, (一社)日本移植学会, Nov. 2017
    Japanese
  • Petersen's hernia after living donor liver transplantation.
    Sodai Sakamoto; Ryoichi Goto; Norio Kawamura; Yasuyuki Koshizuka; Masaaki Watanabe; Minoru Ota; Tomomi Suzuki; Daisuke Abo; Kenichiro Yamashita; Toshiya Kamiyama; Akinobu Taketomi; Tsuyoshi Shimamura
    Surgical case reports, 3, 1, 89, 89, 23 Aug. 2017, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND: Hepaticojejunostomy may be used for biliary reconstruction in certain cases of liver transplantation. In this occasion, Roux-en-Y biliary reconstruction is predominantly performed. Petersen's hernia is an internal hernia that can occur after Roux-en-Y reconstruction, and it may lead to extensive ischemic changes affecting incarcerated portions of the small bowel or Roux limb resulting in severe complications with a poor prognosis. CASE PRESENTATION: The present case was a 44-year-old male who underwent living donor liver transplantation (LDLT) for familial amyloid polyneuropathy and in whom biliary reconstruction was performed with Roux-en-Y hepaticojejunostomy. Two years after liver transplantation, symptomatic bowel strangulation was diagnosed by CT examination and emergent surgery was performed accordingly. On exploration, an ischemic limb associated with Petersen's hernia was observed. Although repositioning of the incarcerated bowel loop gradually improved the color of the limb, the limb failed to completely recover to a normal color. To allow accurate evaluation for the viability of the limb, we decided to perform a second-look operation after 48 h. On re-exploration, the surface of the limb remained a dark color; however, intraoperative endoscopic findings revealed only partial necrosis of the mucosa. Next, we resected the portion of ischemic damaged limb only following side-to-side jejunojejunostomy. Consequently, redoing of biliary reconstruction could be avoided and the original hepaticojejunostomy site was preserved. Although the stricture of the remnant Roux limb occurred 1 month thereafter, it was successfully managed by balloon dilation via percutaneous transhepatic biliary drainage route. CONCLUSIONS: The occurrence of Petersen's hernia should always be considered in cases of liver transplantation with Roux-en-Y biliary reconstruction. On the basis of an accurate assessment of the extent of jejunal limb injury, reanastomosis of the hepaticojejunostomy, a potentially high-risk surgical procedure, can be avoided in emergent situations.
  • 肝移植へのブリッジとしての門脈圧亢進症治療 肝移植へのブリッジとしての門脈圧亢進症治療
    嶋村 剛; 後藤 了一; 腰塚 靖之; 渡辺 正明; 川村 典生; 神山 俊哉
    日本門脈圧亢進症学会雑誌, 23, 3, 98, 98, (一社)日本門脈圧亢進症学会, Aug. 2017
    Japanese
  • 未来の臨床工学技士を考えた新たな業務展開 肝移植医療における臨床工学技士の役割
    太田 稔; 岡本 花織; 千葉 裕基; 柏浦 愛美; 山本 真由美; 川村 典生; 腰塚 靖之; 渡辺 正明; 後藤 了一; 山下 健一郎; 嶋村 剛
    日本臨床工学技士会会誌, 60, 149, 149, (公社)日本臨床工学技士会, Apr. 2017
    Japanese
  • 常染色体劣性多発性嚢胞腎に伴う肝線維症に対し脳死肝移植を施行した1例
    大平 将史; 後藤 了一; 腰塚 靖之; 神山 俊哉; 山下 健一郎; 武冨 紹信; 鈴木 友己; 嶋村 剛
    移植, 52, 1, 60, 66, (一社)日本移植学会, Apr. 2017
    Japanese, 症例は20歳男性で、生後4ヵ月時に腹部膨満を認め、腹部CT検査、腹部超音波検査にて両側腎臓と肝臓に多発する嚢胞を指摘された。3歳時に腎機能障害が出現し、臨床経過から常染色体劣性多発嚢胞腎(ARPKD)が疑われた。16歳時に肝腫大と肝内胆管拡張を認め、肝生検で肝線維化を認めた。臨床的にARPKDの診断基準を満たし、ARPKDに伴う先天性肝線維症と診断された。18歳時に食道静脈瘤を指摘され、内視鏡的静脈瘤結紮術を施行した。19歳時に脳死肝移植登録となった。医学的緊急度8点へ登録修正後138日目に脳死ドナーが発生し、肝移植目的で入院となった。術後は挿管状態のままICUに入室した。術後10日目に抜管し、術後12日目には一般病棟に帰室した。術後77日目に退院となった。周術期ならびに退院後2年迄は血液透析を導入することなく経過したが、次第に腎機能が悪化し、術後2年10ヵ月で血液透析導入となった。
  • 生体肝移植後におけるリンパ球クロスマッチによるDSAモニタリングの有用性
    伊藤 誠; 加畑 馨; 上床 貴代; 魚住 諒; 林 泰弘; 渡邊 千秋; 澁谷 斉; 後藤 了一; 嶋村 剛; 清水 力
    MHC: Major Histocompatibility Complex, 23, 2Suppl., 86, 86, (一社)日本組織適合性学会, Oct. 2016
    Japanese
  • 膵島移植の長期生着のための課題と克服 膵島移植におけるプロテアソーム阻害による早期グラフト障害の抑制
    小野 仁; 旭 よう; 吉田 雅; 腰塚 靖之; 渡辺 正明; 外丸 詩野; 江本 慎; 深井 原; 嶋村 剛; 武冨 紹信; 藤堂 省; 山下 健一郎
    移植, 51, 2-3, 273, 273, (一社)日本移植学会, Aug. 2016, [Peer-reviewed]
    Japanese
  • 炎症性腸疾患に関する治療戦略 Orthodox & Serendipity 生体肝移植における調節性T細胞ベース免疫寛容誘導に関する臨床試験(Immunological research for digestive surgery Clinical Trial of Regulatory T Cell-based Tolerance Induction in Living Donor Liver Transplantation)
    山下 健一郎; 財津 雅昭; 後藤 了一; 長津 明久; 鈴木 友己; 嶋村 剛; 神山 俊哉; 場集田 寿; 奥村 康; 藤堂 省
    日本消化器外科学会総会, 71回, WS24, 5, (一社)日本消化器外科学会, Jul. 2016, [Peer-reviewed]
    English
  • The impact of preformed donor-specific antibodies in living donor liver transplantation depending on graft volume
    Goto Ryoichi; Koshizuka Yasuyuki; Kawamura Norio; Zaitsu Masaaki; Ota Minoru; Kamiyama Toshiya; Yamashita Kenichiro; Taketomi Akinobu; Shimamura Tsuyoshi
    TRANSPLANTATION, 100, 7, S350, Jul. 2016, [Peer-reviewed]
  • A clinical trial of cell therapy-based tolerance induction in living donor liver transplantation: Long-term follow-up results
    Yamashita Kenichiro; Zaitsu Masaaki; Goto Ryoichi; Nagatsu Akihisa; Oura Tetsu; Watanabe Masaaki; Aoyagi Takeshi; Suzuki Tomomi; Shimamura Tsuyoshi; Kamiyama Toshiya; Sato Norihiro; Sugita Junichi; Hatanaka Kanako; Bashuda Hisashi; Okumura Ko; Todo Satoru
    TRANSPLANTATION, 100, 7, S244, Jul. 2016, [Peer-reviewed]
  • Outcomes of Living Donor Liver Transplantation Alone for Patients on Maintenance Renal Replacement Therapy in Japan: Results of a Nationwide Survey.
    Susumu Eguchi; Hiroyuki Furukawa; Shinji Uemoto; Koji Umeshita; Hajime Imamura; Akihiko Soyama; Tsuyoshi Shimamura; Shuji Isaji; Yasuhiro Ogura; Hiroto Egawa; Shigeyuki Kawachi; Mureo Kasahara; Hiroaki Nagano; Yonson Ku; Hideki Ohdan; Yoshihiko Maehara; Shuntaro Sato; Yukihiro Inomata
    Transplantation direct, 2, 6, e74, Jun. 2016, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND: Because simultaneous liver and kidney transplantation has been limited as a standard practice because of a severe shortage of deceased donors in Japan, living donor (LD) liver transplantation alone (LTA) is indicated in most recipients with maintenance renal replacement therapy (MRRT). METHODS: A retrospective nationwide survey of LD LTA was performed for liver transplant patients on MRRT. The characteristics of donors and recipients, postoperative complications, survival rate, and causes of death were analyzed. RESULTS: In the adult cases (n = 28), the overall survival rate at 1 year and 5 years were 66.1% and 57.3%, respectively. When compared with those adults without MRRT (n = 237), it was significantly worse. In the 7 pediatric cases, the overall survival rate at 1 and 5 years were both 83.3%. Three adult recipients died of nonaneurysm cerebral hemorrhage after 1 year and 1 adult recipient died of acute heart failure after 7 months. In adult recipients with MRRT, graft weight versus standard liver volume, and duration and blood loss in LTA surgery were associated with poor outcomes after LD LTA. Multivariate analysis revealed that MRRT was highest hazard ratio on patient survival after LD LTA. CONCLUSIONS: Early post-LD LTA mortality was higher in patients with MRRT than in those without MRRT with characteristic causes. Smaller grafts for size and a complicated surgery were associated with poor outcome after LD LTA. Thus, LD LTA in adult patients on MRRT should be carefully treated with meticulous postoperative management and follow-up.
  • Optimizing Small for Sized Graft: Our Experience in Living Donor Liver Transplantation Using GV/SV Less Than 35% Grafts
    Norio Kawamura; Masaaki Zaitsu; Yasuyuki Koshizuka; Ryoichi Goto; Tomomi Suzuki; Toshiya Kamiyama; Kenichiro Yamashita; Akinobu Taketomi; Tsuyoshi Shimamura
    TRANSPLANTATION, 100, S103, S103, May 2016, [Peer-reviewed]
    English
  • 血液製剤によるHIV/HCV重複感染患者の肝移植に関する研究 HCV/HIV重複感染血友病患者に対する脳死肝移植時の止血管理
    遠藤知之; 嶋村剛; 後藤了一; 藤本勝也
    血液製剤によるHIV/HCV重複感染患者の肝移植に関する研究 平成27年度 総括・分担研究報告書, 9‐11, 2016
    Japanese
  • 血液製剤によるHIV/HCV重複感染患者の肝移植に関する研究 脳死肝移植待機中のHIV/HCV重複感染による肝硬変2症例に対する術前準備
    嶋村剛; 遠藤知之; 後藤了一
    血液製剤によるHIV/HCV重複感染患者の肝移植に関する研究 平成27年度 総括・分担研究報告書, 21‐22, 2016
    Japanese
  • A PROTEASOME INHIBITOR, BORTEZOMIB PREVENTS PANCREATIC ISLET GRAFT LOSS AFTER TRANSPLANTATION.
    Hitoshi Ono; Yoh Asahi; Tadashi Yoshida; Yasuyuki Koshizuka; Masaaki Watanabe; Utano Tomaru; Nozomi Kobayashi; Shin Emoto; Moto Fukai; Tsuyoshi Shimamura; Akinobu Taketomi; Satoru Todo; Kenichiro Yamashita
    TRANSPLANTATION, 99, 11, S122, S122, Nov. 2015, [Peer-reviewed]
    English
  • A proteasome inhibitor, bortezomib prevents pancreatic islet graft loss after transplantation
    Hitoshi Ono; Yoh Asahi; Tadashi Yoshida; Yasuyuki Koshizuka; Masaaki Watanabe; Utano Tomaru; Nozomi Kobayashi; Shin Emoto; Moto Fukai; Tsuyoshi Shimamura; Akinobu Taketomi; Satoru Todo; Kenichiro Yamashita
    XENOTRANSPLANTATION, 22, S75, S75, Nov. 2015, [Peer-reviewed]
    English
  • A CLINICAL TRIAL OF CELL THERAPY-BASED TOLERANCE INDUCTION IN LIVING DONOR LIVER TRANSPLANTATION: AN UPDATE
    Yamashita Kenichiro; Goto Ryoichi; Zaitsu Masaaki; Nagatsu Akihisa; Oura Tetsu; Watanabe Masaaki; Aoyagi Takeshi; Suzuki Tomomi; Shimamura Tsuyoshi; Kamiyama Toshiya; Sato Norihiro; Sugita Junichi; Hatanaka Kanako; Demetris Anthony; Bashuda Hisashi; Okumura Ko; Todo Satoru
    TRANSPLANT INTERNATIONAL, 28, 57, Nov. 2015, [Peer-reviewed]
  • メチルドパにより亜急性型劇症肝炎を発症した1例
    小泉 忠史; 古家 乾; 馬場 英; 定岡 邦昌; 関谷 千尋; 服部 淳夫; 後藤 了一; 青柳 武史; 山下 健一郎; 嶋村 剛
    日本内科学会雑誌, 104, 3, 586, 589, (一社)日本内科学会, 10 Mar. 2015
    Japanese, 40歳女。高血圧症に対しカゼルニジピン内服していた。妊娠を契機としてメチルドパ250mgに変更した。骨盤位で入院し、婦人科に入院となり、メチルドパ750mgに増量した。帝王切開を施行し、術後経過良好で退院した。倦怠感を自覚し、白色便を認めた。黄疸を指摘され、指摘後9日目に入院した。肝炎ウイルスマーカーの上昇は認めず、病歴からメチルドパによる薬剤性肝障害を疑った。メチルドパを休薬し、SNMC、UDCAによる肝庇護療法、FFP輸血で加療した。入院後第2病日に肝生検を施行し、組織像は肝細胞の広範な脱落壊死を認めた。第6病日に肝性脳症が出現し、第10病日より血漿交換を開始し、第11病日より血液濾過透析を併用した。頭部CTでは脳浮腫の悪化、腹部CTでは肝の萎縮と腹水貯留を認めた。脳死肝移植を施行した。術後はサイトメガロウイルス感染や薬物性肝機能障害などを認めたが改善し、退院となった。
  • A Post-Liver Transplant Girl With Recurrent Cramps in the Legs.
    Jiro Abe; Yuma Yamada; Tomomi Suzuki; Tsuyoshi Shimamura; Ichiro Kobayashi
    Global pediatric health, 2, 2333794X14566074, 2015, [International Magazine]
    English, Scientific journal
  • 脳死肝移植後肝動脈狭窄(HAS)に対しPBA翌日にステント留置を追加し狭窄改善し得た1例
    阿保 大介; 曽山 武士; 作原 祐介; 志村 亮祐; 高橋 文也; 工藤 與亮; 山下 健一郎; 嶋村 剛
    IVR: Interventional Radiology, 29, 4, 429, 429, (一社)日本インターベンショナルラジオロジー学会, Dec. 2014
    Japanese
  • 生体肝移植後14年目に胆管狭窄をきたした1例
    石井 大介; 谷口 雅彦; 今井 浩二; 渡邉 賢二; 内田 浩一郎; 鈴木 達也; 古川 博之; 清水 匡; 嶋村 剛; 山下 健一郎
    日本移植学会総会プログラム抄録集, 50回, 444, 444, (一社)日本移植学会, Aug. 2014
    Japanese
  • Successful Withdrawal of Immunosuppression by a Cell Therapy Using Donor Ag-pulsed Tregs in Living Donor Liver Transplantation: An Update on Clinical Trial.
    Yamashita Kenichiro; Zaitsu Masaaki; Nagatsu Akihisa; Goto Ryoichi; Oura Tetsu; Watanabe Masaaki; Aoyagi Takeshi; Suzuki Tomomi; Shimamura Tsuyoshi; Kamiyama Toshiya; Sato Norihiro; Sugita Junichi; Hatanaka Kanako; Bashuda Hisashi; Okumura Ko; Todo Satoru
    LIVER TRANSPLANTATION, 20, S125, S126, Jun. 2014, [Peer-reviewed]
  • 当科における脳死肝移植待機中死亡症例の検討
    青柳 武史; 杉山 昂; 後藤 了一; 大浦 哲; 渡辺 正明; 山下 健一郎; 鈴木 友己; 嶋村 剛; 太田 稔; 山本 真由美; 坂井 絢; 武冨 紹信; 藤堂 省
    移植, 49, 1, 68, 68, (一社)日本移植学会, May 2014
    Japanese
  • 生体肝移植における制御性T細胞治療を用いた免疫寛容誘導の試み 肝移植後の「より良い」長期生着に向けて
    山下 健一郎; 財津 雅昭; 長津 明久; 後藤 了一; 大浦 哲; 渡辺 正明; 青柳 武史; 江本 愼; 鈴木 友己; 嶋村 剛; 佐藤 典宏; 杉田 純一; 畑中 佳奈子; 場集田 寿; 奥村 康; 藤堂 省
    移植, 49, 1, 106, 106, (一社)日本移植学会, May 2014, [Peer-reviewed]
    Japanese
  • 肝移植におけるイノベーション 生体肝移植における制御性T細胞を用いた免疫寛容誘導
    山下 健一郎; 財津 雅昭; 長津 明久; 後藤 了一; 大浦 哲; 渡辺 正明; 青柳 武史; 鈴木 友己; 嶋村 剛; 場集田 寿; 奥村 康; 藤堂 省
    日本外科学会雑誌, 115, 臨増2, 135, 135, (一社)日本外科学会, Mar. 2014, [Peer-reviewed]
    Japanese
  • REGULATORY T CELL-BASED CELL THERAPY FOR TOLERANCE INDUCTION IN LIVING DONOR LIVER TRANSPLANTATION
    Yamashita Kenichiro; Zaitsu Masaaki; Nagatsu Akihisa; Goto Ryoichi; Oura Tetsu; Watanabe Masaaki; Aoyagi Takeshi; Suzuki Tomomi; Shimamura Tsuyoshi; Sato Norihiro; Sugita Junichi; Hatanaka Kanako; Bashuda Hisashi; Okumura Ko; Todo Satoru
    TRANSPLANT INTERNATIONAL, 26, 98, Nov. 2013, [Peer-reviewed]
  • 小児生体肝移植術後に複合的IVRを施行した1例
    阿保 大介; 曽山 武士; 作原 祐介; 長谷川 悠; 寺江 聡; 白土 博樹; 渡辺 正明; 山下 健一郎; 鈴木 友己; 嶋村 剛
    IVR: Interventional Radiology, 28, 4, 484, 484, (一社)日本インターベンショナルラジオロジー学会, Oct. 2013
    Japanese
  • 膵移植後静脈血栓症に対し経動脈的血栓溶解療法が有効であった1例
    藪崎 哲史; 阿保 大介; 曽山 武士; 作原 祐介; 寺江 聡; 渡辺 正明; 鈴木 友己; 嶋村 剛
    IVR: Interventional Radiology, 28, 4, 487, 487, (一社)日本インターベンショナルラジオロジー学会, Oct. 2013
    Japanese
  • 免疫抑制と免疫寛容 制御性T細胞治療を用いた免疫寛容誘導 生体肝移植における臨床試験
    山下 健一郎; 長津 明久; 後藤 了一; 青柳 武史; 鈴木 友己; 嶋村 剛; 江本 愼; 場集田 寿; 奥村 康; 藤堂 省
    移植, 48, 総会臨時, 201, 201, (一社)日本移植学会, Aug. 2013, [Peer-reviewed]
    Japanese
  • A Pilot Study for Tolerance Induction by a Regulatory T Cell-Based Cell Therapy in Living Donor Liver Transplantation.
    Yamashita Kenichiro; Zaitsu Masaaki; Nagatsu Akihisa; Goto Ryoichi; Oura Tetsu; Watanabe Masaaki; Aoyagi Takeshi; Suzuki Tomomi; Shimamura Tsuyoshi; Sato Norihiro; Sugita Junichi; Hatanaka Kanako; Bashuda Hisashi; Okumura Ko; Todo Satoru
    LIVER TRANSPLANTATION, 19, S130, Jun. 2013, [Peer-reviewed]
  • 肝移植術後肝動脈狭窄に対するIVR
    阿保 大介; 作原 祐介; 児玉 芳尚; 清水 匡; 曽山 武士; 山下 健一郎; 嶋村 剛; 寺江 聡; 白土 博樹
    IVR: Interventional Radiology, 28, Suppl., 77, 77, (一社)日本インターベンショナルラジオロジー学会, Apr. 2013
    Japanese
  • 生体肝再移植後に認めた遅発性肝静脈狭窄に対してバルーン拡張術を施行した1例
    脇坂 和貴; 青柳 武史; 巖築 慶一; 大浦 哲; 渡辺 正明; 後藤 了一; 武冨 紹信; 鈴木 友己; 嶋村 剛; 藤堂 省
    日本臨床外科学会雑誌, 74, 2, 595, 595, 日本臨床外科学会, Feb. 2013
    Japanese
  • Histopathological evaluation of the efficacy of antifungals for experimental Trichosporon bloodstream infection.
    Daisuke Sasai; Yoichiro Okubo; Takao Ishiwatari; Takashi Sugita; Takehiko Kaneko; Somay Yamagata Murayama; Tsuyoshi Shimamura; Minoru Shinozaki; Chikako Hasegawa; Aki Mitsuda; Naobumi Tochigi; Megumi Wakayama; Tetsuo Nemoto; Kazutoshi Shibuya
    Japanese journal of infectious diseases, 66, 2, 133, 9, 2013, [Domestic magazines]
    English, Scientific journal, The efficacy of polyene macrolides to treat experimental Trichosporon bloodstream infection was evaluated by histopathological examination and viable cell counts in the kidneys of infected mice. Viable cell counts on the 5th day after infection confirmed that liposomal amphotericin B (L-AMB) is a more effective treatment than fluconazole (FLC) for mice infected with an azole-resistant strain of Trichosporon. Histological examination revealed that the administration of L-AMB induced a transformation from acute purulent inflammation caused by both azole-susceptible and -resistant strain infections to a chronic and subsiding form, whereas FLC failed to convert the acute inflammation induced by the azole-resistant strain to a subsiding form. Our results demonstrate that polyene macrolides can be used as an alternative therapy for infection of azole-resistant strains of Trichosporon and that histopathological evaluation is useful for elucidating the pathophysiology of an experimental Trichosporon infection.
  • 当科における脳死肝移植適応基準
    大浦 哲; 鈴木 友己; 嶋村 剛; 山下 健一郎; 青柳 武史; 後藤 了一; 渡辺 正明; 谷口 雅彦; 古川 博之; 武冨 紹信; 藤堂 省
    移植, 47, 総会臨時, 254, 254, (一社)日本移植学会, Sep. 2012
    Japanese
  • 肝性昏睡合併急性肝不全に対する肝臓内科移植外科協同による地域的診療システムの治療成績 11年間の概括と展望
    姜 貞憲; 松居 剛志; 友成 暁子; 青木 敬則; 山崎 大; 辻 邦彦; 児玉 芳尚; 桜井 康雄; 真口 宏介; 渡辺 正明; 山下 健一郎; 鈴木 友巳; 嶋村 剛; 藤堂 省; 谷口 雅彦; 古川 博之
    移植, 47, 4-5, 342, 343, (一社)日本移植学会, Sep. 2012
    Japanese
  • 生体肝移植術後の過少グラフト症候群に伴う大量腹水にPSEが著効した1例
    山田 健司; 渡辺 正明; 大浦 哲; 山下 健一郎; 鈴木 友己; 嶋村 剛; 藤堂 省; 武富 紹信
    北海道外科雑誌, 57, 1, 75, 75, 北海道外科学会, Jun. 2012
    Japanese
  • 同側に移植した脳死下膵臓・腎臓同時移植の1例
    山田 健司; 渡辺 正明; 鈴木 友己; 岩見 大基; 福澤 信之; 大浦 哲; 山下 健一郎; 森田 研; 嶋村 剛; 近藤 琢磨; 野々村 克也; 藤堂 省
    日本臨床外科学会雑誌, 73, 6, 1604, 1604, 日本臨床外科学会, Jun. 2012
    Japanese
  • 脳死肝移植の現状と我が国における今後の肝移植の展開 臓器移植法改正が急性肝不全診療に与えた臨床的impact 肝臓内科・移植外科協同地域的診療システムにおける検討
    姜 貞憲; 松居 剛志; 金 俊文; 志田 勇人; 友成 暁子; 辻 邦彦; 児玉 芳尚; 桜井 康雄; 真口 宏介; 渡辺 正明; 山下 健一郎; 鈴木 友巳; 嶋村 剛; 藤堂 省; 谷口 雅彦; 古川 博之
    肝臓, 53, Suppl.1, A32, A32, (一社)日本肝臓学会, Apr. 2012
    Japanese
  • 劇症肝不全に対する肝移植における血液浄化療法の役割
    太田 稔; 嶋村 剛; 鈴木 友己; 山下 健一郎; 渡辺 正明; 大浦 哲; 谷口 雅彦; 古川 博之; 藤堂 省
    医工学治療, 24, Suppl., 128, 128, (NPO)日本医工学治療学会, Mar. 2012
    Japanese
  • 生体肝ドナーquality of life尺度の開発および信頼性と妥当性の検討
    師岡 友紀; 梅下 浩司; 武冨 紹信; 前原 喜彦; 山本 真由美; 嶋村 剛; 大下 彰彦; 菅野 啓子; 大段 秀樹; 川岸 直樹; 里見 進; 小川 馨; 萩原 邦子; 永野 浩昭
    移植, 47, 1, 67, 74, (一社)日本移植学会, Mar. 2012
    Japanese, 生体肝ドナーQOL尺度を開発し、実用化に向け項目の精選を図り、信頼性と妥当性を検証することを目的とし大規模調査を実施した。生体肝提供手術を受け、術後1ヵ月以上経過したドナー965例を対象とした。生体肝ドナー20例に対する半構成的インタビューの結果、および先行研究による概念枠組みをもとに独自に質問項目を作成し、QOL尺度素案を作成した。432例を分析対象とした。開発した生体肝ドナーQOL尺度は、構成概念妥当性、基準関連妥当性は十分であると考えられ、QOL評価が可能な妥当性のある尺度とみなすことができた。また、再テストによる安定性、尺度の内的整合性もまずまずで、信頼性があり使用可能な尺度であることを確認した。解釈における配慮事項はあるものの、当面の使用にあたって問題ない妥当性、信頼性が得られているため、本尺度を用いた生体肝ドナーのQOL評価は可能と考えられた。
  • 【臓器移植をめぐる最近の話題;臓器移植法改正後の展開】改正臓器移植法と臓器移植 法改正で何が変わったか
    古川 博之; 谷口 雅彦; 唐崎 秀則; 今井 浩二; 山下 健一郎; 鈴木 友己; 嶋村 剛; 藤堂 省
    Pharma Medica, 29, 11, 9, 13, (株)メディカルレビュー社, Nov. 2011
    Japanese
  • 【移植医療の新展開】臓器移植法改正による新展開 臓器摘出チームの活動
    古川 博之; 谷口 雅彦; 唐崎 秀則; 今井 浩二; 山下 健一郎; 鈴木 友己; 嶋村 剛; 藤堂 省
    外科, 73, 11, 1160, 1163, (株)南江堂, Nov. 2011
    Japanese
  • 肝芽腫に対して生体肝移植を施行した3例
    石黒 友唯; 嶋村 剛; 鈴木 友己; 山下 健一郎; 渡辺 正明; 大浦 哲; 藤堂 省
    日本臨床外科学会雑誌, 72, 10, 2740, 2740, 日本臨床外科学会, Oct. 2011
    Japanese
  • 生体肝移植ドナーの調査研究に対する思い
    師岡友紀; 山本真由美; 萩原邦子; 小川馨; 嶋村剛; 永野浩昭; 梅下浩司
    第42回日本看護学会抄録集, Sep. 2011, [Peer-reviewed]
    Japanese, Research society
  • 肝移植後の門脈圧亢進症 成人間生体肝移植における門脈圧調節の意義
    谷口 雅彦; 永生 高広; 大浦 哲; 渡辺 正明; 山下 健一郎; 鈴木 友己; 嶋村 剛; 古川 博之; 藤堂 省
    日本門脈圧亢進症学会雑誌, 17, 3, 53, 53, (一社)日本門脈圧亢進症学会, Aug. 2011
    Japanese
  • 【Changed!?臓器移植法改正施行後1年の現況】法改正の背景 肝移植における法改正に向けての体制整備
    古川 博之; 谷口 雅彦; 唐崎 秀則; 今井 浩二; 山下 健一郎; 鈴木 友己; 嶋村 剛; 藤堂 省
    肝胆膵, 63, 1, 43, 49, (株)アークメディア, Jul. 2011
    Japanese
  • 生体肝移植術後にde novo AIHを発症したC型肝硬変の一例
    水上 達三; 谷口 雅彦; 渡辺 正明; 山下 健一郎; 鈴木 友己; 嶋村 剛; 藤堂 省; 古川 博之
    北海道外科雑誌, 56, 1, 60, 61, 北海道外科学会, Jun. 2011
    Japanese
  • 【臓器移植の新時代】脳死臓器提供に関する課題 脳死下におけるドナー管理
    谷口 雅彦; 古川 博之; 唐崎 秀則; 今井 浩二; 永生 高広; 藤田 智; 大浦 哲; 渡辺 正明; 山下 健一郎; 鈴木 友己; 嶋村 剛; 藤堂 省
    医学のあゆみ, 237, 5, 459, 465, 医歯薬出版(株), Apr. 2011
    Japanese
  • 生体肝移植後に横隔膜ヘルニアをきたした一例
    小柳 要; 渡辺 正明; 山下 健一郎; 鈴木 友己; 嶋村 剛; 藤堂 省
    日本臨床外科学会雑誌, 72, 4, 1067, 1067, 日本臨床外科学会, Apr. 2011
    Japanese
  • 小児生体肝移植後に食物アレルギーによる慢性下痢症を呈した1例
    神田 真聡; 山下 健一郎; 渡辺 正明; 福森 大介; 内田 浩一郎; 鈴木 友己; 谷口 雅彦; 嶋村 剛; 古川 博之; 藤堂 省
    日本臨床外科学会雑誌, 72, 4, 1067, 1068, 日本臨床外科学会, Apr. 2011
    Japanese
  • 1型糖尿病患者に対する膵腎同時移植の2例
    川俣 太; 鈴木 友己; 渡辺 正明; 谷口 雅彦; 山下 健一郎; 嶋村 剛; 藤堂 省
    日本臨床外科学会雑誌, 72, 4, 1068, 1069, 日本臨床外科学会, Apr. 2011
    Japanese
  • 脳死肝移植実施における現状と問題点 教室における脳死肝移植ドナー選択の検討
    谷口 雅彦; 渡辺 正明; 山下 健一郎; 鈴木 友己; 嶋村 剛; 神山 俊哉; 松下 通明; 古川 博之; 藤堂 省
    移植, 45, 総会臨時, 151, 151, (一社)日本移植学会, Oct. 2010
    Japanese
  • 小児生体肝移植後に食物アレルギーによる難治慢性下痢症を呈した1例
    神田 真聡; 山下 健一郎; 渡辺 正明; 福森 大介; 内田 浩一郎; 鈴木 友己; 谷口 雅彦; 嶋村 剛; 古川 博之; 藤堂 省
    移植, 45, 総会臨時, 322, 322, (一社)日本移植学会, Oct. 2010
    Japanese
  • 生体肝移植術後にde novo AIHを発症したC型肝硬変の一例
    水上 達三; 谷口 雅彦; 渡辺 正明; 山下 健一郎; 鈴木 友己; 嶋村 剛; 古川 博之; 藤堂 省
    移植, 45, 総会臨時, 323, 323, (一社)日本移植学会, Oct. 2010
    Japanese
  • 生体肝移植後の高アンモニア血症に対し、mesocaval shuntのコイル塞栓が有効であった1例
    川俣 太; 谷口 雅彦; 渡辺 正明; 大浦 哲; 山下 健一郎; 嶋村 剛; 藤堂 省; 古川 博之
    移植, 45, 総会臨時, 326, 326, (一社)日本移植学会, Oct. 2010
    Japanese
  • 最近5年間の成人生体肝移植施行例の短期成績とその評価 指定期間に北大病院で施行された成人生体肝移植61例の検討
    鈴木 友己; 嶋村 剛; 谷口 雅彦; 山下 健一郎; 渡辺 正明; 神山 俊哉; 中西 一彰; 蒲池 浩文; 松下 通明; 古川 博之; 藤堂 省
    日本臨床外科学会雑誌, 71, 増刊, 361, 361, 日本臨床外科学会, Oct. 2010
    Japanese
  • 門脈圧亢進症の血行動態 成人生体肝移植における門脈循環調節の検討
    渡辺 正明; 谷口 雅彦; 大浦 哲; 山下 健一郎; 鈴木 友己; 嶋村 剛; 藤堂 省
    日本門脈圧亢進症学会雑誌, 16, 2, 53, 53, (一社)日本門脈圧亢進症学会, Aug. 2010
    Japanese
  • 肝細胞癌切除後再発への治療戦略 Salvage肝移植を考慮して
    神山 俊哉; 中西 一彰; 横尾 英樹; 蒲池 浩文; 田原 宗徳; 福森 大介; 嶋村 剛; 古川 博之; 松下 通明; 藤堂 省
    日本消化器外科学会総会, 65回, 9, 9, (一社)日本消化器外科学会, Jul. 2010
    Japanese
  • Functional Classification of Hepatic Veins and Interrelationships among Hepatic Vessels for Living Donor Liver Transplantation
    Uchida Koichiro; Taniguchi Masahiko; Yamashita Kenichiro; Suzuki Tomomi; Shimamura Tsuyoshi; Kamiyama Toshiya; Matsushita Michiaki; Furukawa Hiroyuki; Todo Satoru
    AMERICAN JOURNAL OF TRANSPLANTATION, 10, 272, Apr. 2010, [Peer-reviewed]
  • PBCに対する生体肝移植後、難治性液性拒絶および遅発性細胞性拒絶をきたした一例
    大村 一将; 山下 健一郎; 谷口 雅彦; 鈴木 友巳; 嶋村 剛; 古川 博之; 藤堂 省
    日本臨床外科学会雑誌, 71, 3, 869, 869, 日本臨床外科学会, Mar. 2010, [Peer-reviewed]
    Japanese
  • 肝切除合併症ゼロを目指して
    神山 俊哉; 中西 一彰; 横尾 英樹; 蒲池 浩文; 田原 宗徳; 福森 大介; 嶋村 剛; 古川 博之; 松下 通明; 藤堂 省
    日本臨床外科学会雑誌, 70, 増刊, 393, 393, 日本臨床外科学会, Oct. 2009
    Japanese
  • 重水含有新規臓器保存液を用いた長期心冷保存の検討
    若山 顕治; 深井 原; 山下 健一郎; 福森 大介; 柴崎 晋; 廣方 玄太郎; 谷口 雅彦; 鈴木 友己; 嶋村 剛; 古川 博之; 尾崎 倫孝; 藤堂 省
    移植, 44, 総会臨時, 271, 271, (一社)日本移植学会, Sep. 2009
    Japanese
  • PBCに対する生体肝移植後、抗体関連拒絶および細胞性拒絶反応をきたした一例
    大村 一将; 山田 健司; 大畑 多嘉宣; 永生 高広; 山下 健一郎; 谷口 雅彦; 鈴木 友己; 嶋村 剛; 古川 博之; 藤堂 省
    移植, 44, 総会臨時, 246, 246, (一社)日本移植学会, Sep. 2009, [Peer-reviewed]
    Japanese
  • Small-for-size graftの診断と治療 成人生体肝移植における肝循環制御の効果
    谷口 雅彦; 渡辺 正明; 大浦 哲; 山下 健一郎; 鈴木 友己; 嶋村 剛; 古川 博之; 藤堂 省
    移植, 44, 1, 117, 118, (一社)日本移植学会, Feb. 2009
    Japanese
  • 診療ガイドラインをどう活用するか 肝癌診療ガイドライン改定に向けて
    神山 俊哉; 中西 一彰; 横尾 英樹; 蒲池 浩文; 田原 宗徳; 福森 大介; 山下 健一郎; 谷口 雅彦; 鈴木 知己; 嶋村 剛; 古川 博之; 松下 通明; 藤堂 省
    北海道外科雑誌, 53, 2, 151, 156, 北海道外科学会, Dec. 2008
    Japanese
  • 肝切除術時の皮膚切開・視野展開法の工夫
    神山 俊哉; 中西 一彰; 横尾 英樹; 蒲池 浩文; 田原 宗徳; 福森 大介; 松下 通明; 嶋村 剛; 古川 博之; 藤堂 省
    日本臨床外科学会雑誌, 69, 増刊, 435, 435, 日本臨床外科学会, Oct. 2008
    Japanese
  • 肝移植後膵液瘻による合併症に対し複合的IVRが奏功した1例
    長谷川 悠; 阿保 大介; 佐原 祐介; 白土 博樹; 清水 匡; 嶋村 剛; 古川 博之; 桑谷 将城; 河上 洋
    IVR: Interventional Radiology, 23, 3, 316, 316, (一社)日本インターベンショナルラジオロジー学会, Jul. 2008
    Japanese
  • 生体肝移植術後に再発したNASHの1例
    旭 よう; 谷口 雅彦; 山下 健一郎; 鈴木 知己; 嶋村 剛; 腰塚 靖之; 蔵谷 大輔; 佐藤 正法; 古川 博之; 藤堂 省; 佐々木 彩美; 伊藤 智雄
    北海道外科雑誌, 53, 1, 120, 121, 北海道外科学会, Jun. 2008
    Japanese
  • Circulating tumor cellの臨床的意義 肝細胞癌切除例における骨髄中、末梢血中微小転移検出の意義
    神山 俊哉; 中西 一彰; 横尾 英樹; 田原 宗徳; 佐々木 彩実; 福森 大介; 山下 健一郎; 谷口 雅彦; 鈴木 克己; 嶋村 剛; 古川 博之; 松下 通明; 藤堂 省
    日本外科学会雑誌, 109, 臨増2, 141, 141, (一社)日本外科学会, Apr. 2008
    Japanese
  • 肝細胞癌治療における外科の役割 肝切除・肝移植 肝細胞癌治療における肝切除の役割
    神山 俊哉; 中西 一彰; 横尾 英樹; 田原 宗徳; 山下 健一郎; 谷口 雅彦; 鈴木 知己; 嶋村 剛; 古川 博之; 松下 通明; 藤堂 省
    日本臨床外科学会雑誌, 68, 増刊, 334, 334, 日本臨床外科学会, Nov. 2007
    Japanese
  • 小児生体肝移植術後の門脈合併症についての検討
    柴崎 晋; 谷口 雅彦; 長津 明久; 山下 健一郎; 鈴木 友己; 嶋村 剛; 古川 博之; 藤堂 省
    日本臨床外科学会雑誌, 68, 増刊, 462, 462, 日本臨床外科学会, Nov. 2007, [Peer-reviewed]
    Japanese
  • 内視鏡的治療が奏功した生体肝移植後膵液瘻の2例
    長津 明久; 谷口 雅彦; 柴崎 晋; 山下 健一郎; 鈴木 友己; 嶋村 剛; 古川 博之; 藤堂 省
    日本臨床外科学会雑誌, 68, 増刊, 463, 463, 日本臨床外科学会, Nov. 2007, [Peer-reviewed]
    Japanese
  • Enlarged polycystic liverに対する動脈塞栓術の経験
    藤間 憲幸; 長谷川 悠; 作原 祐介; 阿保 大介; 白土 博樹; 清水 匡; 嶋村 剛
    IVR: Interventional Radiology, 22, 4, 503, 503, (一社)日本インターベンショナルラジオロジー学会, Oct. 2007
    Japanese
  • 肝移植術時に作成された門脈下大静脈短絡路(PCシャント)をcoil塞栓できた1例
    阿保 大介; 作原 祐介; 長谷川 悠; 藤間 憲幸; 白土 博樹; 清水 匡; 嶋村 剛; 古川 博之
    IVR: Interventional Radiology, 22, 4, 503, 503, (一社)日本インターベンショナルラジオロジー学会, Oct. 2007
    Japanese
  • 肝移植後膵液瘻による合併症に対しIVRにて複合的に対処した1例
    長谷川 悠; 阿保 大介; 作原 祐介; 藤間 憲幸; 白土 博樹; 清水 匡; 嶋村 剛; 古川 博之
    IVR: Interventional Radiology, 22, 4, 505, 505, (一社)日本インターベンショナルラジオロジー学会, Oct. 2007
    Japanese
  • 小児生体肝移植後の門脈合併症の検討
    柴崎 晋; 谷口 雅彦; 長津 明久; 山下 健一郎; 鈴木 友己; 嶋村 剛; 古川 博之; 藤堂 省
    日本臨床外科学会雑誌, 68, 9, 2423, 2424, 日本臨床外科学会, Sep. 2007, [Peer-reviewed]
    Japanese
  • ENPDで治癒した生体肝移植後膵液瘻の2例
    長津 明久; 谷口 雅彦; 柴崎 晋; 山下 健一郎; 鈴木 友己; 嶋村 剛; 古川 博之; 藤堂 省
    日本臨床外科学会雑誌, 68, 9, 2424, 2424, 日本臨床外科学会, Sep. 2007, [Peer-reviewed]
    Japanese
  • マイクロメタの臨床的意義をめぐって マイクロメタの診断は治療戦略、術式選択を変えたか? 肝細胞癌切除例におけるreal time PCR法を用いたAFPmRNA測定の意義
    神山 俊哉; 中西 一彰; 横尾 英樹; 田原 宗徳; 蒲池 浩文; 佐々木 彩実; 嶋村 剛; 古川 博之; 松下 通明; 藤堂 省
    日本消化器外科学会雑誌, 40, 7, 1024, 1024, (一社)日本消化器外科学会, Jul. 2007
    Japanese
  • 【呼吸器と寄生虫】肺の多包性エキノコックス症
    佐藤 直樹; 寺崎 康展; 佐々木 彩実; 柿坂 達彦; 横尾 英樹; 山下 健一郎; 中西 一彰; 嶋村 剛; 神山 俊哉; 松下 通明; 藤堂 省
    日本胸部臨床, 66, 4, 289, 296, 克誠堂出版(株), Apr. 2007
    Japanese
  • 非進行肝細胞癌(ミラノ基準以内)に対する外科治療法の選択
    神山 俊哉; 中西 一彰; 蒲池 浩文; 横尾 英樹; 田原 宗徳; 山下 健一郎; 谷口 雅彦; 鈴木 友己; 嶋村 剛; 古川 博之; 松下 通明; 藤堂 省
    日本臨床外科学会雑誌, 67, 増刊, 268, 268, 日本臨床外科学会, Oct. 2006
    Japanese
  • 【生体肝移植における門脈・肝静脈再建】肝静脈再建 右肝グラフトにおける肝静脈再建
    谷口 雅彦; 古川 博之; 嶋村 剛; 鈴木 友己; 山下 健一郎; 太田 稔; 神山 俊哉; 松下 通明; 藤堂 省
    外科, 68, 3, 295, 300, (株)南江堂, Mar. 2006
    Japanese
  • 肝細胞癌のmicrometastasis
    神山 俊哉; 高橋 将人; 中川 隆公; 中西 一彰; 横尾 英樹; 蒲池 浩文; 嶋村 剛; 古川 博之; 松下 通明; 藤堂 省
    外科治療, 94, 1, 91, 93, (株)永井書店, Jan. 2006
    Japanese, 肝細胞癌のmicrometastasisについて検討した.方法は肝細胞癌初回切除136例の肝切除前に骨髄液を採取し,real time RT-PCR法でAFPmRNAとGAPDHmRNAを測定,AFPmRNA/GAPDHmRNA比を求めた.そして,正常対象者の骨髄中のAFPmRNA/GAPDHmRNA比からカットオフ値を1.92×10^-7とし,この値以上を陽性とした.1)136例中38例(27.9%)が陽性,98例(72.1%)が陰性であった.2)臨床病理学的所見,病理組織学的所見との比較では,組織学的門脈侵襲,Stageと有意な相関を認めた.3)3年生存率は陽性例55.5%,陰性例91.4%,3年無再発性存率は陽性例25.8%,陰性例44.8%と有意に陽性例で不良であった.4)骨髄中AFPmRNAの測定は,循環中に存在する癌細胞が原因の転移,再発,腫瘍死の指標となり,肝移植の成績,適応を推定する上で有用な因子と考えられた
  • 生体部分肝移植患者におけるMicafungin(「Funguard」)の体内動態
    岸野 吏志; 大野 恵子; 望月 伸夫; 嶋村 剛; 古川 裕之; 藤堂 省
    TDM研究, 22, 3, 214, 219, (一社)日本TDM学会, Jul. 2005
    Japanese
  • 【原発性硬化性胆管炎(PSC)の診療をめぐって】PSCの治療 肝移植
    嶋村 剛; 鈴木 友己; 谷口 雅彦; 山下 健一郎; 太田 稔; 萩原 邦子; 古川 博之; 藤堂 省
    胆と膵, 26, 4, 407, 412, 医学図書出版(株), Apr. 2005
    Japanese
  • 【移植の周術期管理】肝臓移植における移植前後の血液浄化
    松下 通明; 嶋村 剛; 太田 稔; 谷口 雅彦; 鈴木 友己; 古川 博之; 藤堂 省
    Clinical Engineering, 16, 3, 235, 240, (株)Gakken, Feb. 2005
    Japanese
  • 【生体肝移植とその短期および長期成績】疾患別の術後管理,長期対策 肝癌
    谷口 雅彦; 古川 博之; 嶋村 剛; 陳 孟鳳; 鈴木 友己; 太田 稔; 萩原 邦子; 高橋 将人; 神山 俊哉; 松下 通明; 藤堂 省
    外科, 66, 9, 1050, 1054, (株)南江堂, Sep. 2004
    Japanese, 肝移植後の対策として,肝癌再発の観点から免疫抑制療法,化学療法,画像追跡,腫瘍分子マーカーの観察などが重要であるが,併存するB型,C型肝炎に対する再発予防策も必須である.我が国の肝癌に対する生体肝移植316例の検討では,生存率は74.7%,再発率は12.7%であり,移植後3年以降の再発は認めなかった.また171例(54.1%)はいわゆるミラノ基準逸脱例であり,うち133例(77.8%)は現時点で無再発であった
  • 当科における生体肝移植ドナー105例の検討
    鈴木 友己; 嶋村 剛; 陳 孟鳳; 谷口 雅彦; 中西 一彰; 中川 隆公; 神山 俊哉; 松下 通明; 古川 博之; 藤堂 省
    移植, 39, 総会臨時, 292, 292, (一社)日本移植学会, Jul. 2004
    Japanese
  • 成人生体肝移植術におけるlarge-for-size graftの経験
    谷 安弘; 谷口 雅彦; 陳 孟鳳; 鈴木 友己; 嶋村 剛; 古川 博之; 藤堂 省
    移植, 39, 総会臨時, 301, 301, (一社)日本移植学会, Jul. 2004
    Japanese
  • 生体部分肝移植術後の門脈狭窄症に対し経皮経肝門脈拡張術が奏効した2例
    藤好 真人; 服部 優宏; 川村 典生; 鈴木 陽三; 谷口 雅彦; 鈴木 友己; 陳 孟鳳; 嶋村 剛; 古川 博之; 藤堂 省; 作原 祐介; 澤田 明宏; 清水 匡
    北海道外科雑誌, 49, 1, 66, 67, 北海道外科学会, Jun. 2004
    Japanese
  • 【臓器移植におけるアフェレシス治療】劇症肝炎に対するアフェレシスの役割 生体肝移植との関わり
    太田 稔; 嶋村 剛; 孔 孟鳳; 鈴木 友己; 谷口 雅彦; 萩原 邦子; 松下 通明; 古川 博之; 藤堂 省
    医工学治療, 16, 1, 26, 31, (NPO)日本医工学治療学会, Apr. 2004
    Japanese
  • 生体部分肝移植患者におけるLinezolid(Zyvox)の体内動態
    岸野吏志; 馬渕朋美; 武隈 洋; 菅原 満; 嶋村 剛; 古川裕之; 藤堂 省; 宮崎勝巳
    TDM研究, 21, 1, 21, 25, Jan. 2004, [Peer-reviewed]
    Japanese, Scientific journal
  • 大腸破裂を合併した亜急性劇症肝不全の一例
    廣方 玄太郎; 古川 博之; 嶋村 剛; 陳 孟鳳; 鈴木 友己; 服部 優宏; 谷口 雅彦; 中木村 繁; 藤堂 省
    日本臨床外科学会雑誌, 64, 11, 2931, 2931, 日本臨床外科学会, Nov. 2003
    Japanese
  • 先天性プロテインC欠損症による門脈血栓症
    佐藤 秀雄; 古川 博之; 嶋村 剛; 陳 孟鳳; 鈴木 友己; 服部 優宏; 谷口 雅彦; 柴崎 晋; 佐藤 祐二; 藤堂 省
    日本臨床外科学会雑誌, 64, 11, 2940, 2940, 日本臨床外科学会, Nov. 2003
    Japanese
  • 急性肝不全に対し内科的治療に並行して行った生体肝移植準備過程の検討
    大西 幸代; 姜 貞憲; 前久保 博士; 萩原 邦子; 鈴木 友己; 嶋村 剛; 古川 博之; 藤堂 省
    肝臓, 44, 11, 616, 616, (一社)日本肝臓学会, Nov. 2003
    Japanese
  • 北海道の臓器移植推進のために 北海道での臓器提供推進の取り組み
    嶋村 剛; 陳 孟鳳; 鈴木 友己; 谷口 雅彦; 太田 稔; 萩原 邦子; 古川 博之; 藤堂 省
    低温医学, 29, 3, 79, 79, 日本低温医学会, Sep. 2003
    Japanese
  • 【成人生体肝移植】肝癌治療における生体肝移植
    嶋村 剛; 古川 博之; 陳 孟鳳; 鈴木 友己; 谷口 雅彦; 太田 稔; 萩原 邦子; 神山 俊哉; 松下 通明; 藤堂 省
    今日の移植, 16, 5, 466, 472, (株)日本医学館, Sep. 2003
    Japanese, 生体肝移植では,臓器分配の妥当性よりもドナーとレシピエント双方のリスクの理解が重視されるため,肝癌に対してその適応が拡大される方向にある.我が国の肝癌に対する生体肝移植225例の検討でも,119例(52.9%)はいわゆるミラノ基準逸脱例であった.解析の結果,逸脱例のなかにも良好な予後を期待できる症例が多数存在しており,これらを識別できる適応基準の確立が待たれる
  • 生体肝移植後の吻合部狭窄に対するPTA
    児玉 芳尚; 清水 匡; 澤田 明宏; 作原 祐介; 阿保 大介; 坂井 亙; 宮坂 和男; 嶋村 剛; 古川 博之; 藤堂 省
    IVR: Interventional Radiology, 18, 2, 189, 190, (一社)日本インターベンショナルラジオロジー学会, Apr. 2003
    Japanese
  • 脳死肝移植3例の経験
    廣方 玄太郎; 中木村 繁; 横山 良司; 谷口 雅彦; 鈴木 友己; 陳 孟鳳; 嶋村 剛; 古川 博之; 藤堂 省
    北海道外科雑誌, 47, 2, 65, 65, 北海道外科学会, Dec. 2002
    Japanese
  • 【肝疾患の診療と栄養治療】肝移植 周術期の栄養管理
    陳 孟鳳; 嶋村 剛; 古川 博之; 萩原 邦子; 鈴木 友巳; 谷口 雅彦; 藤堂 省
    臨床栄養, 100, 7, 860, 865, 医歯薬出版(株), Jun. 2002
    Japanese
  • 【わが国における肝移植の現況と展望】適応拡大への問題点と対策 劇症肝炎症例への移植
    嶋村 剛; 陳 孟鳳; 鈴木 友己; 谷口 雅彦; 蒲池 浩文; 萩原 邦子; 神山 俊哉; 松下 通明; 古川 博之; 藤堂 省
    消化器外科, 25, 3, 297, 304, (株)へるす出版, Mar. 2002
    Japanese, 劇症肝炎患者の多くが肝移植の対象になる.しかし,移植実施施設に紹介された時点で既に非適応と考えられる症例も少なからず存在し,内科医と移植医との早期からの連携,病態に応じた移植適応基準の確立が必要である.術前管理として不可逆的脳障害,大量出血,感染症など移植禁忌となる合併症の発生に留意しなければならない.劇症肝炎に対する緊急生体肝移植の治療成績は1年生存率70%以上で脳死肝移植と同等である.更に,自己肝を一部温存する補助的同所性部分肝移植は,自己肝の再生後に免疫抑制剤から離脱できる利点があり,症例に応じて選択されるべき術式である
  • 肝移植 当科における脳死肝移植の経験
    嶋村 剛; 長佐古 良英; 緒方 俊郎; 陳 盂鳳; 神山 俊哉; 松下 通明; 古川 博之; 藤堂 省; 萩原 邦子
    移植, 36, 総会臨時, 111, 111, (一社)日本移植学会, Dec. 2001
    Japanese
  • Attenuation of ischemia and reperfusion injury of canine livers by inhibition of type II phospholipase A2 with LY329722.
    K Ogata; M B Jin; M Taniguchi; T Suzuki; T Shimamura; N Kitagawa; S Magata; M Fukai; H Ishikawa; T Ono; H Furukawa; M Fujita; S Todo
    Transplantation, 71, 8, 1040, 6, 27 Apr. 2001, [Peer-reviewed], [International Magazine]
    English, Scientific journal
  • Protective effect of agiotensin II type I receptor antagonist, CV-11974, on ischemia and reperfusion injury of the liver.
    H Masuko; M B Jin; H Horiuchi; T Suzuki; M Taniguchi; T Shimamura; M Fukai; S Magata; K Ogata; H Ishikawa; M Fujita; K Nagashima; H Furukawa; S Todo
    Transplantation, 71, 8, 1034, 9, 27 Apr. 2001, [Peer-reviewed], [International Magazine]
    English, Scientific journal
  • What is the limit of graft size for successful living donor liver transplantation in adults?
    H Furukawa; T Shimamura; H Ishikawa; MB Jin; T Kamiyama; M Matsushita; S Todo
    TRANSPLANTATION PROCEEDINGS, 33, 1-2, 1322, 1322, Feb. 2001, [Peer-reviewed]
    English, Scientific journal
  • [Liver transplantation from brain dead patients].
    T Shimamura; H Ishikawa; M Fukai; H Furukawa; S Todo
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 90, 1, 21, 8, 10 Jan. 2001, [Domestic magazines]
    Japanese, Scientific journal
  • 生体肝移植における血管合併症とその対策
    石川 博人; 今井 敦; 折茂 達也; 萩原 邦子; 嶋村 剛; 古川 博之; 藤堂 省; 児玉 芳尚; 清水 匡
    北海道外科雑誌, 45, 2, 85, 86, 北海道外科学会, Dec. 2000
    Japanese
  • Metabolism of prostaglandins in porcine liver transplantation with a graft harvested after 30- and 60-minute warm ischemia.
    H Isai; J Kimura; K Ito; M Tamura; H Kon; H Kamachi; M Takahashi; K Yamashita; T Shimamura; Y Nakajima
    Surgery today, 28, 7, 746, 52, 1998, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal
  • Primary hepatic carcinoid tumor.
    Y Une; Y Li; K Uemura; T Kamiyama; T Shimamura; J Uchino; T Nojima
    Oncology reports, 3, 6, 1091, 5, Nov. 1996, [International Magazine]
    English, Scientific journal, We report the case of primary hepatic carcinoid tumor of which diagnosis was made by fine needle biopsy of a liver mass. The patient was treated successfully by left hepatic trisegmentectomy. This patient presented with complaints of generalized fatigue, but denied the presence of flushing, diarrhea, or other endocrine symptoms. Physical examination was unremarkable. A biopsy specimen revealed Grimelius stained cells that were immunoreactive for chromogranin A. Careful pre- and intraoperative examinations revealed no other primary lesions. Argyrophilia of the tumor cells suggested that the tumor was of fore five cases of primary hepatic carcinoid tumors previously reported in the literature are also reviewed.
  • Primary hepatic carcinoid tumor: A case report and review of the literature
    Y Une; Y Li; K Uemura; T Kamiyama; T Shimamura; J Uchino; T Nojima
    ONCOLOGY REPORTS, 3, 6, 1091, 1095, Nov. 1996, [Peer-reviewed]
    English, Scientific journal
  • Cystadenoma of the liver treated by hepatic resection.
    Y Une; A Kawata; Y Kawamukai; T Nakagawa; T Nojima; T Shimamura; J Uchino
    Oncology reports, 3, 4, 719, 22, Jul. 1996, [International Magazine]
    English, Scientific journal, The aim of this study is to report a case of cystadenoma in the liver and to discuss the difficulty of differential diagnosis from malignant tumor and the importance of complete resection of the lesion. The patient had epigastric pain and abdominal distension. Hepatic ultrasonography, abdominal CT, magnetic resonance imaging, and angiography showed the presence of a large cystic tumor occupying the right hepatic lobe indicating malignant cystadenocarcinoma. Needle biopsy of the cyst wall with sampling of the cyst fluid was performed, which revealed no malignant cells. However, CEA and CA19-9 were markedly elevated in the cyst fluid. A right trisegmentectomy via laparotomy was performed successfully. The resected tumor was 11.5x9x9 cm in size and weighed 1,240 g. The cut surface revealed the tumor with multiple cysts, in some parts of which large papillary projections into lumina were seen. Though the gross features were similar to those of cystadenocarcinoma, the final histological diagnosis was benign cystadenoma of the liver. The postoperative course was uneventful, and the patient is in good condition six years postoperatively without evidence of recurrence of the disease.
  • Water jet scalpel for liver resection in hepatocellular carcinoma with or without cirrhosis
    Y Une; J Uchino; T Shimamura; T Kamiyama; Saiki, I
    INTERNATIONAL SURGERY, 81, 1, 45, 48, Jan. 1996, [Peer-reviewed]
    English, Scientific journal
  • Risk of needle biopsy applying to alveolar echinococcosis of the liver
    K Yamashita; K Furuya; N Sato; T Namieno; T Shimamura; Y Une; Y Nakajima; M Matsushita; J Uchino
    XXX WORLD CONGRESS OF THE INTERNATIONAL COLLEGE OF SURGEONS, VOLS 1-2, 1825, 1828, 1996, [Peer-reviewed]
    English, International conference proceedings
  • Clinicopathological features and treatments of intrahepatic cholangiocellular carcinoma
    K Yamashita; Y Une; T Shimamura; K Misawa; T Hata; Y Nakajima; N Sato; M Matsushita; J Uchino
    2ND WORLD CONGRESS - INTERNATIONAL HEPATO-PANCREATO-BILIARY ASSOCIATION, VOL II: BILIARY-PANCREAS, 831, 835, 1996, [Peer-reviewed]
    English, International conference proceedings
  • Efficacy of color Doppler ultrasonogram and arterial ketone body ratio in detection of hepatic arterial and portal thrombosis after liver transplantation.
    Y Nakajima; Y Hata; H Isai; J Kimura; K Ito; T Omura; M Nishikawa; M Tamura; A Kataoka; T Shimamura
    Transplantation proceedings, 26, 4, 2233, 4, Aug. 1994, [International Magazine]
    English, Scientific journal
  • CLINICOPATHOLOGICAL STUDIES ON RESECTED CASES OF GIANT HEPATOCELLULAR CARCINOMA
    MASUKO Yoshihiro; UNE Yoshie; MISAWA Kazuhito; KAMIYAMA Toshiya; NAKAJIMA Yasuaki; SATO Naoki; MATSUSHITA Michiaki; SHIMAMURA Tsuyoshi; YASUHARA Mitsuo; MATSUOKA Shinichi; OGASAWARA Kazuhiro; UCHINO Junichi
    Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 55, 2, 335, 339, Japan Surgical Association, 1994
    Between January 1985 and June 1992, 208 cases of hepatocellular carcinoma (HCC) were resected in the institute. In this study 22 cases of giant HCC (larger than 10cm in diameter) were clinicopathologically compared to the other 186 cases of HCC (smaller than 10cm). The mean age of 22 patients with giant HCC was 51.0 years old. There were 14 males and 8 females. The frequency of positive HBsAg was higher, while the frequency of concomitant liver cirrhosis was lower than the smaller HCC group. More than 50% of cases showed higher α-fetoprotein above 1000ng/ml. Eighteen cases out of 22 cases underwent more than 2 segment hepatectomy. Portal invasion and intrahepatic metastasis showed significantly higher frequency. The cumulative 3-year survival rate of giant HCCs was 28.4%, versus 61.7% in the smaller HCC group. Three out of 22 cases alived more than 5 years after the operation. These cases were treated by adjuvant chemotherapy, 2 of them received 5-FU via the portal vein and the other was infused adriamycin via the hepatic artery after hepatectomy.
  • ANALYSIS OF HEPATOCELLULAR CARCINOMAS MISSING TYPICAL FINDINGS IN ANGIOGRAM
    KAMACHI Hirofumi; NAKAJIMA Yasuaki; SATO Naoki; MATSUOKA Sinichi; MISAWA Kazuhito; KAMIYAMA Toshiya; SHIMAMURA Tsuyoshi; TOMIOKA Nobumoto; UNE Yoshie; UCHINO Junichi
    Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 55, 5, 1115, 1118, Japan Surgical Association, 1994
    Angiographic findings on hepatocellular carcinomas (HCCs), including tumor vessels and tumor staining, are important for the diagnosis. It is, therefore, difficult to diagnose HCCs lacking in typical findings in angiogram. Of 113 HCCs which were resected at the department for four years (Sep. 87-Sep. 91), seven cases (6.8%) had this type of HCCs. Five cases had moderately differentiated HCC less than 3cm in diameter and 2 cases, undifferentiated carcinoma more than 5cm in diameter. It has been said so far that HCCs lacking typical angiographic findings occur in small and well differentiated tumors. However, none of these 7 cases showed such histologic findings. In large undifferentiated carcinomas, pathological features such as undeveloped blood sinusoids and unidentified capsule due to invasive tumor growth were supposed to be attributable to the lack in typical angiogram.
■ Other Activities and Achievements
■ Syllabus
  • 医学総論, 2024年, 博士後期課程, 医学研究科
  • 基本医学研究, 2024年, 修士課程, 医学院
  • 基本医学総論, 2024年, 修士課程, 医学院
  • 医学総論, 2024年, 博士後期課程, 医学院
  • 基盤医学研究, 2024年, 博士後期課程, 医学院
  • 臨床医学研究, 2024年, 博士後期課程, 医学院
  • 外科学特論, 2024年, 学士課程, 医学部
■ Research Themes
  • Proton isotope effect as the method to repair marginal liver graft by extracorporeal perfusion
    Grants-in-Aid for Scientific Research
    01 Apr. 2023 - 31 Mar. 2026
    嶋村 剛; 深井 原; 暮地本 宙己; 亀田 浩之; 西川 祐司; 惠 淑萍
    Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), Hokkaido University, 23K28467
  • Proton isotope effect as the method to repair marginal liver graft by extracorporeal perfusion
    Grants-in-Aid for Scientific Research
    01 Apr. 2023 - 31 Mar. 2026
    嶋村 剛; 深井 原; 惠 淑萍; 暮地本 宙己; 亀田 浩之; 西川 祐司
    Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), Hokkaido University, 23H03779
  • 易傷害性肝グラフトの至適体外灌流法と非侵襲的グラフト機能評価法の開発
    科学研究費助成事業
    01 Apr. 2020 - 31 Mar. 2023
    嶋村 剛; 杉森 博行; 深井 原; 暮地本 宙己; 藤好 真人; 木村 太一
    本研究の目的はラットExpanded Criteria Donor (脂肪肝、心停止肝) を用いた肝移植の術後成績を向上させるグラフト灌流法、コンディショニング法を開発し、術後成績を予測できる移植前グラフト機能評価法を確立することである。その実現のために、メタボローム解析とタンパク質機能解析が不可欠であり、前処理の条件検討を行った。トリクロロ酢酸 (TCA) によりタンパク質解析(沈殿)とメタボローム解析用(上清)の試料を同時に取得した。メタボローム解析用の試料は、LC-MS/MS、NMR、ラマン分光解析に供する目的でそれぞれに至適な条件を検討した。特にNMR、ラマン分光解析は試料のpHが測定結果に影響するため、ジエチルエーテルとの混和によるTCAの除去を繰り返し、安定した測定条件を見出した。これにより、NMR解析は600円/試料、LC-MS/MS解析は6000円/試料程度の費用で測定できる目処が立った (外注では約12万円/試料)。本課題におけるもっとも重要な評価系の一部が確立された。脂肪肝モデルも検討し、肝移植のグラフトとしての検討に資する30-60%の大滴性脂肪肝を安定して作成する方法を確立した。灌流液中のFMN濃度がグラフトのミトコンドリアComplex1の傷害マーカーになることが報告されているが、多くは灌流液の蛍光強度のみの測定であり、同じ蛍光を発するリボフラビン (RF)、フラビンアデニンジモノヌクレオチド (FMN)、フラビンアデニンジヌクレオチド (FAD)由来の蛍光の合算を"FMN"と称している。われわれはこれらの分子をHPLCで分離し、蛍光検出することにより、肝冷保存や体外灌流中のRF, FMN, FAD の漏出を5分以内で定量できるシステムを確立した。
    日本学術振興会, 基盤研究(B), 北海道大学, 20H03737
  • Exploration of the new method to stimulate protective protein function during machine perfusion of steatotic graft
    Grants-in-Aid for Scientific Research
    01 Apr. 2019 - 31 Mar. 2022
    Wakayama Kenji
    We have established a reliable steatostic rat model and evaluated the time course of the potential prognostic markers of ischemia reperfusion injury (IRI) using MALDI imaging mass spectrometry (IMS) method. We found some promising candidates of injury markers, which could predict the severity of IRI due to the ischemic time regardless of the grade of the fatty change. Lysophosphatidylinositol (LPI) 18:0 showed excellent correlation with the post-repefusion injury, such as blood ALT level and injury score. Furthermore, distribution of LPI (18:0) revealed the ischemia time dependent accumulation during ischemia, specific to the Zone1 area. Some other indices also showed a potential to predict IRI. Accordingly, IMS appeared to show its ability to detect regional subtle change due to the ischemic insult.
    Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 19K09088
  • Renal graft conditioning by simultaneous upregulation of 14-3-3 and Nrf2 during machine perfusion
    Grants-in-Aid for Scientific Research
    01 Apr. 2017 - 31 Mar. 2021
    Fukai Moto
    The aims of this study are to establish a method to strengthen the protective ability of renal grafts by pharmacological interventions during machine perfusion, and to resolve the donor shortage in renal transplantation. In vitro study mimicking machine perfusion of the renal graft, using human renal tubular cell line, revealed that pharmacological conditioning successfully upregulated 14-3-3 zeta protein level and nuclear translocation of Nrf2 within 3 hours. Further, these conditioning reduced cellular injury at least in in vitro. Although these drugs seemed to be promising, in organ and in animal levels, it could not be reconfirmed due to its water-insolubility and solvent (DMSO) toxicity. After resolving the drug solubility and delivery issues, it would become a promising candidate to condition the renal graft outside the body.
    Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 17K10500
  • Exploration of graft conditioning methods during machine perfusion to augment mitochondrial function and antioxidant ability in steatotic liver graft
    Grants-in-Aid for Scientific Research
    01 Apr. 2016 - 31 Mar. 2020
    Shimamura Tsuyoshi
    To establish the methods for pre-conditioning the steatotic graft by machine perfusion, and to find out the reliable marker to predict later severity of ischemia and reperfusion injury (IRI), we explored the following issues. Using steatotic rat livers and hepatocytes cell line treated by fatty acids-rich culture, they were subjected to cold storage and/or machine perfusion (or mimicking conditions) in various temperatures, preservation and perfusion solutions commercially available, with or without supplementation of antioxidant and other agents to augment some protective proteins. We found that pre-conditioning during machine perfusion with antioxidant and some agents, having property to induce expression of protective proteins and to activate protective transcription factors, effectively prevent progression of IRI. These results indicate that properly pre-conditioned steatotic graft could become a safe source of liver transplantation.
    Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), Hokkaido University, 16H05398
  • 体外誘導免疫制御性リンパ球を用いた細胞治療による免疫寛容誘導に関する研究
    科学研究費助成事業
    01 Apr. 2014 - 31 Mar. 2019
    山下 健一郎; 嶋村 剛; 後藤 了一; 奥村 康; 藤堂 省
    本研究では、自己リンパ球を生体外にて免疫制御性リンパ球へと誘導し、この細胞を体内へ投与する細胞治療を行うことで、免疫抑制剤服用中である肝移植後レシピエントの免疫抑制剤減量・中止を図り、安全な免疫寛容誘導法を確立するため、
    1) 生体肝移植術後レシピエントを対象として細胞治療を行い、その免疫抑制剤減量や免疫寛容誘導効果の検討する、
    2) 誘導した免疫制御性リンパ球を解析し、その免疫抑制メカニズムの解明する、
    3) 細胞治療を行ったレシピエントの末梢血リンパ球やグラフト組織を解析し、細胞治療による免疫寛容誘導作用のメカニズムを探求する、ことを目的として研究を推進している。
    本年度は、上記1) 細胞治療を用いた免疫寛容誘導効果を検討する臨床試験を実施するため、新たに施行された「再生医療等の安全性の確保等に関する法律」に則り、必要な諸手続きを進めてきた。また、上記3) 免疫寛容誘導作用のメカニズムを解明するため、細胞治療を行った症例の末梢血リンパ球を経時的に解析した。細胞治療後は早期にCD25+Foxp3+もしくはCD127lo Foxp3+制御性フェノタイプを有するCD4+T細胞が末梢血中で著増していることが確認された。更に、これらの制御性フェノタイプを発現するCD4+T細胞は、治療約6ヶ月後には治療前値に復したものの、以降は再漸増して高めに維持されている事が判明した。免疫寛容誘導の成否との直接的な関連性は不明であり、今後更に検討が必要である。
    日本学術振興会, 基盤研究(A), 北海道大学, 26253068
  • Regulation of chaperone expression outside the body
    Grants-in-Aid for Scientific Research
    01 Apr. 2015 - 31 Mar. 2017
    Mino Kazuhiro
    Human renal tubular cell line (HK-2) or 14-3-3ζ overexpressed HK-2 (ζHK-2) were subjected to cold preservation in UW solution for 72 hours. Cellular death, ATP content, and MTT catabolism were evaluated.Despite possessing many potentially protective functions, 14-3-3ζ worsen the cellular injury under hypothermic oxygenated condition. 14-3-3ζ accelerates mitochondrial functions together with iron-dependent oxidative damage.The upregulation of 14-3-3ζ could be a method to maintain mitochondrial function under hypothermic oxygenated condition, shown in HMP of renal grafts, when appropriate antioxidant treatment is applied.
    Japan Society for the Promotion of Science, Grant-in-Aid for Challenging Exploratory Research, Hokkaido University, 15K15578
  • Novel methods to regulate hepatic graft by extracorporial perfusion : Chaperoen mediated mechanisms
    Grants-in-Aid for Scientific Research
    01 Apr. 2014 - 31 Mar. 2017
    Shimamura Tsuyoshi
    The role of 14-3-3 zeta on the cellular injury and energy production during and after hypothermic storage with or without oxygen, using mouse hepatocytes derived cell line (AML12). 14-3-3 zeta overexpression was introduced by gene delivery or some small molecule. After confirmation of 14-3-3 zeta protein level, cells were subjected to hypothermic oxygenate condition mimicking the cellular environment during organ perfusion. Combination of 14-3-3 zeta inducing molecule and hydrogen sulfide strengthen the mitochondrial functions related to oxidative phosphorylation, drug (MTT) metabolism, and antioxidant ability, due to the prevention of protein dephosphorylation (14-3-3) and stimulation of ARE-binding transcription factors (NaHS). These results revealed novel strategy to pre-condition the marginal graft not by gene delivery but by transcriptional and post-translational regulations.
    Japan Society for the Promotion of Science, Grant-in-Aid for Challenging Exploratory Research, Hokkaido University, 26670572
  • Repair method of steatotic grafts aiming to resolve the organ shortage
    Grants-in-Aid for Scientific Research
    01 Apr. 2013 - 31 Mar. 2016
    Tsuyoshi Shimamura; Taketomi Akinobu; Fukai Moto; Kimura Taichi; Nishikawa Yuji; Ohsawa Ikuro
    We succeeded to obtain the "Proof of Concept" that combined therapy against the marginal grafts, including steatosis and DCD liver, could reduce ischemia and reperfusion injury. Using novel preservation solution, perfusate for machine perfusion, and hydrogen gas, graft weight gain and intrahepatic resistance during CS , HOPE and/or reperfusion were well controlled. Although bile production was not fully resucitated in DCD graft subjected to extended cold preservation, it would be resolved by perfusion from the artery. We believe that our method would become a choice to utilize the marginal grafts, and thereby resolving, at least to some extent, organshortage.
    Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), Hokkaido University, 25293272
  • Mesothelin and CA 125 expression in digestive carcinoma
    Grants-in-Aid for Scientific Research
    2011 - 2012
    SHIMAMURA Tsuyoshi; TODO Satoru; KAMIYAMA Toshiya; OZAKI Michitaka; KAMACHI Hirofumi
    In our analysis, 110 cases of gastric, 91 cases of colorectal and 61 cases of extrahepatic bile duct adenocarcinoma were immunohistochemically examined and the localization of mesothelin in luminal membrane was also evaluated to explore the clinicopathological significance of the mesothelin expression in these cancers. In addition, lymphatic invasion assay using the colon cancer cell line with enforced mesothelin expression was also performed to examine its biological role. “Luminal membrane positive” of mesothelin was significantly correlated with unfavorable patients’ outcome in these three types of adenocarcinoma. In addition, lymphatic invasion assay revealed that ERC/mesothelin significantly promoted the invasion of colorectal adenocarcinoma cell lines. In conclusion, mesothelin could be a novel therapeutic target to suppress the spread of tumors through the lymphatic system in various types of digestive cancers. (Br J Cancer. 2012, Int J Oncol.2012, J Gastroenterol. 2013)
    Japan Society for the Promotion of Science, Grant-in-Aid for Challenging Exploratory Research, Hokkaido University, 23659289
  • Development of a novel organ preservation solution for the use of liver transplantation
    Grants-in-Aid for Scientific Research
    2010 - 2012
    TODO Satoru; OZAKI Michitaka; FURUKAWA Hiroyuki; YAMASHITA Kenichiro; FUKAI Moto; SUGAWARA Mitsuru; MATSUSHITA Michiaki; SHIMAMURA Tsuyoshi; TANIGUCHI Masahiko; SUZUKI Tomomi
    We explored the necessary condition of heavy water containing buffer for the use of simple cold preservation. The novel solution appeared to show excellent cytoprotection in various cells, and rat liver and heart, due to the inhibition of cytosolic Ca2+ overload and cytoskeletal breakdown, and stimulation of aerobic respiration. However, these beneficial effects were abolished in liver and kidney preservation and transplantation of dogs, possibly due to the stimulation of intravascular agglutination by PEG. To proceed to the clinical application, customization of PEG concentration should be explored. Further, since the main action of heavy water containing buffer is stimulation of aerobic respiration, we should find better way to provide oxygen without agglutination for the next step.
    Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (A), Hokkaido University, 22249048
  • The novel NF-kB inhibitor, dehydroxymethylepoxyquinomicin, prevents local intestinal ischemia/reperfusion injury in rats
    Grants-in-Aid for Scientific Research
    2007 - 2008
    SUZUKI Tomomi; YAMASITA Kennitirou; OZAKI Michitaka
    Nuclear factor-κB (NF-κB)は炎症惹起因子である敗血症、活性酸素などの刺激により腸管で活性化されることが知られている。このNF-κBの核内への移行を阻害する新規NF-KB活性阻害剤(DHMEQ)を用いたラット小腸虚血再灌流障害に対するNF-κB阻害作用の効果について検討した。その結果、ラット60分小腸虚血再灌流障害モデルにおいてDHMEQ治療群は無治療群と比較して、生存日数の有意な延長を認め、再灌流後の小腸組織血流量を良好に維持できた。また、DHMEQ治療群は炎症性サイトカインであるTNF-αとIL-6の産生を有意に抑え、病理組織学的に小腸および遠隔臓器である肺障害をも軽減できた。翌年度は、これらの知見から潰瘍性大腸炎のモデルであるマウスDSS誘発大腸炎モデルに対してもDHMEQの治療効果が期待できると判断し、その有効性について検討した。結果、DHMEQ治療群はコントロール群と比較して炎症性サイトカインであるIL-8を有意に抑制し、臨床症状である血便の改善を認めた。以上より、DHMEQはラット小腸虚血再灌流障害およびマウスDSS誘発大腸炎モデルに対して抗炎症効果を示したとの結論を得た。
    Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 19591470
  • アデノシン関連物質による臓器虚血再潅流障害の予防
    科学研究費助成事業
    2004 - 2006
    藤堂 省; 古川 博之; 嶋村 剛; 鈴木 友己; 谷口 雅彦; 尾崎 倫孝
    【背景】肝の阻血再灌流障害の発生機序として、1980年代から活性酸素群が注目されている。これらの活性酸素群の生成に関してはいくっかの反応系が知られているが、阻血中のATPの分解によるHypoxanthineやXanthineの上昇とXanthine DehydrogenaseのOxidaseへのConversionを母地として発生する系が重要視されている。ATPの代謝産物であるアデノシンはアデノシン自体が持つ血管拡張作用の他に、High Energy Phosphatesのsubstrateとしての役割も有しており、これらの作用により近年、内因性アデノシンを増強させるnucleotide transport inhibitor等は臓器の阻血-再灌流障害の軽減に強力な作用を有することで注目されている。そこで、本研究はアデノシン関連物質を応用した安全な肝切除術の確立、肝移植におけるグラフト機能不全の改善、新しい臓器保存液の開発、あるいは多臓器不全の治療法の確立などを目的として行われた。【方法】ビーグル犬を使った2時間の完全肝虚血モデルを用いて、代表的な抗血小板薬であるジピリダモール(DYP)とアデノシンA_1リセプターのアンタゴニストであるKW3092[8-(noradamantan-3-yl)-1,3-dipropylxanthine]の効果を検討した。【結果】DYP投与群はnucleoside transport inhibitorの一つとして組織中のadenosine濃度を高める一方、phosphodiesterase inhibitorとしても虚血・再灌流障害を軽減し、動物生存日数の有意な延長を認めた。また、KW3092投与群は肝組織中のcAMPの上昇を認め、虚血・再灌流障害を軽減し、同様に動物生存日数の有意な延長を認めた。【まとめ】アデノシン関連物質は肝切除術、肝移植術、臓器保存における肝虚血-再灌流障害を軽減させ臨床における患者の安全性を高める効果を十分に期待できるものであると考えられた。また、これらの研究成果は2編の論文として報告された。
    日本学術振興会, 萌芽研究, 北海道大学, 16659345
  • Development of a gene therapy based new strategy in small bowel transplantation
    Grants-in-Aid for Scientific Research
    2004 - 2006
    FURUKAWA Hiroyuki; TODO Satoru; UEDA Toshimitsu; SHIMAMURA Tsuyoshi; OZAKI Michitaka; YAMASHITA Kenichiro
    Advances in both surgical techniques and immunosuppression have made small bowel transplantation (SBTx) as an established treatment for patients with irreversible intestinal failure. However, further refinements in immunosuppression and graft preservation including protection against ischemia/reperfusion (IR) injury are necessary to improve SBTx patient survival and their quality of life. In this study, we aimed to establish a new strategy for SBTx based on a gene therapy. In rats, blockade of CD80/86-CD28 and/or CD4O-CD154 costimulatory signals by applying the adenoviral vector coding CTLA4Ig or CD40Ig markedly prolonged a fully MHC mismatched small intestinal allograft. Most of these allografts survived for over 300 days, however, progression of chronic rejection was inevitable. Despite the success of this gene therapy based costimulation blockade in SBTx, adeno-virus mediated gene therapy became unpractical because serious side-effects occurred following such therapy during its clinical trials. The event has led us to reconsider the approaches to accomplish our aim of this study. We have examined the immunosuppressive properties of new Leflunomide derivatives, FK778/FK779 and a novel NF-kB inhibitor, DHMEQ in rodent transplantation models, and demonstrated that these newly developed agents have a significant ability to prevent acute cellular rejection and to prolong allograft survival. Also in this study, we have shown that a degree of lipid peroxidation within the organ correlates with severity of I/R, injury, and that the free radical scavenging agent, Edaravone and NF-kB inhibitor DHMEQ ameliorate FR injury in dogs and rats. Although further studies are warranted to establish a new strategy in SBTx, we conclude that especially, costimulatory signal blockers and NF-kB inhibitor are effective agents for preventing small bowel allograft rejection and preservation/IR injuries that seems to be potential candidates for clinical use in SBTx.
    Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), Hokkaido University, 16390368
  • Tolerance induction by gene therapy in organ transplantation
    Grants-in-Aid for Scientific Research
    2001 - 2005
    TODO Satoru; UEDE Toshimitsu; FUJITA Hiroyoshi; MATSUSHITA Michiaki; FURUKAWA Hiroyuki; SHIMAMURA Tsuyoshi
    In this project, we aimed to develop a strategy to achieve potent immunosuppression and to induce tolerance in organ transplantation by applying a gene therapy. We examined the effect of B7-CD28 and CD40-CD154 costimulatory signaling blockades by using adenoviral vectors coding such as CTLA4Ig and CD40Ig genes, and found that a single gene therapy is potent enough to induce antigen specific tolerance in liver transplantation using a rat model. Although such gene therapies also allowed long-term acceptance of heart and small intestinal allografts in rats, progression of chronic rejection was not fully abrogated in these transplants. The mechanism of tolerance induction by CD40Ig gene therapy was exploited, and we found that CD40Ig enhances IL-2 production in CD4^+ T cells and generates CD4^+CD25^+ regulatory T cells. Concomitant use of calcineurin inhibitors did not abolish tolerance induction by the CD40Ig gene therapy, while some treatment strategy together with calcineurin inhibition have accelerated chronic allograft rejection in rodent heart transplantation models. To develop a suitable adjunct therapy for the gene therapy, effects of SDF-1/CXCR4 signaling blockade, a new pirimidine synthesis inhibitor Malononitrilamides and NF-κB inhibitor DHMEQ was further examined in this study. Due to the severe side-effects of viral mediated gene therapy noted in clinical trials, we developed several ways to reduce the amount of viral vector use and also applied cre/loxP system. We also tried non-viral gene transduction by utilizing an electroporation method; however, we found that it is not practical. We therefore examined the effect of a new human CD40 monoclonal antibody, 4D11 in sub-human primate kidney transplantation. Treatment with 4D11 (10-40 mg/kg) for one or 2.5 months allowed long-term renal allograft survival, without showing adverse effects such as thromboembolism or infection, which indicating 4D11 as a promising candidate for clinical use to block CD40-CD154 interactions.
    Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (S), HOKKAIDO UNIVERSITY, 13854019
  • 慢性拒絶におけるSDF-1の役割-In vitroでの機能解析と中和抗体を用いた治療実験-
    科学研究費助成事業
    2003 - 2004
    嶋村 剛; 藤堂 省; 古川 博之; 陳 孟鳳
    昨年、マウス動脈移植モデルにおいてグラフト慢性拒絶に伴いSDF-1発現量が移植血管片で経時的に増加することや、拒絶に伴いレシピエント末梢血液中のhematopoietic stem cell (HSC)が増加し、これらHSCの98.9%はSDF-1のレセプターであるCXCR4を発現していること等を見いだし報告した。
    本年度は、先ず慢性拒絶に伴いグラフト内膜を形成する平滑筋細胞がレシピエント骨髄由来か否かを雌BALB/cマウスをドナー、雄C3H(H-2k)マウスをレシピエントとする動脈移植モデルで検討した。グラフトを抗レシピエントMHC class I (H-2k^k)抗体及び抗CXCR4抗体で二重染色したところ、グラフト内膜に増殖するCXCR4陽性血管平滑筋細胞の多くは抗MHC class I (H-2k^k)抗体にも陽性であった。更に、グラフト内膜内組織では雄性遺伝子SRY抗原とCXCR4が共発現しており、慢性拒絶に伴いグラフトにレシピエント由来の細胞が存在することを確認した。従って本モデルにおけるグラフト慢性拒絶にはSDF-1及びCXCR4陽性なレシピエント由来HSCが重要であることが示唆された。次に、抗SDF-1抗体投与が慢性拒絶反応の抑制に有用な治療法となり得るか検討した。マウス動脈移植を行い、レシピエントにSDF-1中和抗体もしくはコントロール(IgG)抗体を各々10μg/回で腹腔内に3週間投与し、レシピエント末梢血液中のHSC数及びグラフトの慢性拒絶進行度を比較した。移植6週間後の末梢血液中HSC数(10万個当り)はコントロール群で平均17.1個に対し抗SDF1抗体投与群では5.1個と有意に抑制された。また、グラフト血管内膜肥厚も抗SDF-1抗体投与群ではコントロール群の約30%と優位に抑制され、抗SDF-1抗体投与は慢性拒絶反応の治療に有用であることが示された。
    日本学術振興会, 萌芽研究, 北海道大学, 15659301
  • Development of a new immunosuppressive strategy by targeting pyrimidine synthesis
    Grants-in-Aid for Scientific Research
    2003 - 2004
    SHIMAMURA Tsuyoshi; FURUKAWA Hiroyuki; TODO Satoru
    Leflunomide is a strong immunosuppressant that exerts its effect by blocking de novo pyrimidine synthesis. It has been shown that Leflunomide is a useful immunosuppressive agent in clinical trials of autoimmune diseases. However, due to the drug's long half-life, Leflunomide has never been clinically applied in the field of organ transplantation. A new Leflunomide derivative, FK778 and FK779, that has a shorter half-life than its mother drug were developed to resolve such problem. In this study, we have examined immunosuppressive effect, pharmacokinetics and side-effects of FK778 and FK779 in rat heart transplantation and dog kidney transplantation. In addition, we assessed immunosuppressive effect of FK778 and FK779 in combination with calcineurin inhibitors, tacrolimus (TAC) and cydosporine (CsA). In both rat and dog transplantation models, FK778 and/or FK779 prolonged allograft survival Also, there was an additive or synergistic effect when given with these calcineurin inhibitors. In a dog transplantation model, a slight leukocytopenia and anemia was observed when FK778 was administered at 6 mg/kg/day ; however, no serious side-effect was noted. We further examined an immunosuppressive effect of FK779 in a hamster-to-rat heart xenotransplantation model. FK779 effectively controlled both acute vascular and acute cellular xenograft rejections and markedly prolonged xenograft survival when combined with calcineurin inhibitors (TAC/CsA) or CD40-CD154/B7-CD28 costimulation blockades. We conclude that FK778 and FK779 are powerful and useful immunosuppressant that has a potential for clinical application in organ transplantation.
    Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), Hokkaido University, 15390388
  • Development of safety methods for adult to adult living donor liver transplantation focused on cyclic AMP signal pathway.
    Grants-in-Aid for Scientific Research
    2001 - 2003
    FURUKAWA Hiroyuki; SHIMAMURA Tsuyoshi; JIN Maeng bong; TODO Satoru
    First of all, small-for size graft syndrome is probably due to relative liver ischemia. Although, to dissolve this problem, port-caval shunt, splenic ligation, and splenectomy are used as surgical interventions, there have been few cases treated by pharmacological pre-conditioning. We try to improve liver damage caused by congestion using 2hr-canine warm ischemic model.
    Secondly, while right lobe grafting is the most effective alternative for the strategy against small-for-size liver syndrome, the suboptimal hepatic venous outflow may lead to serious graft function. The 3 dimensional (3D) images constructed by multiditector CT were used for pre-operative virtual donor hepatectomy and grafting with reconstruction of MHV tributaries. The emphasizing point in our 3D images is that this method can calculate each volume of the are, of which each hepatic vein drains.
    Thirdly, the reason why we made up clinical pathways for adult to adult living donor liver transplantation is not only for developing theoretical and technical surgical performance, but also for verifying the validity of our patient care strategy in the other liver transplantation programs.
    Fourthly, the patients after liver transplantation suffered from small-for-size syndrome, basically, need much amount of albumin product, because the ability of the small liver allografts seem to require long time to get mature productivity. In such situation, young surgeons are likely to use much more albumin product than appropriate dose. To lead them to proper direction, we showed our manual haw to use albumin product.
    Finally, we summarized present status of adult to adult liver transplantation in both Japanese and western countries. In addition, we compared the treatments of graft dysfunction between our program and the others.
    Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), HOKKAIDO UNIVERSITY, 13557102
  • Development of new preservation solution to maintain vascular endothelial Integlity.
    Grants-in-Aid for Scientific Research
    2001 - 2003
    JIN Maeng bong; SHIMAMURA Tsuyoshi; FURUKAWA Hiroyuki; TODO Satoru; KURAUCHI Nobuaki
    A. The effect of vaso-reactive substances on the organ preservation were investigated. Vaso-active substances could reduce neutrophil infiltration into reperfused liver tissue. They also promoted the maintenance of hepatic tissue blood flow even after 2hr complete hepatic warm ischemia using total hepatic vascular occlusion model. Moreover, they attempted remarkable recovery of hepatic energy metabolism.
    B. For example, we tried a brand new Rho-associated protein kinase, Y 27632 to prove that Rho-kinase can play a key role even in the hepatic ischemia reperfusion injury. Male SD rats were engaged in a 70% partial hepatic ischemia model. Animals were divided into two groups, a no-treated group, a group treated with 10mg/kg Y-27632 p.o before 90 min warm ischemia, Survival, arterial pressure, hart rate, hepatic tissue blood flow, ALT, ET-1, Hyauronic acid, MPO activity, Mac-1 stain, and pathological history were investigated. The treatment ameliorated survival, hepatic tissue blood flow, ALT, ET-1, HA, and MPO, significantly, and also reduced the number of Mac-1 positive neutrophil infiltration into liver tissue.
    C. A brand new substance, edaravone, was tested for its ability as a radical scavenger using canine kidney auto transplantation model after 72hr cold preservation in HTK solution. Animal were randomly divided into two groups, treated one and untreated control. Edaravone was infused systematically before graft procurment, given into preservation solution, and administered systematically after grafting. The treatment unproved urine volume, NAG/Cr, FENa, and lessened Cr level, acute tubular necrosis, and MDA level in kidney draft.
    Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), HOKKAIDO UNIVERSITY, 13557101
  • 心停止ドナーからの肝臓移植法の開発
    科学研究費助成事業
    2000 - 2002
    藤堂 省; 陳 孟鳳; 古川 博之; 松下 通明; 嶋村 剛
    心停止ドナーで最も大きな障害となる温阻血再灌流障害は肝臓の微小循環障害を契機として肝機能不全を惹起する。この微小循環障害は肝類洞内皮障害に基づくものであり、アデノシンA1受容体・エンドセリン-1A受容体・アンギンテンシンII type I受容体等の拮抗剤で改善されることを明らかにしてきた。これらの受容体にリガンドが結合するとinhibitor small G proteinがリン酸化され細胞内セカンドメッセンジャーであるサイクリックAMPを減少させる。そこでサイクリックAMPの分解酵素であるホスホジエステラーゼIIIの阻害剤を投与し細胞内サイクリックAMPの濃度を虚血再灌流時にも減少させないようにすれば障害が緩和されるのではないかという仮説をたてた。ビーグル犬の肝臓に流入する血流を2時間完全に遮断し温阻血モデルを作成した。動物は以下の4群(n=6)に分類した。Group 1、薬剤非投与群;Group 2、温阻血1時間前にホスホジエステラーゼIII阻害剤投与;Group 3、2時間温阻血再灌流後1時間ホスホジエステラーゼIII阻害剤投与;Group 4、温阻血前後各々1時間ホスホジエステラーゼIII阻害剤投与。Group 2とGroup 3の動物は全例2週間以上生存したがGroup 1は33%が2週間生存しGroup 4は全例実験中の低血圧が原因で死亡した。生存グループでは血流再灌流後15分の時点でコントロール群に比べ約50%サイクリックAMP組織濃度が高値でありレーザードップラー血流計で測定した肝微小循環は生存グループでは温阻血前値に比べほぼ同等であったのに対しコントロール群では30%台にまで低下していた。現在この大動物での実験結果を基にしてラット肝灌流モデルを用い細胞内サイクリックAMPシグナル増強の臓器保護効果機構を転写因子レベルで解析中である。
    日本学術振興会, 基盤研究(A), 北海道大学, 12357008